Viral particles retargeted to nervous system tissues

Abstract

Provided herein are compositions and methods for retargeting viral particles, e.g., adeno-associated virus (AAV) particles, to p75NTR-expressing cells using p75NTR-targeting ligands. AAV adapted accordingly may be a viable gene therapy platform to target nervous system cells (e.g., dorsal root ganglia, trigeminal ganglia, etc.) for the treatment or prevention of pain, itch, or a neurological disease or disorder in a subject in need thereof.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims priority to U.S. Provisional Application No. 63 / 619.765, filed on January 11, 2024, the disclosure of which is hereby incorporated by reference in its entirety. SEQUENCE LISTING

[0002] The official copy of the sequence listing is submitted electronically via EFS-Web with a file named, “11566WO01 Sequence Listing XML.xml,” created on January 10, 2025, and having a size of 665 kilobytes, and is filed concurrently with the specification. The sequence listing contained in the XML formatted document is part of the specification and is herein incorporated by reference in its entirety7. TECHNICAL FIELDS

[0003] The disclosure herein relates to methods of making and using recombinant viral particles, e.g., recombinant AAV particles, comprising capsid proteins retargeted to p75 neurotrophin receptor (p75NTR), useful for modification of p75NTR-expressing cells, e.g., nervous system cells, such as dorsal root ganglion and trigeminal ganglion cells, in vitro or in vivo. BACKGROUND OF THE INVENTION

[0004] The delivery of genes into particular target cells has become one of the most important technologies in modem medicine for the potential treatment of a variety of chronic and genetic diseases. Ideally, a gene delivery vehicle is able to stably introduce genetic material into desired cells and avoid introducing genetic material into non-target cells.

[0005] Viral particles, particularly those based on adeno-associated viruses (AAV), as gene delivery vehicles have been the focus of much research since AAVs are capable of transducing a wide range of primate species and tissues in vivo with no evidence of toxicity or pathogenicity7. (Muzyczka, et al. (1992) Current Topics in Microbiology’ and Immunology, 158:97-129). Moreover. AAV safely transduces postmitotic tissues. Although the virus can occasionally integrate into host chromosomes, it does so very infrequently into a safe-harbor locus in human chromosome 19, and only when the replication (Rep) proteins are supplied in trans. AAV genomes rapidly circularize and concatemerize in infected cells, and exist in a stable, episomal state in infected cells to provide long-term stable expression of their payloads.

[0006] Additionally, manipulating and redirecting AAV infection to specific cells has been achieved in recent years. Many of the advances in targeted gene therapy using viral particles may be summarized as non-recombinatorial (non-genetic) or recombinatorial (genetic) modification of the viral particle, which result in the pseudotyping, expanding, and / or retargeting of the natural tropism of the viral particle. (Reviewed in Nicklin and Baker (2002) Curr. Gene Ther. 2:273-93; Verheiji and Rottier (2012) Advances Virol 2012:1-15).

[0007] In a direct recombinatorial targeting approach, a targeting ligand is directly inserted into, or coupled to, a viral capsid, i.e., protein viral capsid genes are modified to express capsid proteins comprising a heterologous targeting ligand. The targeting ligand than redirects, e g., binds, a receptor or marker preferentially or exclusively expressed on a target cell. (Stachler et al. (2006) Gene Ther. 13:926-931; White et al. (2004) Circulation 109:513519; see also Park et al., (2007) Frontiers in Bioscience 13:2653-59; Girod et al. (1999) Nature Medicine 5:1052-56; Grifman et al. {2QQ\) Molecular Therapy 3:964-75; Shi et al. (2001) Human Gene Therapy 12:1697-1711; Shi and Bartlett (2003) Molecular Therapy 7:515-525).

[0008] In indirect recombinatorial approaches, a viral capsid is modified with a heterologous “scaffold”, which then links to an adaptor that includes a targeting ligand. The adaptor binds to the scaffold and the target cell. (Arnold et al. (2006) Mol. Ther. 5:125-132; Ponnazhagen et al. (2002)7. Virol. 76:12900-907; see also WO 97 / 05266) Scaffolds such as (1) Fc binding molecules (e.g., Fc receptors, Protein A, etc.), which bind to the Fc of antibody adaptors, (2) (strept)avidin, which binds to biotinylated adaptors, (3) biotin, which binds to adaptors fused with (strept)avidin, (4) a detectable label, which is useful for detection and / or isolation of viral particles, bound by a bispecific adaptor able to non-covalently bind the detectable label and target molecule, and recently (5) protein:protein binding pairs that form isopeptide bonds have been described for a variety of viral particles. {See, e.g., Gigout et al. (2005)Molecular Therapy 11:856-865; Stachler et al. (2008) Molecular Therapy 16:1467-1473; Quetglas et al. (2010) Virus Research 153:179-196; Ohno et al. (1997) Nature Biotechnology 15:763-767; Klimstra et al. (2005) Virology 338:921).

[0009] With the advances providing the ability to direct AAV infection, there remains a need to discover targets for the specific transfer of nucleic acids of interest to a cell of interest, e.g., ap75NTR-expressing cell, e.g., a mammalian nervous system cell. SUMMARY OF THE INVENTION

[0010] It is shown herein that an AAV capsid protein may be modified to allow for the targeted introduction of a nucleotide of interest into p75NTR-expressing cells, e.g., mammalian nervous system cells.

[0011] Viral particles as described herein are particularly suited for the targeted introduction of a nucleotide of interest specifically to a p75NTR-expressing cell since the viral capsid or viral capsid protein(s) described herein comprise a targeting ligand that binds p75NTR jn some embodiments, a viral capsid or viral capsid protein comprises a first member of a binding pair, associated with its cognate second member of the binding pair, wherein the second member is linked (e.g., fused to) a targeting ligand that binds a nervous system cell-specific surface protein. In some embodiments, the targeting ligand is operably linked to the second member, e.g., fused to the second member, optionally via a linker. In some embodiments, a targeting ligand may be a binding moiety, e.g., a natural ligand, antibody, a multispecific binding molecule, etc. In some embodiments, the targeting ligand is an antibody or portion thereof. In some embodiments, the targeting ligand is an antibody comprising a variable domain that binds p75NTR, e.g., on a nervous system cell, and a heavy chain constant domain. In some embodiments, the targeting ligand is an antibody comprising a variable domain that binds p75NTR on a target cell and an IgG heavy chain constant domain. In some embodiments, the targeting ligand is an antibody comprising a variable domain that binds a nervous system cell-specific surface protein on a target cell and an IgG heavy chain constant domain, wherein the IgG heavy chain constant domain is operably linked, e.g., via a linker, to a protein (e.g., second member of a protein:protein binding pair) that forms an isopeptide covalent bond with the first member. In some embodiments, a capsid protein described herein comprises a first member comprising SpyTag operably linked to the viral capsid protein, and covalently linked to the SpyTag, a second member comprising SpyCatcher linked to a targeting ligand comprising an antibody variable domain and an IgG heavy chain domain, wherein SpyCatcher and the IgG heavy chain domain are linked via an amino acid linker, e.g.. GSGESG. (SEQ ID NO: 638). In some embodiments, the targeting ligand binds mammalian p75NTR, e.g.. human p75NTR. In some embodiments, the targeting ligand comprises a heavy chain variable domain, light chain variable domain, heavy chain variable domain / light chain variable domain pair, HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, LCDR3, and / or set of HCDR1-HCDR2-HCDR3-LCDR1-LCDR2-LCDR3 comprising an amino acid sequence of a heavy chain variable domain, light chain variable domain, heavy chain variable domain / light chain variable domain pair, HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, LCDR3, and / or set of HCDR1-HCDR2-HCDR3-LCDR1-LCDR2-LCDR3 as set forth in or encoded by a sequence or sequences as set forth in Table 1 and / or any one of SEQ ID NOs: 1-617.

[0012] Also described herein are pharmaceutical compositions comprising the recombinant AAV particle as disclosed herein, methods of delivering a nucleotide of interest to a mammalian p75NTR-expressing cell using the recombinant AAV particle as disclosed herein, and methods of using the recombinant AAV particle as disclosed herein for, e.g., the manufacture of a medicament for, treating or preventing pain, itch, or a neurological disease or disorder in a subject in need thereof.

[0013] Further described herein are compositions comprising an AAV particle and a multispecific binding protein that binds to p75NTR. In some embodiments, the composition comprises (a) an AAV particle encapsulating a nucleotide of interest: and (b) a multispecific binding protein comprising: (i) a first antigen-binding domain that binds a mammalian p75 neurotrophin receptor (p75NTR), and (ii) a second antigen-binding domain that binds to one or more epitopes of an AAV capsid protein of the AAV particle. In some embodiments, the composition further comprises a pharmaceutically acceptable carrier or excipient.

[0014] Also described herein are methods of using the composition comprising an AAV particle and a multispecific binding protein that binds to p75NTR as described herein. In some embodiments, a method of delivering a nucleotide of interest to a mammalian p75NTR-expressing cell comprises contacting the mammalian p75NTR-expressing cell with the composition as described herein. In some embodiments, a method of treating or preventing pain, itch, or a neurological disease or disorder in a subject in need thereof comprises administering to the patient the composition disclosed herein, wherein the nucleotide of interest encodes a therapeutic protein, a suicide gene, an antibody or a fragment thereof, a CRISPR / Cas system or a portion(s) thereof, an antisense oligonucleotide, a ribozyme, an RNAi molecule, or a shRNA molecule. In some embodiments, provided herein is the use of the composition disclosed herein for, e.g., the manufacture of a medicament for, treating or preventing pain, itch, or a neurological disease or disorder, wherein the nucleotide of interest encodes a therapeutic protein, a suicide gene, an antibody or a fragment thereof, a CRISPR / Cas system or a portion(s) thereof, an antisense oligonucleotide, a ribozyme, an RNAi molecule, or a shRNA molecule. BRIEF DESCRIPTION OF THE DRAWINGS

[0015] Figures 1A-1B show WT AAV9 and AAV9-based retargeted virus infections delivering green fluorescent protein (GFP) to NIH 3T3 cell lines that are genetically modified to express mouse, cynomolgus or human P75NTR. Parental NIH 3T3 cells (3T3) or NIH 3T3 cells expressing human TrkA (3T3-hTrkA) alone were used as controls. (A) The scatter plots are obtained from use of flow cytometry to quantify green fluorescent protein (GFP) expression by parental NIH 3T3 cells or NIH 3T3 cells positive (+) for control target human TrkA expression after infection with WT AAV9 particles, detargeted AAV9 W503A particles, detargeted AAV9 W503A SpyTag particles conjugated to an antibody targeting Betvl . or detargeted AAV9 W503A SpyTag particles conjugated to different antibodies targeting P75NTR (blockers: REGN14152, REGN14155, REGN14177, and REGN14187; nonblockers: REGN19516, REGN19517, REGN19515, REGN19514, and REGN19513). Also shown are scatter plots obtained from flow cytometry evaluation of GFP expression by cells positive (+) for mouse p75NTR (3T3-m P75). cynomolgus p75NTR (3T3-mf P75) or human P75NTR (373.^ P75) af[er infection with WT AAV9 particles, detargeted AAV9 W503A particles, detargeted AAV9 W503A SpyTag conjugated to an antibody targeting BetVl, or detargeted AAV9 W503A AAV9 SpyTag conjugated to antibodies targeting anti-P75NTR. Viruses express GFP as a marker of transduction. (B) The graphs quantify the percentage (left) and mean fluorescence intensity (right) of GFP+ cells from the flow cytometry plots in Figure 1A.

[0016] Figure 2 displays GFP gene expression assessed by confocal imaging in whole dorsal root ganglia (DRG; cervical, thoracic and lumbar segments of wild type C57BL / 6J mice) three weeks after tail vein injection of 4E+11 vg / mouse of WT AAV9 (top), detargeted AAV9 W503A (middle), and detargeted AAV9 W503A conjugated to an example antibody targeting p75NTR (bottom). Scale bar. 500 pm.

[0017] Figure 3 displays quantification of GFP fluorescence in DRG of wild type C57BL / 6J mice three weeks after tail vein injection of 4E+11 vg / mouse of WT AAV9, detargeted AAV9 W503A. and detargeted AAV9 W503A conjugated to antibodies targeting p75NTR (blockers: REGN14152, REGN14155, REGN14177, and REGN14187; non-blockers: REGN19516, REGN19517, REGN19515, REGN19514, and REGN19513). (A) The percentage of pixels in the DRG that are GFP positive are shown. (B) Mean GFP intensity' measured as the average pixel value of all pixels in the DRG above an intensity threshold specific to GFP injected tissue.

[0018] Figure 4 shows confocal imaging of the whole liver to evaluate AAV-driven GFP expression following tail vein, intravenous delivery of (A) WT AAV9, (B) detargeted AAV9 W503A, and (C) detargeted AAV9 W503A conjugated to an example antibody targeting p75NTR. (D) The graph shows quantification of mean GFP fluorescence pixel intensity of whole images of the liver for WT AAV9, detargeted AAV9 W503A. and detargeted AAV9 W503A conjugated to antibodies targeting p75NTR (blockers: REGN14152, REGN14155, REGN14177, and REGN14187; non-blockers: REGN19516, REGN19517, REGN19515, REGN19514, and REGN19513). Scale bar, 500 pm.

[0019] Figure 5 shows GFP expression in DRG three weeks after tail vein intravenous administration of AAVs at varying doses in wildtype C57BL / 6J mice. Lumbar DRG at LI and L4 are shown as representative examples of all DRG for: (A)-(C) WT AAV9 injected intravenously at (A) 2.5E+10 vg, (B) 1E+11 vg, and (C) 4E+11 vg; (D)-(F) detargeted AAV9 W503A injected at (D) 2.5E+10 vg, (E) 1E+11 vg, and (F) 4E+11 vg; and (G)-(I) detargeted AAV9 W503A conjugated to antibodies targeting p75NTRinjected intravenously at (G) 2.5E+10 vg, (H) 1E+11 vg, and (I) 4E+11 vg. Scale bar, 500 pm.

[0020] Figure 6 shows the GFP intensity in individual DRG neurons in tissue collected from C57BL / 6J mice three w eeks follow ing intravenous injection of AAV. DRGs were cryosectioned and labeled with anti-TUBB3 to identify individual neurons. Using a mask to outline the area of individual neurons in DRG, the GFP fluorescence intensity was measured per cell for three doses of AAV (2.5E+10 vg, 1E+11 vg, and 4E+11 vg) and three formats of AAV injected (WT AAV9, detargeted AAV9 W503A, or detargeted AAV9 W503A conjugated to an example antibody targeting p75NTR).

[0021] Figures 7A-7C show immunohistochemistry (IHC) staining for eGFP expression in the (A)-(B) spinal cord and DRG, and (C) liver, heart, and kidney of WT C57BL / 6J mice following injection of 4E+11 vg / mouse of wildtype AAV9, detargeted AAV9 W503A or detargeted AAV9 W503A conjugated to an example antibody targeting p75NTR i?igure 7 a depicts representative images of eGFP IHC at lower magnification for sections of spinal cord and DRG, while Figure 7B depicts representative eGFP IHC at higher magnification of coronal sections of planes featuring DRG. Naive indicates DRG harvest from mice that were no injected with AAV as a control for background signal. Figure 7C shows immunohistochemistry staining for eGFP expression in the liver, heart, and kidney of WT C57BL / 6J mice following intravenous injection of 4E+11 vg / mouse of AAV9, detargeted AAV9 W503A or detargeted AAV9 W503A conjugated to an example antibody targeting p75NTR.

[0022] Figure 8 shows fluorescent images of AAV-driven GFP expression in (A) trigeminal ganglion, (B) DRG. (C) kidney, (D) liver, and (E) colon following unilateral, subcutaneous injection of 2.5E+10 vg of WT AAV9, detargeted AAV9 W503A, or detargeted AAV9 W503A conjugated to an example antibody targeting p75NTR in the mouse whisker pad. Scale bars, 500 pm.

[0023] Figure 9 shows fluorescent images of AAV-driven GFP expression in in trigeminal ganglion and DRG following unilateral, intra-synovial injection of 5E+10 vg of WT AAV9 (top), detargeted AAV9 W503A (middle), or detargeted AAV9 W503A particles conjugated to any example antibody targeting p75NTR (bottom) into C57BL / 6J mouse knee. Scale bar, 500 pm.

[0024] Figure 10 displays quantification of GFP fluorescent area in DRG of wild ty pe C57BL / 6J mice three weeks after injection of (A) 5E+10 vg into the synovial space in the knee or (B) varying doses via tail intravenous vein injection of WT AAV9, detargeted AAV9 W503A, and detargeted AAV9 W503A conjugated to an example antibody targeting P75NTR j-fog percentage of pixels that are labeled as GFP positive due to being above a fluorescence threshold are measured in maximum projection images of confocal Z stacks of whole DRG.

[0025] Figure 11 demonstrates that delivery of detargeted AAV9 W503A particles conjugated to an exemplified antibody targeting p75NTR and encapsulating a nucleic acid molecule expressing guide RNAs targeting mouse Navi.7 to the masseter muscle significantly reduces mechanical pain induced by Complete Freud’s Adjuvant (CFA). Mice genetically modified to express Cas9 were injected with detargeted AAV9 W503A conjugated to a representative antibody targeting p75NTR and encapsulating a nucleic acid molecule expressing guide RNAs targeting either mouse Navi.7 (7.48 x 109 vg, n=8) or mouse transthyretin (TTR) (1.44 x 1012 vg, n=7) into the masseter muscle. Three weeks after AAV injections, CFA was injected into the masseter muscle to induce inflammation and hypersensitivity to mechanical stimulus.

[0026] Figure 12 shows that anti-p75NTR antibody is internalized in ex vivo dorsal root ganglion (DRG) tissue. Live, time-lapse confocal imaging of DRGs grown ex vivo. Alexa 647 conjugated antibodies were applied at t=0, maximum projections of 3 confocal optical slices 10 pm apart are shown. Axons are labeled within 5 minutes of addition of fluorescently conjugated anti-p75NTR antibody to the culture media. Internalization into neuronal cell bodies is seen 1-4 hours post antibody addition.

[0027] Figures 13A-13B show that anti-p75NTR antibody is internalized in ex vivo DRG tissue. Live, time-lapse confocal imaging of DRGs grown ex vivo. Alexa 647 conjugated antibodies were applied at t=0, maximum projections of 3 confocal optical slices 10 pm apart are shown. Axons are labeled within 5 minutes of addition of fluorescently conjugated anti-p75NTR antibody to the culture media. Internalization into neuronal cell bodies is seen 1 -4 hours post antibody addition.

[0028] Figures 14A-14F show' that anti-p75NTR antibody internalizes in DRGs following intraplantar injection. Maximum projection of confocal Z stack images of whole DRGs harvested 5 days post injection of fluorescently conjugated antibody into the hind foot pad. Figures 14A-14C depict representative images showing lumbar DRG ipsilateral to intraplantar injection of anti-Fel DI (Figure 14A), or anti-p75NTR antibody, REGN14155 (Figure 14B), or anti-p75NTR antibody, REGN14187 (Figure 14C). Figures 14D-14F depict representative images showing Lumbar DRG contralateral to intraplantar injection of anti-Fel DI (Figure 14D), or anti-p75NTR antibody, REGN14155 (Figure 14E), or anti-p75NTR antibody, REGN14187 (Figure 14F). CT-B labels DRG neurons on the ipsilateral side of injection (Figures 14A-14C), but not the contralateral side (Figures 14D-14F). Anti-p75NTR antibody shows uptake in DRGs on both sides. CT-B, Cholera Toxin subunit B - Alexa 488.

[0029] Figures 15A-15C show that anti-p75NTR antibody internalizes in trigeminal ganglion (TG) following intraplantar injection. Maximum projection of confocal Z stack images of whole trigeminal ganglia harvested 5 days post injection of fluorescently conjugated antibody into the hind foot pad. Transmitted light and fluorescent image of trigeminal ganglion from: intraplantar injection of anti-Fei DI (Figure 15A): intraplantar injection of anti-p75NTR antibody, REGN14155 (Figure 15B); intraplantar injection of anti-p7$NTR anybody, REGN14187 (Figure 15C).

[0030] Figures 16A-16F show that anti-p75NTR antibody internalizes in DRGs and TG following intramuscular injection. Maximum projection of confocal Z stack images of whole DRGs harvested 5 days post injection of fluorescently conjugated antibody into the gastrocnemius muscle. Figure 16A depicts lumbar DRG ipsilateral to intramuscular injection of anti-Fel D antibody. Figure 16B depicts lumbar DRG ipsilateral to intramuscular injection of anti-p75NTR antibody, REGN14187. Figure 16C depicts lumbar DRG contralateral to intramuscular injection of anti-Fel DI antibody. Figure 16D depicts lumbar DRG contralateral to intramuscular injection of anti-p75NTR REGN14187. Figure 16E depicts trigeminal ganglia from mouse injected with anti-Fel DI antibody in gastrocnemius muscle. Figure 16F depicts trigeminal ganglia from mouse injected with anti-p75NTR antibody, REGN14187, in gastrocnemius muscle. CT-B labels DRG neurons on the ipsilateral side of injection (Figures 16A-16B), but not the contralateral side (Figures 16C-16D) or TG (Figures 16E-16F). Anti-p75NTR antibody shows uptake in DRGs on both sides and uptake in trigeminal ganglion. CT-B, Cholera Toxin subunit B - Alexa 488.

[0031] Figure 17 shows that anti-p75NTR antibody internalizes in all lumbar DRGs 3 days following subcutaneous injection. Fluorescent anti-p75NTR antibody is detected in all lumbar DRGs 3 days post subcutaneous injection of 0.5 mg / kg fluorescently tagged antibody. Alexa Fluor 647 (A647) fluorescent image of lumbar DRGs overlayed onto transmitted light image of DRG is shown.

[0032] Figures 18A-18B show that anti-p75NTR antibody internalizes in DRG neurons 3 days following subcutaneous injection. 20X confocal single slice images with 1.5x zoom allow visualization of intracellular distribution of fluorescently tagged anti-p75NTR antibiody, REGN14187, in DRG neurons. Punctate, intracellular anti-p75NTR antibody is detected in neurons.

[0033] Figures 19A-19C show that anti-p75NTR antibody internalizes in DRG neurons that express the marker of peripheral neurons, peripherin. Widefield, fluorescent images of DRG sections from mice that were injected with subcutaneously anti-p75NTR antibody. REGN14187, then stained with anti-peripherin to identify neurons.

[0034] Figures 20A-20N show that anti-p75NTR antibody internalizes in DRGs, TG, colon, eye and sympathetic ganglia 5 days following subcutaneous injection. Fluorescent anti-p75NTR antibody is detected in TG (Figure 20B), cervical DRG (Figure 20D), thoracic DRG (Figure 20E) and lumbar DRGs (Figure 20F) 5 days post subcutaneous injection of 0.7 mg / kg fluorescently tagged antibody. A647 fluorescent image of TG and DRGs overlayed onto transmitted light image of DRG is shown in Figures 20A-20F. Fluorescent anti-p75NTR antibody is detected in colon (Figure 20H). Higher magnification image of colon tissue shows that fluorescent anti-p75NTR antibody internalizes in cells in the myenteric plexus (Figure 201). Fluorescent anti-p75NTR antibody is detected in the eye (Figure 20K). A647 fluorescent confocal image of colon or eye tissue is shown in Figures 20G-20K. Fluorescent anti-p75NTR antibody is detected in sympathetic ganglia (Figure 20M). A647 fluorescent widefield image of ventral side of the thoracic spinal cord and is shown in Figures 20L-20M. In all tissue, subcutaneous injection of fluorescent anti-Fel DI does not show fluorescent signal (Figures 20A, 20C, 20G, 20J, and 20L). Co-labeling with neuron and glial markers in DRG confirmed that anti-p75NTR antibodies internalized in DRG neurons and not surrounding satellite glia (Figure 20N).

[0035] Figures 21A-21F show that that anti-p75NTR antibody has undetectable presence in cerebellum (Figure 21A). hippocampus (Figure 21B), liver (Figure 21C) and spinal cord (Figure 21F) following subcutaneous injection. Low detection of anti-p75NTR antibody is detected in choroid plexus (Figure 21B), kidney (Figure 21C) and heart (Figure 21E) following subcutaneous injection. Confocal images of DAPI and A647 channels are shown.

[0036] Figures 22A-22D show that anti-p75NTR antibody is detected in choroid plexus following subcutaneous injection. 10X confocal images of sagittal brain sections show anti-p75NTR antibody observed in choroid plexus (arrows) 5 days following subcutaneous injection, with little or no detection in other regions of the brain.

[0037] Figures 23A-23D show that low levels of anti-p75NTR antibodies are detected in the brain following ICV injection. Fluorescent, 5x confocal images of sagittal brain sections demonstrate low accumulation of anti-p75NTR specific labeling in ventral and cortical regions (Figure 23D). Both anti-Fel DI (Figure 23B) and anti-p75NTR antibodies (Figure 23D) show accumulation in the ventricle, the site of injection.

[0038] Figures 24A-24H shows that internalization of fluorescent anti-p75NTR antibody of the disclosure into neurons was observed following intravenous injection of REGN19516 in the trigeminal ganglia (Figure 15D) and DRG (Figure 24H). Intravenous injection of fluorescent isotype control antibody, REGN1945, did not demonstrate labeling in TG or DRGs (Figures 24B, 24F). DETAILED DESCRIPTION

[0039] Dorsal Root Ganglions (DRG) and Trigeminal Ganglions (TG) in the peripheral nervous system play a crucial role in pain transmission since they contain the cell bodies of first order pain neurons that underlie nociception. As key drivers of chronic pain states, DRG and TG neurons are target cells for pain therapeutics. In addition, due to their high level of vascularization, DRG and TG are particularly amenable to systemic delivery of therapeutics, which include naked nucleic acids, lipid nanoparticles, sh / siRNAs, or viral vectors. Among those possible therapeutic vehicles, retargeted AAV constitute a particularly promising approach to deliver pain therapeutics specifically to DRG and TG sensory neurons, while reducing off-target effects and toxicity in other tissues such as the central nervous system, liver, pulmonary and cardiac systems.

[0040] To enhance delivery of therapeutic payloads to specific, e.g., nervous system, tissues and mitigate off-target effects, described herein are viral particles, e.g., AAV viral particles, that target p75NTR.

[0041] Neurotrophins regulate development, maintenance, and function of vertebrate nervous systems. Neurotrophins activate two different classes of receptors, the Trk family of receptor tyrosine kinases and p75KTR, a member of the tumor necrosis factor (INF) receptor superfamily. p75NTR (also known as nerve grow th factor receptor) binds with approximately equal affinity to each of the four identified mammalian neurotrophins: nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), neurotrophin-3 (NT-3), and neurotrophin-4 (NT-4).

[0042] The multifunctional neurotrophin receptor p75NTR is expressed by DRG and TG. Indeed, the strong potential of p75NTR as surface antigen of choice for antibody-mediated retargeting of AAV to DRG and TG sensory neurons has been demonstrated by internal biodistribution studies using fluo-labeled anti-p75NTR monoclonal antibodies that showed robust binding in those tissues in vivo, while displaying minimal binding in the CNS or peripheral organs, after intraplantar, intramuscular, or subcutaneous injection.

[0043] Described herein are p75NTR-retargeted AAV, generated by conjugating a diverse panel of anti-p75NTR monoclonal antibodies to liver-detargeted AAV9 capsid variants through a SpyTag-SpyCatcher conjugation system. All of the anti-p75NTR antibodies were first shown to have robust binding in vitro to cell lines overexpressing mouse, non-human primate, or human p75NTR proteins. In addition, all the liver-detargeted AAV9 conjugated to the anti-p75NTR antibodies show strong and specific transduction of the p75NTR-expressing cell lines, validating the capacity of the p75NTR-retargeed AAV to target efficiently p75NTR in vitro. In vivo, using the measurement of a reporter viral transgene expression level as readout, some p75NTR-retargeted AAV showed enhanced transduction of DRG neurons after intravenous delivery at a fixed dose of 4E+11 vg / mouse in comparison to wild type AAV9.

[0044] The gene encoding human p75NTR (NGFR) is located on the long arm of chromosome 17, comprises 6 coding exons and is approximately 19,716 nucleotides in length. An exemplary human NGFR CDS DNA sequence is assigned NCBI Version Number NM_002507.3 (SEQ ID NO: 618) and an exemplary7 human p75NTR (NGFR) amino acid sequence is assigned NCBI Version Number NP_002498.1 (SEQ ID NO: 619). The gene encoding mouse p75NTR (Ngfr) is located on chromosome 11. comprises 6 coding exons, and is 18,918 nucleotides in length. An exemplary mouse Ngfr CDS DNA sequence is assigned NCBI Version Number NM_033217.3 (SEQ ID NO: 620) and an exemplary mouse p75NTR (Ngfr) amino acid sequence is assigned NCBI Version Number NP_150086.2 (SEQ ID NO: 621).

[0045] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.

[0046] Singular forms “a”, “an”, and “the” include plural references unless the context clearly dictates otherwise. Thus, for example, a reference to “a method” includes one or more methods, and / or steps of the type described herein and / or which will become apparent to those persons skilled in the art upon reading this disclosure.

[0047] The "percent (%) identity" or the like may be readily determined for amino acid or nucleotide sequences, over the full-length of a protein, or a portion thereof. A portion may be at least about 5 amino acids or 24 nucleotides, respectively, in length, and may be up to about 700 amino acids or 2100 nucleotides, respectively. Generally, when referring to "identity", "homology ", or "similarity " between two different adeno-associated viruses, "identity", "homology" or "similarity’" is determined in reference to "aligned" sequences. "Aligned" sequences or "alignments" refer to multiple nucleic acid sequences or protein (amino acids) sequences, often containing corrections for missing or additional bases or amino acids as compared to a reference sequence.

[0048] Alignments may be performed using any of a variety' of publicly or commercially available Multiple Sequence Alignment Programs. Sequence alignment programs are available for amino acid sequences, e.g., the "Clustal X", "MAP", "PIMA", "MSA", "BLOCKMAKER", "MEME", and "Match-Box" programs. Generally, any of these programs are used at default settings, although one of skill in the art can alter these settings as needed. Alternatively, one of skill in the art can utilize another algorithm or computer program which provides at least the level of identity or alignment as that provided by the referenced algorithms and programs. See, e.g., J. D. Thomson et al, Nucl. Acids. Res., "A comprehensive comparison of multiple sequence alignments", 27(13):2682-2690 (1999).

[0049] Multiple sequence alignment programs are also available for nucleic acid sequences. Examples of such programs include. "Clustal W". "CAP Sequence Assembly". "MAP", and "MEME", which are accessible through Web Servers on the internet. Other sources for such programs are known to those of skill in the art. Alternatively, Vector NTI utilities are also used. There are also a number of algorithms known in the art that can be used to measure nucleotide sequence identity, including those contained in the programs described above. As another example, polynucleotide sequences can be compared using FASTA™, a program in GCG Version 6.1. Fasta™ provides alignments and percent sequence identity of the regions of the best overlap between the query and search sequences. For instance, percent sequence identity between nucleic acid sequences can be determined using FASTA™ with its default parameters (a word size of 6 and the NOPAM factor for the scoring matrix) as provided in GCG Version 6.1, herein incorporated by reference.

[0050] “Significant identity’’ encompasses amino acid or nucleic acid sequences alignments that are at least 90%, e.g., at least 93%, e.g., at least 95%, e.g., at least 96%, e.g., at least 97%, e.g., at least 98%, e.g., at least 99%, or e.g., at least 100% identical.

[0051] The term “chimeric” encompasses a functional gene or polypeptide comprising nucleic acid sequences or amino acid sequences, respectively, from at least two different AAV serotype, e.g., portions of a gene or polypeptide of at least a first and second AAV, wherein the at least first and second portions are operably linked to form a functional chimeric AAV nucleic acid that encodes a functional amino acid. Unless specified as chimeric, nucleotide sequences, genes, polypeptides, and amino acids are considered nonchimeric in that the nucleotide sequences, genes, polypeptides, and amino acids comprise a nucleic acid sequence or amino acid sequence having significant identity to a nucleic acid sequence or amino acid sequence, respectively, of a single AAV serotype.

[0052] The term "antibody” includes immunoglobulin molecules comprising four polypeptide chains, two heavy (H) chains and two light (L) chains inter-connected by disulfide bonds. Each heavy chain comprises a heavy chain variable domain (Vh) and a heavy chain constant region (Ch). The heavy chain constant region comprises at least three domains, ChI, Ch2, Ch3 and optionally CH4. Each light chain comprises a light chain variable domain (Ch) and a light chain constant region (Cl). The heavy chain and light chain variable domains can be further subdivided into regions of hypervariability , termed complementarity determining regions (CDR), interspersed with regions that are more conserved, termed framework regions (FR). Each heavy and light chain variable domain comprises three CDRs and four FRs, arranged from amino-terminus to carboxy-terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4 (heavy chain CDRs may be abbreviated as HCDR1, HCDR2 and HCDR3; light chain CDRs may be abbreviated as LCDR1, LCDR2 and LCDR3. Typical tetrameric antibody structures comprise two identical antigen-binding domains, each of which formed by association of the Vh and Vl domains, and each of which together with respective Ch and Cl domains form the antibody Fv region. Single domain antibodies comprise a single antigen-binding domain, e.g., a Vh or a Vl. The antigen-binding domain of an antibody, e.g., the part of an antibody that recognizes and binds to the first member of a specific binding pair of an antigen, is also referred to as a “paratope / ’ It is a small region (of 5 to 10 amino acids) of an antibody's Fv region, part of the fragment antigen-binding (Fab region), and may contain parts of the antibody's heavy and / or light chains. A paratope specifically binds a first member of a specific binding pair when the paratope binds the first member of a specific binding pair with a high affinity. The term “high affinity” antibody refers to an antibody that has a Kd with respect to its target first member of a specific binding pair about of 10'9 M or lower (e.g., about 1 x 10'9 M, 1 x 10'10 M, 1 x 10-11 M, or about 1 x 10'12 M). In one embodiment, Kd is measured by surface plasmon resonance, e.g., BIACORE™; in another embodiment, Kd is measured by ELISA.

[0053] The phrase “complementarity determining region.” or the term “CDR,” includes an amino acid sequence encoded by a nucleic acid sequence of an organism’s immunoglobulin genes that normally (i.e., in a wild-type animal) appears between two framework regions in a variable region of a light or a heavy chain of an immunoglobulin molecule (e.g.. an antibody or a T cell receptor). A CDR can be encoded by. for example, a germ line sequence or a rearranged or unrearranged sequence, and, for example, by a naive or a mature B cell or a T cell. A CDR can be somatically mutated (e.g., vary from a sequence encoded in an animal’s germ line), humanized, and / or modified with amino acid substitutions, additions, or deletions. In some circumstances (e.g., for a CDR3), CDRs can be encoded by two or more sequences (e.g., germ line sequences) that are not contiguous (e.g., in an unrearranged nucleic acid sequence) but are contiguous in a B cell nucleic acid sequence, e.g., as the result of splicing or connecting the sequences (e.g., V-D-J recombination to form a heavy chain CDR3).

[0054] The phrase “light chain” includes an immunoglobulin light chain sequence from any organism, and unless otherwise specified includes human k and X light chains and a VpreB, as well as surrogate light chains. Light chain variable domains typically include three light chain CDRs and four framework (FR) regions, unless otherwise specified. Generally, a full-length light chain includes, from amino terminus to carboxyl terminus, a variable domain that includes FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4, and a light chain constant region. A light chain variable domain is encoded by a light chain variable region gene sequence, which generally comprises Vl and Jl segments, derived from a repertoire of V and J segments present in the germ line. Sequences, locations and nomenclature for V and J light chain segments for various organisms can be found in IMGT database, www.imgt.org. Light chains include those, e g., that do not selectively bind either a first or a second first member of a specific binding pair selectively bound by the first member of a specific binding pairbinding protein in which they appear. Light chains also include those that bind and recognize, or assist the heavy chain or another light chain with binding and recognizing, one or more first member of a specific binding pairs selectively bound by the first member of a specific binding pair-binding protein in which they appear. Common or universal light chains include those derived from a human Vk1-39Jk gene or a human Vk3-20Jk gene, and include somatically mutated (e.g., affinity matured) versions of the same. Exemplary human Vl segments include a human Vk1-39 gene segment, a human Vk3-20 gene segment, a human VL I -40 gene segment, a human VL 1 -44 gene segment, a human VX2-8 gene segment, a human VX2-14 gene segment, and human VL3-2I gene segment, and include somatically mutated (e.g., affinity matured) versions of the same. Light chains can be made that comprise a variable domain from one organism (e.g., human or rodent, e.g., rat or mouse; or bird, e.g., chicken) and a constant region from the same or a different organism (e.g.. human or rodent, e.g., rat or mouse; or bird, e.g., chicken).

[0055] The term '‘about” or ‘'approximately” includes being within a statistically meaningful range of a value. Such a range can be within an order of magnitude, preferably within 50%, more preferably within 20%, still more preferably within 10%, and even more preferably within 5% of a given value or range. The allowable variation encompassed by the term '‘about” or ‘'approximately” depends on the particular system under study, and can be readily appreciated by one of ordinary skill in the art.

[0056] The phrase “heavy chain,” or “immunoglobulin heavy chain” includes an immunoglobulin heavy chain sequence, including immunoglobulin heavy chain constant region sequence, from any organism. Heavy chain variable domains include three heavy chain CDRs and four FR regions, unless otherwise specified. Fragments of heavy' chains include CDRs, CDRs and FRs, and combinations thereof. A typical heavy chain has, following the variable domain (from N-terminal to C-terminal), a Cnl domain, a hinge, a Ch2 domain, and a Ch3 domain. A functional fragment of a heavy chain includes a fragment that is capable of specifically recognizing an first member of a specific binding pair (e.g, recognizing the first member of a specific binding pair with a Kd in the micromolar, nanomolar, or picomolar range), that is capable of expressing and secreting from a cell, and that comprises at least one CDR. Heavy chain variable domains are encoded by variable region nucleotide sequence, which generally comprises Vh, Dh, and Jh segments derived from a repertoire of Vh, Dh, and Jh segments present in the germline. Sequences, locations and nomenclature for V, D, and J heavy chain segments for various organisms can be found in IMGT database, which is accessible via the internet on the world wide web (www) at the URL “imgt.org.”

[0057] The term "heavy chain only antibody," "heavy chain only antigen binding protein," "single domain antigen binding protein," "single domain binding protein" or the like refers to a monomeric or homodimeric immunoglobulin molecule comprising an immunoglobulin-like chain comprising a variable domain operably linked to a heavy chain constant region, that is unable to associate with a light chain because the heavy chain constant region typically lacks a functional ChI domain. Accordingly, the term "heavy chain only antibody." "heavy chain only antigen binding protein." "single domain antigen binding protein," "single domain binding protein" or the like encompasses a both (i) a monomeric single domain antigen binding protein comprising one of the immunoglobulin-like chain comprising a variable domain operably linked to a heavy chain constant region lacking a functional ChI domain, or (ii) a homodimeric single domain antigen binding protein comprising two immunoglobulin-like chains, each of which comprising a variable domain operably linked to a heavy chain constant region lacking a functional ChI domain. In various aspects, a homodimeric single domain antigen binding protein comprises two identical immunoglobulin-like chains, each of which comprising an identical variable domain operably linked to an identical heavy chain constant region lacking afunctional ChI domain. Additionally, each immunoglobulin-like chain of a single domain antigen binding protein comprises a variable domain, which may be derived from heavy chain variable region gene segments (e.g., Vh, Dh, Jh), light chain gene segments (e.g., Vl, Jl), or a combination thereof, linked to a heavy chain constant region (Ch) gene sequence comprising a deletion or inactivating mutation in a Cnl encoding sequence (and, optionally, a hinge region) of a heavy chain constant region gene, e.g., IgG, IgA, IgE, IgD, or a combination thereof. A single domain antigen binding protein comprising a variable domain derived from heavy chain gene segments may be referred to as a "Vh-single domain antibody" or "Vn-single domain antigen binding protein”, see, e.g.. U.S. Patent No. 8,754.287; U.S. Patent Publication Nos. 20140289876; 20150197553; 20150197554; 20150197555; 20150196015; 20150197556 and 20150197557, each of which is incorporated in its entirety7 by reference. A single domain antigen binding protein comprising a variable domain derived from light chain gene segments may be referred to as a or "Vt-single domain antigen binding protein," see, e.g., U.S. Publication No. 20150289489, incorporated in its entirety by reference.

[0058] The phrase '‘light chain” includes an immunoglobulin light chain sequence from any organism, and unless otherwise specified includes human kappa (k) and lambda ( / .) light chains and a VpreB, as well as surrogate light chains. Light chain variable domains ty pically include three light chain CDRs and four framework (FR) regions, unless otherwise specified. Generally, a full-length light chain includes, from amino terminus to carboxyl terminus, a variable domain that includes FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4, and a light chain constant region amino acid sequence. Light chain variable domains are encoded by the light chain variable region nucleotide sequence, which generally comprises light chain Vl and light chain Jl gene segments, derived from a repertoire of light chain V and J gene segments present in the germline. Sequences, locations and nomenclature for light chain V and J gene segments for various organisms can be found in IMGT database, which is accessible via the internet on the world wide web (www) at the URL “imgt.org.” Light chains include those, e.g., that do not selectively bind either a first or a second first member of a specific binding pair selectively bound by the first member of a specific binding pair-binding protein in which they appear. Light chains also include those that bind and recognize, or assist the heavy chain with binding and recognizing, one or more first member of a specific binding pairs selectively bound by the first member of a specific binding pair-binding protein in yvhich they appear. Light chains also include those that bind and recognize, or assist the heavy chain with binding and recognizing, one or more first member of a specific binding pairs selectively bound by the first member of a specific binding pair-binding protein in which they appear. Common or universal light chains include those derived from a human Vk1-39Jk5 gene or a human Vk3-20Jk1 gene, and include somatically mutated (e.g., affinity matured) versions of the same.

[0059] The phrase "operably linked", as used herein, includes a physical juxtaposition (e.g., in three-dimensional space) of components or elements that interact, directly or indirectly with one another, or otherwise coordinate with each other to participate in a biological event, which juxtaposition achieves or permits such interaction and / or coordination. To give but one example, a regulatory' element (e.g., an expression control sequence) in a nucleic acid is said to be "operably linked" to a coding sequence when it is located relative to the coding sequence such that its presence or absence impacts expression and / or activity of the coding sequence. In many embodiments, “operable linkage” involves covalent linkage of relevant components or elements with one another. Those skilled in the art will readily appreciate that, in some embodiments, covalent linkage is not required to achieve effective operable linkage. For example, proteins operably linked together may be associated with each other, e.g., via a covalent bond or a non-covalent bond. As a nonlimiting example, a capsid protein as described herein may be operably linked to a targeting ligand, where the capsid protein is non-covalently bound to the targeting ligand, or covalently bound to the targeting ligand, optionally with or without a scaffold and / or adaptor between the capsid protein and the targeting ligand. As another example, in some embodiments, nucleic acid regulatory7 elements that are operably linked with coding sequences that they control are contiguous with the nucleotide of interest. Alternatively or additionally, in some embodiments, one or more such regulatory7 elements acts in trans or at a distance to control a coding sequence of interest. In some embodiments, the term "regulatory element" as used herein refers to polynucleotide sequences which are necessary and / or sufficient to affect the expression and processing of coding sequences to which they are ligated. In some embodiments, a regulatory element may be or comprise appropriate transcription initiation, termination, promoter and / or enhancer sequences; efficient RNA processing signals such as splicing and polyadenylation signals; sequences that stabilize cytoplasmic mRNA; sequences that enhance translation efficiency (e.g., Kozak consensus sequence); sequences that enhance protein stability7; and / or, in some embodiments, sequences that enhance protein secretion. In some embodiments, one or more regulatory elements are preferentially or exclusively active in a particular host cell or organism, or type thereof. To give but one example, in prokaryotes, regulatory elements may typically include promoter, ribosomal binding site, and transcription termination sequence; in eukaryotes, in many embodiments, regulatory elements may ty pically include promoters, enhancers, and / or transcription termination sequences. Those of ordinary skill in the art will appreciate from context that, in many embodiments, the term "regulatory elements" refers to components whose presence is essential for expression and processing, and in some embodiments includes components whose presence is advantageous for expression (including, for example, leader sequences, targeting sequences, and / or fusion partner sequences).

[0060] ’'Retargeting" or “redirecting” may include a scenario in which the wildtype particle targets several cells within a tissue and / or several organs within an organism, and general targeting of the tissue or organs is reduced or abolished by insertion of the heterologous amino acid, and retargeting to more a specific cell in the tissue or a specific organ in the organism is achieved with the targeting ligand (e g., via a targeting ligand) that binds a marker expressed by the specific cell. Such retargeting or redirecting may also include a scenario in which the wildtype particle targets a tissue, and targeting of the tissue is reduced to or abolished by insertion of the heterologous amino acid, and retargeting to a completely different tissue is achieved with the targeting ligand.

[0061] “Specific binding pair,” “binding pair,” “protein:protein binding pair” and the like includes two members (e.g., a first member (e.g., a first polypeptide) and a second cognate member (e.g., a second polypeptide)) that interact to form a bond (e.g., a non-covalent bond between a first member epitope and a second member antigen-binding portion of an antibody that recognizes the epitope; a covalent bond between e.g., proteins capable of forming isopeptide bonds; split inteins that recognize each other and, through the process of protein trans-splicing, mediate ligation of the flanking proteins and their own removal). In some embodiments, the term "cognate" refers to components that function together. Epitopes and cognate antibodies thereto, particularly epitopes that may also act as a detectable label (e.g.. c-myc) are well-known in the art. Specific protein:protein binding pairs capable of interacting to form a covalent isopeptide bond are reviewed in Veggiani et al. (2014) Trends BiotechnoL 32:506, and include peptide:peptide binding pairs such as SpyTag:SpyCatcher, SpyTag002:SpyCatcher002; SpyTag:KTag; isopeptag:pilin C, SnoopTag:SnoopCatcher, etc., and variants thereof, e.g., SpyTag003:SpyCatcher003. Generally, a first member of a protein:protein binding pair refers to member of a protein:protein binding pair, which is generally less than 30 amino acids in length, and which forms a spontaneous covalent isopeptide bond with the second cognate protein, wherein the second cognate protein is generally larger, but may also be less than 30 amino acids in length such as in the SpyTag:KTag system.

[0062] The term "isopeptide bond" refers to an amide bond between a carboxyl or carboxamide group and an amino group at least one of which is not derived from a protein main chain or alternatively viewed is not part of the protein backbone. An isopeptide bond may form within a single protein or may occur between two peptides or a peptide and a protein. Thus, an isopeptide bond may form intramolecularly within a single protein or intermolecularly i.e., between two peptide / protein molecules, e.g. between two peptide linkers. Typically, an isopeptide bond may occur between a lysine residue and an asparagine, aspartic acid, glutamine, or glutamic acid residue or the terminal carboxyl group of the protein or peptide chain or may occur between the alpha-amino terminus of the protein or peptide chain and an asparagine, aspartic acid, glutamine or glutamic acid. Each residue of the pair involved in the isopeptide bond is referred to herein as a reactive residue. In preferred embodiments of the invention, an isopeptide bond may form between a lysine residue and an asparagine residue or between a lysine residue and an aspartic acid residue. Particularly, isopeptide bonds can occur between the side chain amine of lysine and carboxamide group of asparagine or carboxyl group of an aspartate.

[0063] The SpyTag: SpyCatcher system is described in U.S. Patent No. 9,547,003 and Zaveri et al. (2012) PNAS 109:E690-E697, each of which is incorporated herein in its entirety by reference, and is derived from the CnaB2 domain of the Streptococcus pyogenes fibronecting-binding protein FbaB. By splitting the domain, Zakeri et al. obtained a peptide “SpyTag” having the sequence AHIVMVDAYKPTK (SEQ ID NO: 622) which forms an amide bond to its cognate protein “SpyCatcher,” an 112 amino acid polypeptide having the amino acid sequence set forth in SEQ ID NO: 623. (Zakeri (2012), supra). An additional specific binding pair derived from CnaB2 domain is SpyTag:KTag, which forms an isopeptide bond in the presence of SpyLigase (SEQ ID NO: 632). (Fierer (2014) PNAS 111:E1176-1181) SpyLigase was engineered by excising the P strand from SpyCatcher that contains a reactive lysine, resulting in KTag, 10-residue first member of a protein:protein binding pair having the amino acid sequence ATHIKFSKRD (SEQ ID NO: 624). The SpyTag002:SpyCatcher002 system is described in Keeble et al (2017) Angew Chem Int Ed Engl 56:16521-25, incorporated herein in its entirety7 by reference. SpyTag002 has the amino acid sequence VPTIVMVDAYKRYK, set forth as SEQ ID NO: 626, and binds SpyCatcher002 (SEQ ID NO: 627). SpyTagOO3 has the amino acid sequence RGVPHIVMVDAYKRYK, set forth as SEQ ID NO: 628, and binds SpyCatcher003 (SEQ ID NO: 629).

[0064] The SnoopTag:SnoopCatcher system is described in Veggiani (2016) PNAS 113:1202-07. The D4 Ig-like domain of RrgA, an adhesion from Streptococcus pneumoniae, was split to form SnoopTag (residues 734-745; SEQ ID NO: 630) and SnoopCatcher (residues 749-860; SEQ ID NO: 631). Incubation of SnoopTag and SnoopCatcher results in a spontaneous isopeptide bond that is specific between the complementary proteins. Veggiani (2016)), supra.

[0065] The isopeptag:pilin-C specific binding pair was derived from the major pilin protein Spy0128 from Streptococcus pyogenes. (Zakeir and Howarth (2010).7 Am. Chem. Soc. 132:4526-27). Isopeptag has the amino acid sequence TDKDMTITFTNKKDAE, set forth as SEQ ID NO: 625, and binds pilin-C (residues 18-299 of Spy0128). Incubation of Isopeptag and pilin-C results in a spontaneous isopeptide bond that is specific between the complementary proteins. Zakeir and Howarth (2010), supra.

[0066] The term “detectable label” includes a polypeptide sequence that is a member of a specific binding pair, e.g., that specifically binds via a non-covalent bond with another polypeptide sequence, e.g., an antibody paratope, with high affinity. Exemplary and nonlimiting detectable labels include hexahistidine tag, FLAG tag, Strep II tag, streptavidin-binding peptide (SBP) tag, calmodulin-binding peptide (CBP), glutathione S-transferase (GST), maltose-binding protein (MBP), S-tag, HA tag, and the myc tag from c-myc (SEQ ID NO: 639). (Reviewed in Zhao et al. (2013) J. Analytical Meth. Chem. 1-8; incorporated herein by reference). A common detectable label for primate AAV is the Bl epitope (SEQ ID NO: 640). Some AAV capsid proteins described herein, which do not naturally comprise the Bl epitope, may be modified herein to comprise a Bl epitope. Generally, AAV capsid proteins described herein may comprise a sequence with substantial homology to the Bl epitope within the last 10 amino acids of the capsid protein. Accordingly, in some embodiments, a non-primate AAV capsid protein of the invention may be modified with one but less than five point mutations within the last 10 amino acids of the capsid protein such that the AAV capsid protein comprises a B1 epitope.

[0067] The term "target cells" includes any cells in which expression of a nucleotide of interest is desired. Preferably, target cells exhibit a receptor on their surface that allows the cell to be targeted with a targeting ligand, as described below.

[0068] The term "transduction" or “infection” or the like refers to the introduction of a nucleic acid into a target cell nucleus by a viral particle. The term efficiency in relation to transduction or the like, e.g.. “transduction efficiency” refers to the fraction (e.g.. percentage) of cells expressing a nucleotide of interest after incubation with a set number of viral particles comprising the nucleotide of interest. Well-know n methods of determining transduction efficiency include flow cytometry of cells transduced with a fluorescent reporter gene, RT-PCR for expression of the nucleotide of interest, etc.

[0069] Generally, “reference” viral capsid protein / capsid / particle are identical to test viral capsid protein / capsid / particle but for the change for which the effect is to be tested. For example, to determine the effect, e.g., on transduction efficiency, of inserting a first member of a specific binding pair into a test viral particle, the transduction efficiencies of the test viral particle (in the absence or presence of an appropriate targeting ligand) can be compared to the transduction efficiencies of a reference viral particle (in the absence or presence of an appropriate targeting ligand if necessary ) which is identical to the test viral particle in every instance (e.g., additional point mutations, nucleotide of interest, numbers of viral particles and target cells, etc.) except for the presence of a first member of a specific binding pair. In some embodiments, a reference viral capsid protein is one that is able to form a capsid with a second viral capsid protein modified to comprise at least a first member of a protein:protein binding pair, where the reference viral capsid protein does not comprise the first member of a protein:protein binding pair, preferably wherein the capsid formed by the reference viral capsid protein and the modified viral capsid protein is a mosaic capsid. Adeno-associatedviruses (AAV)

[0070] "AAV" is an abbreviation for adeno-associated virus and may be used to refer to the virus itself or derivatives thereof. AAVs are small, non-enveloped. single-stranded DNA viruses. Generally, a wildtype AAV genome is 4.7 kb and is characterized by two inverted terminal repeats (ITR) and two open reading frames (ORFs), rep and cap. The wildtype rep reading frame encodes four proteins of molecular weight 78 kD (“Rep78”), 68 kD (££Rep68”), 52 kD (“Rep52”) and 40 kD ("Rep 40'’). Rep78 and Rep68 are transcribed from the p5 promoter, and Rep52 and Rep40 are transcribed from the pl9 promoter. These proteins function mainly in regulating the transcription and replication of the AAV genome. The wildtype cap reading frame encodes three structural (capsid) viral proteins (VPs) having molecular weights of 83-85 kD (VP1), 72-73 kD (VP2) and 61-62 kD (VP3). More than 80% of total proteins in an AAV virion (capsid) comprise VP3; in mature virions VP1, VP2 and VP3 are found at relative abundance of approximately 1:1:10, although ratios of 1:1:8 have been reported. Padron et al. (2005) J. Virology 79:5047-58.

[0071] The genomic sequences of various seroty pes of AAV, as well as the sequences of the native inverted terminal repeats (ITRs), Rep proteins, and capsid subunits are known in the art. Such sequences may be found in the literature or in public databases such as GenBank. See, e g., GenBank Accession Numbers NC_002077 (AAV1), AF063497 (AAV1), NC001401 (AAV-2), AF043303 (AAV2), NC_001729 (AAV3), NC_001829 (AAV4), U89790 (AAV4), NC_006152 (AAV5), AF513851 (AAV7), AF513852 (AAV8), and NC 006261 (AAV8); the disclosures of which are incorporated by reference herein for teaching AAV nucleic acid and amino acid sequences. See also, e.g., Srivistava et al. (1983) J. Virology 45:555; Chiorini et al. (1998) J. Virology 71:6823; Chiorini et al. (1999) J. Virology 73: 1309: Bantel-Schaal et al. (1999) J. Virology 73:939; Xiao et al. (1999) J. Virology 73:3994; Muramatsu et al. (1996) Virology 221:208; Shade et al.,(1986) J. Virol. 58:921; Gao et al. (2002) Proc. Nat. Acad. Sci. USA 99: 11854; Mons et al. (2004) Virology 33:375-383; US Patent Publication 20170130245; international patent publications WO 00 / 28061, WO 99 / 61601, WO 98 / 11244; and U.S. Pat. No. 6,156,303, each of which is incorporated by reference in its entirety by reference. Table 2 herein provides sequences of various non-primate AAV.

[0072] ’‘AAV” encompasses all subtypes and both naturally occurring and modified forms that are well-known in the art. AAV includes primate AAV (e.g., AAV type 1 (AAV1), primate AAV type 2 (AAV2), primate AAV type 3 (AAV3B), primate AAV type 4 (AAV4), primate AAV type 5 (AAV5), primate AAV type 6 (AAV6), primate AAV type 7 (AAV7), primate AAV type 8 (AAV8), primate AAV type 9 (AAV9), AAV10, AAV11, AAV12, AAV13, AAVDJ, Anc80L65, AAV2G9, AAV-LK03, primate AAV type rhlO (AAV rhlO), AAV type hlO (AAV hlO), AAV type hul 1 (AAV hull), AAV type rh32.33 (AAV rh32.33), AAV retro (AAV retro), AAV PHP.B. AAV PHP eB, AAV PHP S, AAV2 / 8. etc., non-primate animal AAV (e.g., avian AAV (AAAV)) and other non-primate animal AAV such as mammalian AAV (e.g., bat AAV, sea lion AAV, bovine AAV, canine AAV, equine AAV, caprine AAV, and ovine AAV etc.), squamate AAV (e.g., snake AAV, bearded dragon AAV), etc. "Primate AAV" refers to AAV generally isolated from primates. Similarly, "non-primate animal AAV" refers to AAV isolated from non-primate animals.

[0073] As used herein, “of a [specified] AAV” in relation to a gene (e.g., rep, cap, etc.), capsid protein (e.g., a VP1 capsid protein, a VP2 capsid protein, a VP3 capsid protein, etc.), region of a capsid protein of a specified AAV (e.g., PLA2 region. VPl-u region, VP1 / VP2 common region, VP3 region), nucleotide sequence (e.g., ITR sequence), e.g., a cap gene or capsid protein of AAV etc., encompasses, in addition to the gene or the polypeptide respectively comprising a nucleic acid sequence or amino acid sequence set forth herein for the specified AAV, also variants of the gene or polypeptide, including variants comprising the least number of nucleotides or amino acids required to retain one or more biological functions. As used herein, a variant gene or a variant polypeptide comprises a nucleic acid sequence or amino acid sequence that differs from the nucleic acid sequence or amino acid sequence set forth herein for the gene or polypeptide of a specified AAV, wherein the difference(s) does not generally alter at least one biological function of the gene or polypeptide, and / or the phylogenetic characterization of the gene or polypeptide, e.g., where the difference(s) may be due to degeneracy of the genetic code, isolate variations, length of the sequence, etc. For example, rep gene and the cap gene as used here may encompass rep and cap genes that differ from the wildtype gene in that the genes may encode one or more Rep proteins and Cap proteins, respectively. In some embodiments, a Rep gene encodes at least Rep78 and / or Rep68. In some embodiments, cap gene includes those may differ from the wildtype in that one or more alternative start codons or sequences between one or more alternative start codons are removed such that the cap gene encodes only a single Cap protein, e.g., wherein the VP2 and / or VP3 start codons are removed or substituted such that the cap gene encodes a functional VP 1 capsid protein but not a VP2 capsid protein or a VP3 capsid protein. Accordingly, as used herein, a rep gene encompasses any sequence that encodes a functional Rep protein. A cap gene encompasses any sequence that encodes at least one functional cap gene.

[0074] It is well-known that the wildtype cap gene expresses all three VP1. VP2. and VP3 capsid proteins from a single open reading frame of the cap gene under control of the p40 promoter found in the rep ORF. The term "capsid protein,” ‘'Cap protein” and the like includes a protein that is part of the capsid of the virus. For adeno-associated viruses, the capsid proteins are generally referred to as VP1. VP2 and / or VP3, and may be encoded by the single cap gene. For AAV, the three AAV capsid proteins are produced in nature an overlapping fashion from the cap ORF alternative translational start codon usage, although all three proteins use a common stop codon. The ORF of a wildtype cap gene encodes from 5’ to 3‘ three alternative start codons: “the VP1 start codon,” “the VP2 start codon,” and “the VP3 start codon”; and one “common stop codon”. The largest viral protein, VP1. is generally encoded from the VP1 start codon to the “common stop codon.” VP2 is generally encoded from the VP2 start codon to the common stop codon. VP3 is generally encoded from the VP3 start codon to the common stop codon. Accordingly, VP1 comprises at its N-terminus sequence that it does not share with the VP2 or VP3, referred to as the VP 1-unique region (VPl-u). The VPl-u region is generally encoded by the sequence of a wildtype cap gene starting from the VP1 start codon to the “VP2 start codon.” VPl-u comprises a phospholipase A2 domain (PLA2), which may be important for infection, as well as nuclear localization signals which may aid the virus in targeting to the nucleus for uncoating and genome release. The VP1, VP2. and VP3 capsid proteins share the same C-terminal sequence that makes up the entirety of VP3, which may also be referred to herein as the VP3 region. The VP3 region is encoded from the VP3 start codon to the common stop codon. VP2 has an additional ~ 60 amino acids that it shares with the VP1. This region is called the VP1 / VP2 common region.

[0075] In some embodiments, one or more of the Cap proteins of the invention may be encoded by one or more cap genes having one or more ORFs. In some embodiments, the VP proteins of the invention may be expressed from more than one ORF comprising nucleotide sequence encoding any combination of VP1, VP2, and / or VP3 by use of separate nucleotide sequences operably linked to at least one expression control sequence for expression in packaging cell, each producing one or more of VP1, VP2, and / or VP3 capsid proteins of the invention. In some embodiments, a VP capsid protein of the invention may be expressed individually from an ORF comprising nucleotide sequence encoding any one of VP1, VP2, or VP3 by use of separate nucleotide sequences operably linked to one expression control sequence for expression in a viral replication cell, each producing only one of VP1, VP2, or VP3 capsid protein. In another embodiment, VP proteins may be expressed from one ORF comprising nucleotide sequences encoding VP1, VP2, and VP3 capsid proteins operably linked to at least one expression control sequence for expression in a viral replication cell, each producing VP1, VP2, and VP3 capsid protein. Accordingly, although amino acid positions provided herein may be provided in relation to the VP1 capsid protein of the referenced AAV, a skilled artisan would be able to respectively and readily determine the position of that same amino acid within the VP2 and / or VP3 capsid protein of the AAV, and the corresponding position of amino acids among different AAV.

[0076] The phrase '^Inverted terminal repeat7’ or “ITR” includes symmetrical nucleic acid sequences in the genome of adeno-associated viruses required for efficient replication. ITR sequences are located at each end of the AAV DNA genome. The ITRs serve as the origins of replication for viral DNA synthesis and are essential cis components for generating AAV particles, e.g., packaging into AAV particles.

[0077] AAV ITR comprise recognition sites for replication proteins Rep78 or Rep68. A"D" region of the ITR comprises the DNA nick site where DNA replication initiates and provides directionality to the nucleic acid replication step. An AAV replicating in a mammalian cell typically comprises two ITR sequences.

[0078] A single ITR may be engineered with Rep binding sites on both strands of the “A” regions and two symmetrical D regions on each side of the ITR palindrome. Such an engineered construct on a double-stranded circular DNA template allows Rep78 or Rep68 initiated nucleic acid replication that proceeds in both directions. A single ITR is sufficient for AAV replication of a circular particle. In methods of producing an AAV viral particle of the invention, the rep encoding sequence encodes a Rep protein or Rep protein equivalent that is capable of binding an ITR comprised on the transfer plasmid.

[0079] The Cap proteins of the invention, when expressed with appropriate Rep proteins by a packaging cell, may encapsidate a transfer plasmid comprising a nucleotide of interest and an even number of two or more ITR sequences. In some embodiments, a transfer plasmid comprises one ITR sequence. In some embodiments, a transfer plasmid comprises two ITR sequences.

[0080] Either Rep78 and / or Rep68 bind to unique and known sites on the sequence of the ITR hairpin, and act to break and unwind the hairpin structures on the end of an AAV genome, thereby providing access to replication machinery of the viral replication cell. As is well-known, Rep proteins may be expressed from more than one ORF comprising nucleotide sequence encoding any combination of Rep78, Rep68, Rep 52 and / or Rep40 by use of separate nucleotide sequences operably linked to at least one expression control sequence for expression in a viral replication cell, each producing one or more of Rep78, Rep68, Rep 52 and / or Rep40 Rep proteins. Alternatively, Rep proteins may be expressed individually from an ORF comprising a nucleotide sequence encoding any one of Rep78, Rep68, Rep 52, or Rep40 by use of separate nucleotide sequences operably linked to one expression control sequence for expression in a packaging cell, each producing only one Rep78. Rep68. Rep 52, or Rep40 Rep protein. In another embodiment, Rep proteins may be expressed from one ORF comprising nucleotide sequences encoding Rep78 and Rep52 Rep proteins operably linked to at least one expression control sequence for expression in a viral replication cell each producing Rep78 and Rep52 Rep protein.

[0081] In a method of producing an AAV virion, e.g., viral particle, of the invention, a rep encoding sequence and a cap gene of the invention may be provided a single packaging plasmid. However, a skilled artisan will recognize that such proviso is not necessary. Such viral particles may or may not include a genome.

[0082] A '‘chimeric AAV capsid protein” includes an AAV capsid protein that comprises amino acid sequences, e.g., portions, from two or more different AAV and that is capable of forming and / or forms an AAV viral capsid / viral particle. A chimeric AAV capsid protein is encoded by a chimeric AAV capsid gene, e.g., a chimeric nucleotide comprising a plurality, e.g., at least two. nucleic acid sequences, each of which plurality is identical to a portion of a capsid gene encoding a capsid protein of distinct AAV, and which plurality together encodes a functional chimeric AAV capsid protein. Association of a chimeric capsid protein to a specific AAV indicates that the capsid protein comprises one or more portions from a capsid protein of that AAV and one or more portions from a capsid protein of a different AAV. For example, a chimeric AAV2 capsid protein includes a capsid protein comprising one or more portions of a VP1, VP2, and / or VP3 capsid protein of AAV2 and one or more portions of a VP1, VP2, and / or VP3 capsid protein of a different AAV.

[0083] The term “portion’" refers to at least 5 amino acids or at least 15 nucleotides, but less than the full-length polypeptide or nucleic acid molecule, with 100% identity to a sequence from which the portion is derived, see Penzes (2015) J. General Virol. 2769. A “portion” encompasses any contiguous segment of amino acids or nucleotides sufficient to determine that the polypeptide or nucleic acid molecule form which the portion is derived is “of a [specified] AAV” or has “significant identity” to a particular AAV, e.g., a non-primate animal AAV or remote AAV. In some embodiments, a portion comprises at least 5 amino acids or 15 nucleotides with 100% identity to a sequence associated with the specified AAV. In some embodiments, a portion comprises at least 10 amino acids or 30 nucleotides with 100% identity to a sequence associated with the specified AAV. In some embodiments, a portion comprises at least 15 amino acids or 45 nucleotides with 100% identity to a sequence associated with the specified AAV. In some embodiments, a portion comprises at least 20 amino acids or 60 nucleotides with 100% identity to a sequence associated with the specified AAV. In some embodiments, a portion comprises at least 25 amino acids or 75 nucleotides with 100% identity to a sequence associated with the specified AAV. In some embodiments, a portion comprises at least 30 amino acids or 90 nucleotides with 100% identity to a sequence associated with the specified AAV. In some embodiments, a portion comprises at least 35 amino acids or 105 nucleotides with 100% identity to a sequence associated with the specified AAV. In some embodiments, a portion comprises at least 40 amino acids or 120 nucleotides with 100% identity to a sequence associated with the specified AAV. In some embodiments, a portion comprises at least 45 amino acids or 135 nucleotides with 100% identity to a sequence associated w ith the specified AAV. In some embodiments, a portion comprises at least 50 amino acids or 150 nucleotides with 100% identity to a sequence associated with the specified AAV. In some embodiments, a portion comprises at least 60 amino acids or 180 nucleotides with 100% identity to a sequence associated with the specified AAV. In some embodiments, a portion comprises at least 70 amino acids or 210 nucleotides with 100% identity to a sequence associated with the specified AAV. In some embodiments, a portion comprises at least 80 amino acids or 240 nucleotides with 100% identity to a sequence associated with the specified AAV. In some embodiments, a portion comprises at least 90 amino acids or 270 nucleotides with 100% identity to a sequence associated with the specified AAV. In some embodiments, a portion comprises at least 100 amino acids or 300 nucleotides with 100% identity to a sequence associated with the specified AAV. Virus capsid proteins, viral particles, viral nucleic acids

[0084] In some embodiments, a Cap protein, e.g., a VP1 capsid protein as described herein, a VP2 capsid protein as described herein, and / or a VP3 capsid protein as described herein, is modified to comprise any one or combination of e.g., insertion of a targeting ligand, a chemical modification, a first member of a binding pair, a detectable label, point mutation, etc.

[0085] Generally, modification of gene or a polypeptide of a specified AAV, or variants thereof, results in nucleic acid sequence or an amino acid sequence that differs from the nucleic acid sequence or amino acid sequence set forth herein for the specified AAV, wherein the modification alters, confers, or removes one or more biological functions, but does not change the phylogenetic characterization of, the gene or polypeptide as an AAV gene or AAV polypeptide. Modifications may include any one or a combination of: substitution of sequences of a first AAV serotype with sequences of a second AAV serotype to create chimerism; chemical modification; an insertion of: a first member of a binding pair, and / or a point mutation; etc., such that the natural tropism of the capsid protein is reduced to abolished, the tropism of the capsid protein may be more easily redirected, and / or such that the capsid protein comprises a detectable label. Modifications as described herein generally do not alter and preferably decrease the low to no recognition of the modified capsid by preexisting antibodies found in the general population that were produced during the course of infection with another AAV. e.g., infection with serotypes such as AAV1, AAV2, AAV3, AAV4. AAV5. AAV6, AAV7, AAV8, AAV9, AAV10, AAVI1. AAV12, AAV13, AAVDJ, Anc80L65, AAV2G9, AAV-LK03, virions based on such serotypes, virions from currently used AAV gene therapy modalities, or a combination thereof.

[0086] In some embodiments, a Cap protein, e.g., a VP1 capsid protein as described herein, a VP2 capsid protein as described herein, and / or a VP3 capsid protein as described herein, is unmodified, i.e., comprises a wildtype AAV sequence. Targeting ligand

[0087] Modifications described herein may pertain to the association (e.g., display, operable linkage, binding, etc.) of a targeting ligand to a modified capsid protein and / or capsid comprising a modified capsid protein. Generally, a targeting ligand as described herein binds a surface protein expressed by a mammalian nervous system cell, e.g., a protein that is expressed on the surface of a mammalian nervous system cell, e.g., a mammalian nervous system cell-specific surface protein. In some embodiments, a modified capsid protein and / or modified capsid comprises a targeting ligand that binds mammalian p75NTR, e.g., a human p75NTR.

[0088] Table 1 provides a summary of the SEQ ID NO for each binding portion (e.g., heavy chain variable domain (HCVR), light chain variable domain (LCVR), and CDR1, CDR2, and CDR3) and thee full heavy chain (HC) and light chain (LC) sequences of nonlimiting and exemplary anti-human-p75NTR monoclonal antibodies (mAb ID) that may be used to redirect an AAV capsid as described herein. In some embodiments, an AAV capsid as described herein comprises a targeting ligand that binds human p75KTR, wherein the targeting ligand comprises heavy chain variable domain, light chain variable domain, heavy chain variable domain / light chain variable domain pair, HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, LCDR3, and / or set of HCDR1-HCDR2-HCDR3-LCDR1-LCDR2-LCDR3 amino acid sequence(s) at least 90% identical to, respectively, an amino acid sequence of a heavy chain variable domain, light chain variable domain, heavy chain variable domain / light chain variable domain pair, HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, LCDR3, and / or set of HCDR1-HCDR2-HCDR3-LCDR1-LCDR2-LCDR3 set forth in or encoded by a sequence or sequences as set forth in Table 1 and / or any one of SEQ ID NOs: 1-617. In some embodiments, an AAV capsid as described herein comprises a targeting ligand that binds human p75NTR, wherein the targeting ligand comprises a heavy chain variable domain, light chain variable domain, heavy chain variable domain / light chain variable domain pair, HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, LCDR3. and / or set of HCDR1-HCDR2- HCDR3-LCDR1-LCDR2-LCDR3 amino acid sequence at least 95% identical to, respectively, amino acid sequence(s) of a heavy chain variable domain, light chain variable domain, heavy chain variable domain / light chain variable domain pair, HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, LCDR3, and / or set of HCDR1-HCDR2-HCDR3-LCDR1-LCDR2-LCDR3 set forth in or encoded by a sequence or sequences as set forth in Table 1 and / or any one of SEQ ID NOs: 1-617. In some embodiments, an AAV capsid as described herein comprises a targeting ligand that binds human p75NTR, wherein the targeting ligand comprises a heavy chain variable domain, light chain variable domain, heavy chain variable domain / light chain variable domain pair, HCDR1, HCDR2. HCDR3. LCDR1. LCDR2, LCDR3, and / or set of HCDR1-HCDR2-HCDR3-LCDR1-LCDR2-LCDR3 amino acid sequence at least 97% identical to amino acid sequence(s) of a heavy chain variable domain, light chain variable domain, heavy chain variable domain / light chain variable domain pair, HCDR1, HCDR2, HCDR3, LCDR1, LCDR2. LCDR3, and / or set of HCDR1-HCDR2-HCDR3-LCDR1-LCDR2-LCDR3 set forth in or encoded by a sequence or sequences as set forth in Table 1 and / or any one of SEQ ID NOs: 1-617. In some embodiments, an AAV capsid as described herein comprises a targeting ligand that binds human p75NTR, wherein the targeting ligand comprises a heavy chain variable domain, light chain variable domain, heavychain variable domain / light chain variable domain pair. HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, LCDR3, and / or set of HCDR1-HCDR2-HCDR3-LCDR1-LCDR2-LCDR3 ammo acid sequence(s) at least 98% identical to amino acid sequence(s) of a heavy chain variable domain, light chain variable domain, heavy chain variable domain / light chain variable domain pair, HCDR1, HCDR2, HCDR3, LCDR1. LCDR2, LCDR3, and / or set of HCDR1-HCDR2-HCDR3-LCDR1-LCDR2-LCDR3 set forth in or encoded by a sequence or sequences as set forth in Table 1 and / or any one of SEQ ID NOs: 1-617. In some embodiments, an AAV capsid as described herein comprises a targeting ligand that binds human p75NTR. wherein the targeting ligand comprises a heavy chain variable domain, light chain variable domain, heavy chain variable domain / light chain variable domain pair, HCDR1, HCDR2, CDR3, LCDR1, LCDR2, LCDR3, and / or set of HCDR1-HCDR2-HCDR3-LCDR1-LCDR2-LCDR3 amino acid sequences 99% identical to amino acid sequences of a heavy chain variable domain, light chain variable domain, heavy chain variable domain / light chain variable domain pair, HCDR1, HCDR2, HCDR3, LCDR1. LCDR2, LCDR3, and / or set of HCDR1-HCDR2-HCDR3-LCDR1-LCDR2-LCDR3 set forth in or encoded by a sequence or sequences as set forth in Table 1 and / or any one of SEQ ID NOs: 1-617. Also described herein are antibodies, or antigen-binding fragments thereof, comprising a set of six CDRs (i.e.. HCDR1-HCDR2-HCDR3-LCDR1-LCDR2-LCDR3) contained within an HCVR / LCVR amino acid sequence pair as defined by any of the exemplary anti-p75NTRantibodies listed in Table 1. In some embodiments, atargeting ligand as described herein comprises the HCDR1-HCDR2-HCDR3-LCDR1-LCDR2-LCDR3 amino acid sequences set contained within an HCVR / LCVR amino acid sequence pair selected from the group consisting of SEQ ID NOs: 2 / 10, 22 / 30, 42 / 50, 58 / 66, 78 / 86, 98 / 106. 116 / 124. 136 / 144, 155 / 162, 173 / 179, 189 / 197, 207 / 215, 227 / 235, 245 / 251, 261 / 269, 279 / 287, 297 / 304, 315 / 323, 331 / 339, 349 / 357, 369 / 377, 387 / 391, 401 / 409, 417 / 409, 427 / 409, 437 / 409, 445 / 409, 455 / 409, 465 / 409, 475 / 409, 484 / 409, 493 / 409, 503 / 409, 513 / 409, 519 / 409, 529 / 537, 549 / 557, 569 / 577, 589 / 597, and 609 / 597. In some embodiments, atargeting ligand as described herein comprises an HCVR / LCVR amino acid sequence pair selected from the group consisting of SEQ ID NOs: 2 / 10, 22 / 30, 42 / 50, 58 / 66, 78 / 86, 98 / 106, 116 / 124, 136 / 144, 155 / 162, 173 / 179, 189 / 197, 207 / 215, 227 / 235, 245 / 251, 261 / 269, 279 / 287, 297 / 304, 315 / 323, 331 / 339, 349 / 357, 369 / 377, 387 / 391, 401 / 409, 417 / 409, 427 / 409, 437 / 409, 445 / 409. 455 / 409, 465 / 409, 475 / 409, 484 / 409, 493 / 409, 503 / 409, 513 / 409, 519 / 409, 529 / 537, 549 / 557. 569 / 577. 589 / 597, and 609 / 597. Table 1. SEQ ID NOs of Amino Acid Sequences of Domains in Antibodies or Antigenbinding Fragments (e.g., Fabs or scFv Molecules) that may be used to retarget AAV to human p75NTR. SEQ ID NOs for corresponding DNA sequences are presented in parentheses below each amino acid sequence. mAb ID HCVR HCDR1 HCDR2 HCDR3 LCVR LCDR1 LCDR2 LCDR3 HC LC REGN14148 2 (1) 4 (3) 6 (5) 8 (7) 10 (9) 12 (11) 14 (13) 16 (15) 18 (17) 20 (19) REGN14149 22 (21) 24 (23) 26 (25) 28 (27) 30 (29) 32 (31) 34 (33) 36 (35) 38 (37) 40 (39) REGN14150 42 (41) 44 (43) 46 (45) 48 (47) 50 (49) 12 (11) 14 (13) 52 (51) 54 (53) 56 (55) REGN14151 58 (57) 60 (59) 62 (61) 64 (63) 66 (65) 68 (67) 70 (69) 72 (71) 74 (73) 76 (75) REGN14152 78 (77) 80 (79) 82 (81) 84 (83) 86 (85) 88 (87) 90 (89) 92 (91) 94 (93) 96 (95) REGN14153 98 (97) 100 (99) 102 (101) 104 (103) 106 (105) 108 (107) 34 (33) 110 (109) 112 (111) 114 (113) REGN14154 116 (115) 118 (117) 120 (119) 122 (121) 124 (123) 126 (125) 128 (127) 130 (129) 132 (131) 134 (133) REGN14155 136 (135) 138 (137) 140 (139) 142 (141) 144 (143) 146 (145) 90 (147) 149 (148) 151 (150) 153 (152) REGN14156 155 (154) 100 (156) 158 (157) 160 (159) 162 (161) 164 (163) 90 (165) 167 (166) 169 (168) 171 (170) REGN14157 173 (172) 100 (156) 175 (174) 177 (176) 179 (178) 181 (180) 70 (69) 183 (182) 185 (184) 187 (186) REGN14158 189 (188) 191 (190) 193 (192) 195 (194) 197 (196) 199 (198) 14 (13) 201 (200) 203 (202) 205 (204) REGN14159 207 (206) 209 (208) 211 (210) 213 (212) 215 (214) 217 (216) 219 (218) 221 (220) 223 (222) 225 (224) REGN14160 227 (226) 229 (228) 231 (230) 233 (232) 235 (234) 237 (236) 14 (13) 239 (238) 241 (240) 243 (242) REGN14161 245 (244) 100 (156) 247 (246) 249 (248) 251 (250) 253 (252) 70 (69) 255 (254) 257 (256) 259 (258) REGN14162 261 (260) 263 (262) 265 (264) 267 (266) 269 (268) 271 (270) 90 (165) 273 (272) 275 (274) 277 (276) REGN14163 279 (278) 281 (280) 283 (282) 285 (284) 287 (286) 289 (288) 14 (13) 291 (290) 293 (292) 295 (294) REGN14164 297 (296) 299 (298) 193 (300) 302 (301) 304 (303) 237 (305) 307 (306) 309 (308) 311 (310) 313 (312) REGN14165 315 (314) 317 (316) 319 (318) 321 (320) 323 (322) 12 (11) 14 (13) 325 (324) 327 (326) 329 (328) REGN14175 331 (330) 333 (332) 335 (334) 337 (336) 339 (338) 237 (236) 341 (340) 343 (342) 345 (344) 347 (346) REGN14176 349 (348) 351 (350) 353 (352) 355 (354) 357 (356) 359 (358) 361 (360) 363 (362) 365 (364) 367 (366) REGN14177 369 (368) 371 (370) 373 (372) 375 (374) 377 (376) 379 (378) 90 (165) 381 (380) 383 (382) 385 (384) REGN14178 387 (386) 138 (137) 319 (318) 389 (388) 391 (390) 393 (392) 361 (360) 395 (394) 397 (396) 399 (398) REGN14179 401 (400) 403 (402) 405 (404) 407 (406) 409 (408) 237 (236) 14 (13) 411 (410) 413 (412) 415 (414) REGN14180 417 (416) 419 (418) 421 (420) 423 (422) 409 (408) 237 (236) 14 (13) 411 (410) 425 (424) 415 (414) REGN14181 427 (426) 429 (428) 431 (430) 433 (432) 409 (408) 237 (236) 14 (13) 411 (410) 435 (434) 415 (414) REGN14182 437 (436) 191 (438) 335 (439) 441 (440) 409 (408) 237 (236) 14 (13) 411 (410) 443 (442) 415 (414) REGN14183 445 (444) 447 (446) 449 (448) 451 (450) 409 (408) 237 (236) 14 (13) 411 (410) 453 (452) 415 (414) REGN14184 455 (454) 457 (456) 459 (458) 461 (460) 409 (408) 237 (236) 14 (13) 411 (410) 463 (462) 415 (414) REGN14185 465 (464) 467 (466) 469 (468) 471 (470) 409 (408) 237 (236) 14 (13) 411 (410) 473 (472) 415 (414) REGN14186 475 (474) 477 (476) 158 (478) 480 (479) 409 (408) 237 (236) 14 (13) 411 (410) 482 (481) 415 (414) REGN14187 484 (483) 486 (485) 283 (487) 489 (488) 409 (408) 237 (236) 14 (13) 411 (410) 491 (490) 415 (414) REGN14188 493 (492) 495 (494) 497 (496) 499 (498) 409 (408) 237 (236) 14 (13) 411 (410) 501 (500) 415 (414) REGN14189 503 (502) 505 (504) 507 (506) 509 (508) 409 (408) 237 (236) 14 (13) 411 (410) 511 (510) 415 (414) REGN14190 513 (512) 138 (137) 319 (318) 515 (514) 409 (408) 237 (236) 14 (13) 411 (410) 517 (516) 415 (414) REGN14191 519 (518) 521 (520) 523 (522) 525 (524) 409 (408) 237 (236) 14 (13) 411 (410) 527 (526) 415 (414) REGN19513 529 (528) 531 (530) 533 (532) 535 (534) 537 (536) 539 (538) 541 (540) 543 (542) 545 (544) 547 (546) REGN19514 549 (548) 551 (550) 553 (552) 555 (554) 557 (556) 559 (558) 561 (560) 563 (562) 565 (564) 567 (566) REGN19515 569 (568) 571 (570) 573 (572) 575 (574) 577 (576) 579 (578) 581 (580) 583 (582) 585 (584) 587 (586) REGN19516 589 (588) 591 (590) 593 (592) 595 (594) 597 (596) 599 (598) 601 (600) 603 (602) 605 (604) 607 (606) REGN19517 609 (608) 611 (610) 613 (612) 615 (614) 597 (596) 599 (598) 601 (600) 603 (602) 617 (616) 607 (606) REGN14148 HCVR DNA Sequence GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTCCAGCCTGGGGGGTCCCTG AGACTCTCCTGTGCGGCCTCTGGATTCACCTTTAATAACTATTGGATGAGCTGGA TCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGGTGGCCAACATAAAGCCAGATG GAAGTGAGAAATCATATGTGGACTCTGTGAAGGGCCGATTCACCATCTCCAGAG ACAACGCCAAGAAATCACTGTTTCTGCAAATGACCAGCCTGAGAGCCGAGGACA CGGCTGTTTATTACTGTGCGACGAACTGGGGGTTTGACTGGGGCCAGGGAACCCT GGTCACCGTCTCCTCA (SEQ ID NO: 1) HCVR Amino Acid Sequence EVQLVESGGGLVQPGGSLRLSCAASGFTFNNYWMSWIRQAPGKGLEWVANIKPDGS EKSYVDSVKGRFTISRDNAKKSLFLQMTSLRAEDTAVYYCATNWGFDWGQGTLVT vss (SEQ ID NO: 2) CDR1 DNA Sequence GGA ETC ACC TTT AAT AAC TAT TGG (SEQ ID NO: 3) CDR1 Amino Acid Sequence GFTFNNYW (SEQ ID NO: 4) CDR2 DNA Sequence ATA AAG CCA GAT GGA AGT GAG AAA (SEQ ID NO: 5) CDR2 Amino Acid Sequence I K P D G S E K (SEQIDNO: 6) CDR3 DNA Sequence GCG ACG AAC TGG GGG TTT GAC (SEQIDNO: 7) CDR3 Amino Acid Sequence A T N W G F D (SEQIDNO: 8) LCVR DNA Sequence GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTGGGAGACAGAG TCACCGTCACTTGCCGGGCAAGTCAGGACATTAGAAATGATTTAGGCTGGTTTCA GCAGAAACCAGGGAAAGCCCCTAAGCGCCTGATCTATGCTGCATCCAGTTTGCA AAGTGGGGTCCCATCAAGGTTCAGCGGCAGTGGATCTGGGACAGACTTCACTCT CACAATCAGCAGCCTGCAGCCTGAAGATTTTGCAACTTATTACTGTCTACAGTAT AATAGTTACCCGTGGACGTTCGGCCAAGGGACCAAGGTGGAAATCAAA (SEQIDNO: 9) LCVR Amino Acid Sequence DIQMTQSPSSLSASVGDRVTVTCRASQDIRNDLGWFQQKPGKAPKRLIYAASSLQSG VPSRFSGSGSGTDFTLTISSLQPEDFATYYCLQYNSYPWTFGQGTKVEIK (SEQIDNO: 10) CDR1 DNA Sequence CAG GAC ATT AGA AAT GAT (SEQIDNO: 11) CDR1 Amino Acid Sequence Q D I R N D (SEQIDNO: 12) CDR2 DNA Sequence GCT GCA TCC (SEQIDNO: 13) CDR2 Amino Acid Sequence A A S (SEQIDNO: 14) CDR3 DNA Sequence CTA CAG TAT AAT AGT TAC CCG TGG ACG (SEQIDNO: 15) CDR3 Amino Acid Sequence LQYNSYPWT (SEQIDNO: 16) HC DNA Sequence GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTCCAGCCTGGGGGGTCCCTG AGACTCTCCTGTGCGGCCTCTGGATTCACCTTTAATAACTATTGGATGAGCTGGA TCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGGTGGCCAACATAAAGCCAGATG GAAGTGAGAAATCATATGTGGACTCTGTGAAGGGCCGATTCACCATCTCCAGAG ACAACGCCAAGAAATCACTGTTTCTGCAAATGACCAGCCTGAGAGCCGAGGACA CGGCTGTTTATTACTGTGCGACGAACTGGGGGTTTGACTGGGGCCAGGGAACCCT GGTCACCGTCTCCTCAGCCTCCACCAAGGGCCCATCGGTCTTCCCCCTGGCGCCC TGCTCCAGGAGCACCTCCGAGAGCACAGCCGCCCTGGGCTGCCTGGTCAAGGAC TACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGC GTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCG TGGTGACCGTGCCCTCCAGCAGCTTGGGCACGAAGACCTACACCTGCAACGTAG ATCACAAGCCCAGCAACACCAAGGTGGACAAGAGAGTTGAGTCCAAATATGGTC CCCCATGCCCACCGTGCCCAGCACCACCTGTGGCAGGACCATCAGTCTTCCTGTT CCCCCCAAAACCCAAGGACACTCTCATGATCTCCCGGACCCCTGAGGTCACGTGC GTGGTGGTGGACGTGAGCCAGGAAGACCCCGAGGTCCAGTTCAACTGGTACGTG GATGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTTCAA CAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAAC GGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGGCCTCCCGTCCTCCATCGAG AAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAGCCACAGGTGTACACCCTG CCCCCATCCCAGGAGGAGATGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTC AAAGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCG GAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCC TCTACAGCAGGCTCACCGTGGACAAGAGCAGGTGGCAGGAGGGGAATGTCTTCT CATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACACAGAAGTCCCTCTC CCTGTCTCTGGGTAAATGA (SEQIDNO: 17) HC Amino Acid Sequence EVQLVESGGGLVQPGGSLRLSCAASGFTFNNYWMSWIRQAPGKGLEWVANIKPDGS EKSYVDSVKGRFTISRDNAKKSLFLQMTSLRAEDTAVYYCATNWGFDWGQGTLVT VSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPA VLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPP VAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTK PREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQ VYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSF FLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK* (SEQIDNO: 18) LC DNA Sequence GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTGGGAGACAGAG TCACCGTCACTTGCCGGGCAAGTCAGGACATTAGAAATGATTTAGGCTGGTTTCA GCAGAAACCAGGGAAAGCCCCTAAGCGCCTGATCTATGCTGCATCCAGTTTGCA AAGTGGGGTCCCATCAAGGTTCAGCGGCAGTGGATCTGGGACAGACTTCACTCT CACAATCAGCAGCCTGCAGCCTGAAGATTTTGCAACTTATTACTGTCTACAGTAT AATAGTTACCCGTGGACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGAACT GTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTG GAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAGT ACAGTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAGGAGAGTGTCAC AGAGCAGGACAGCAAGGACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGAG CAAAGCAGACTACGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGGG CCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGTTAG (SEQIDNO: 19) LC Amino Acid Sequence DIQMTQSPSSLSASVGDRVTVTCRASQDIRNDLGWFQQKPGKAPKRLIYAASSLQSG VPSRFSGSGSGTDFTLTISSLQPEDFATYYCLQYNSYPWTFGQGTKVEIKRTVAAPSV FIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDST YSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC* (SEQIDNO: 20) REGN14149 HCVR DNA Sequence GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTG AGACTCTCCTGTGCAGCCTCTGGATTCACCTTTACCACCTATGCCATGAGCTGGG TCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGGTCTCAGCTATTAGTGCTACTG GTAGTGGCACATACTATGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCAGAG AGAATTCCAAGAACACGCTGTATCTGCAAATGAAAAGCCTGAGAGCCGAGGACA CGGCCGTATATTACTGTGTGAAAGGTCCGTATAGTAACAGCCGGAACGTGGGCTT CCAGCACTGGGGCCAGGGCACCCTGGTCACCGTCTCCTCA (SEQIDNO: 21) HCVR Amino Acid Sequence EVQLVESGGGLVQPGGSLRLSCAASGFTFTTYAMSWVRQAPGKGLEWVSAISATGS GTYYADSVKGRFTISRENSKNTLYLQMKSLRAEDTAVYYCVKGPYSNSRNVGFQH WGQGTLVTVSS (SEQIDNO: 22) CDR1 DNA Sequence GGA TTC ACC TTT ACC ACC TAT GCC (SEQIDNO: 23) CDR1 Amino Acid Sequence GFTFTTYA (SEQIDNO: 24) CDR2 DNA Sequence ATT AGT GCT ACT GGT AGT GGC ACA (SEQIDNO: 25) CDR2 Amino Acid Sequence I S A T G S G T (SEQIDNO: 26) CDR3 DNA Sequence GTG AAA GGT CCG TAT AGT AAC AGC CGG AAC GTG GGC TTC CAG CAC (SEQIDNO: 27) CDR3 Amino Acid Sequence VKGPYSNSRNVGFQH (SEQIDNO: 28) LCVR DNA Sequence GATATTGTGATGACTCAGTCTCCACTCTCCCTGCCCGTCACCCCTGGAGAGCCGG CCTCCATCTCCTGCAGGTCTAGTCAGAGCCTCCTACATAGTAATGGATACAACTA TTTGGATTGGTACCTGCAGAAGCCAGGGCAGTCTCCACAACTCCTGATCTATTTG GGTTCTAATCGGGCCTCCGGGGTCCCTGACAGGTTCAGTGGCAGTGGATCAGGC ACAGATTTTACACTGAAAATCAGCAGAGTGGAGGCTGAGGATGTTGGGGTTTATT TCTGCATGCAACATCTACAAACTCCCATGTACACTTTTGGCCAGGGGACCAAGCT GGAGATCAAA (SEQIDNO: 29) LCVR Amino Acid Sequence DIVMTQSPLSLPVTPGEPASISCRSSQSLLHSNGYNYLDWYLQKPGQSPQLLIYLGSN RASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYFCMQHLQTPMYTFGQGTKLEIK (SEQIDNO: 30) CDR1 DNA Sequence CAG AGC CTC CTA CAT AGT AAT GGA TAC AAC TAT (SEQIDNO: 31) CDR1 Amino Acid Sequence QSLLHSNGYNY (SEQIDNO: 32) CDR2 DNA Sequence TTG GGT TCT (SEQIDNO: 33) CDR2 Amino Acid Sequence L G S (SEQIDNO: 34) CDR3 DNA Sequence ATG CAA CAT CTA CAA ACT CCC ATG TAC ACT (SEQIDNO: 35) CDR3 Amino Acid Sequence MQHLQTPMYT (SEQIDNO: 36) HC DNA Sequence GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTG AGACTCTCCTGTGCAGCCTCTGGATTCACCTTTACCACCTATGCCATGAGCTGGG TCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGGTCTCAGCTATTAGTGCTACTG GTAGTGGCACATACTATGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCAGAG AGAATTCCAAGAACACGCTGTATCTGCAAATGAAAAGCCTGAGAGCCGAGGACA CGGCCGTATATTACTGTGTGAAAGGTCCGTATAGTAACAGCCGGAACGTGGGCTT CCAGCACTGGGGCCAGGGCACCCTGGTCACCGTCTCCTCAGCCTCCACCAAGGG CCCATCGGTCTTCCCCCTGGCGCCCTGCTCCAGGAGCACCTCCGAGAGCACAGCC GCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGA ACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCCTC AGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCACG AAGACCTACACCTGCAACGTAGATCACAAGCCCAGCAACACCAAGGTGGACAAG AGAGTTGAGTCCAAATATGGTCCCCCATGCCCACCGTGCCCAGCACCACCTGTGG CAGGACCATCAGTCTTCCTGTTCCCCCCAAAACCCAAGGACACTCTCATGATCTC CCGGACCCCTGAGGTCACGTGCGTGGTGGTGGACGTGAGCCAGGAAGACCCCGA GGTCCAGTTCAACTGGTACGTGGATGGCGTGGAGGTGCATAATGCCAAGACAAA GCCGCGGGAGGAGCAGTTCAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGT CCTGCACCAGGACTGGCTGAACGGCAAGGAGTACAAGTGCAAGGTCTCCAACAA AGGCCTCCCGTCCTCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCG AGAGCCACAGGTGTACACCCTGCCCCCATCCCAGGAGGAGATGACCAAGAACCA GGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTACCCCAGCGACATCGCCGTGGAG TGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTG GACTCCGACGGCTCCTTCTTCCTCTACAGCAGGCTCACCGTGGACAAGAGCAGGT GGCAGGAGGGGAATGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACC ACTACACACAGAAGTCCCTCTCCCTGTCTCTGGGTAAATGA (SEQIDNO: 37) HC Amino Acid Sequence EVQLVESGGGLVQPGGSLRLSCAASGFTFTTYAMSWVRQAPGKGLEWVSAISATGS GTYYADSVKGRFTISRENSKNTLYLQMKSLRAEDTAVYYCVKGPYSNSRNVGFQH WGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGAL TSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYG PPCPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDG VEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISK AKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTP PVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK* (SEQIDNO: 38) LC DNA Sequence GATATTGTGATGACTCAGTCTCCACTCTCCCTGCCCGTCACCCCTGGAGAGCCGG CCTCCATCTCCTGCAGGTCTAGTCAGAGCCTCCTACATAGTAATGGATACAACTA TTTGGATTGGTACCTGCAGAAGCCAGGGCAGTCTCCACAACTCCTGATCTATTTG GGTTCTAATCGGGCCTCCGGGGTCCCTGACAGGTTCAGTGGCAGTGGATCAGGC ACAGATTTTACACTGAAAATCAGCAGAGTGGAGGCTGAGGATGTTGGGGTTTATT TCTGCATGCAACATCTACAAACTCCCATGTACACTTTTGGCCAGGGGACCAAGCT GGAGATCAAACGAACTGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGAT GAGCAGTTGAAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATC CCAGAGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCCAATCGGGTAACT CCCAGGAGAGTGTCACAGAGCAGGACAGCAAGGACAGCACCTACAGCCTCAGC AGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTACGCCTGC GAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGA GAGTGTTAG (SEQIDNO: 39) LC Amino Acid Sequence DIVMTQSPLSLPVTPGEPASISCRSSQSLLHSNGYNYLDWYLQKPGQSPQLLIYLGSN RASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYFCMQHLQTPMYTFGQGTKLEIKRT VAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQ DSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC* (SEQIDNO: 40) REGN14150 HCVR DNA Sequence CAGGTTCAGCTGGTGCAGTCTGGAGCTGAGGTGAAGAAGCCTGGGGCCTCAGTG AAAGTCTCCTGTAAGGCTTCTGGTTACACCTTTAGTAGCCATGGTATCACCTGGG TGCGACAGGCCCCTGGACAAGGGCTTGAGTGGATGGGATGGATCAGCGCTTATA ATGGTGACACAAACTATGCACAGAAAGTCCAGGGCAGAGTCACCATGACCACAG ACACATCCACGAGTACAGCCTACATGGAACTGAGGAGCCTGAGATCTGACGACA CGGCCGTGTTTTACTGTGCGCGATATAGGGGAATAGTAGGTCGTAATTACAACTA CTATGGTATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCA (SEQIDNO: 41) HCVR Amino Acid Sequence QVQLVQSGAEVKKPGASVKVSCKASGYTFSSHGITWVRQAPGQGLEWMGWISAYN GDTNYAQKVQGRVTMTTDTSTSTAYMELRSLRSDDTAVFYCARYRGIVGRNYNYY GMDVWGQGTTVTVSS (SEQIDNO: 42) CDR1 DNA Sequence GGT TAC ACC TTT AGT AGC CAT GGT (SEQIDNO: 43) CDR1 Amino Acid Sequence GYTFSSHG (SEQIDNO: 44) CDR2 DNA Sequence ATC AGC GCT TAT AAT GGT GAC ACA (SEQIDNO: 45) CDR2 Amino Acid Sequence I S A Y N G D T (SEQIDNO: 46) CDR3 DNA Sequence GCG CGA TAT AGG GGA ATA GTA GGT CGT AAT TAC AAC TAC TAT GGT ATG GAC GTC (SEQIDNO: 47) CDR3 Amino Acid Sequence ARYRGIVGRNYNYYGMDV (SEQIDNO: 48) LCVR DNA Sequence GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGAGAGAG TCACCATCACTTGCCGGGCAAGTCAGGACATTAGAAATGATTTAGGCTGGTATCA GCAGAAACCAGGGAAAGCCCCTAAGCGCCTGATGTATGCTGCATCCAGTTTGCA AAGTGGGGTCCCATCAAGGTTCAGCGGCAGTGGATCTGGGACAGAATTCACTCT CACAATCAGCACCCTGCAGCCTGAAGATTTTGCAACTTATTACTGTCTACAGCAT AATAGTTACCCCCTCACTTTCGGCGGAGGGACCAAGGTGGAGATCAAA (SEQIDNO: 49) LCVR Amino Acid Sequence DIQMTQSPSSLSASVGERVTITCRASQDIRNDLGWYQQKPGKAPKRLMYAASSLQSG VPSRFSGSGSGTEFTLTISTLQPEDFATYYCLQHNSYPLTFGGGTKVEIK (SEQIDNO: 50) CDR1 DNA Sequence CAG GAC ATT AGA AAT GAT (SEQIDNO: 11) CDR1 Amino Acid Sequence Q D I R N D (SEQIDNO: 12) CDR2 DNA Sequence GCT GCA TCC (SEQIDNO: 13) CDR2 Amino Acid Sequence A A S (SEQIDNO: 14) CDR3 DNA Sequence CTA CAG CAT AAT AGT TAC CCC CTC ACT (SEQIDNO: 51) CDR3 Amino Acid Sequence LQHNSYPLT (SEQIDNO: 52) HC DNA Sequence CAGGTTCAGCTGGTGCAGTCTGGAGCTGAGGTGAAGAAGCCTGGGGCCTCAGTG AAAGTCTCCTGTAAGGCTTCTGGTTACACCTTTAGTAGCCATGGTATCACCTGGG TGCGACAGGCCCCTGGACAAGGGCTTGAGTGGATGGGATGGATCAGCGCTTATA ATGGTGACACAAACTATGCACAGAAAGTCCAGGGCAGAGTCACCATGACCACAG ACACATCCACGAGTACAGCCTACATGGAACTGAGGAGCCTGAGATCTGACGACA CGGCCGTGTTTTACTGTGCGCGATATAGGGGAATAGTAGGTCGTAATTACAACTA CTATGGTATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCAGCCTCC ACCAAGGGCCCATCGGTCTTCCCCCTGGCGCCCTGCTCCAGGAGCACCTCCGAGA GCACAGCCGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGG TGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCT ACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGC TTGGGCACGAAGACCTACACCTGCAACGTAGATCACAAGCCCAGCAACACCAAG GTGGACAAGAGAGTTGAGTCCAAATATGGTCCCCCATGCCCACCGTGCCCAGCA CCACCTGTGGCAGGACCATCAGTCTTCCTGTTCCCCCCAAAACCCAAGGACACTC TCATGATCTCCCGGACCCCTGAGGTCACGTGCGTGGTGGTGGACGTGAGCCAGG AAGACCCCGAGGTCCAGTTCAACTGGTACGTGGATGGCGTGGAGGTGCATAATG CCAAGACAAAGCCGCGGGAGGAGCAGTTCAACAGCACGTACCGTGTGGTCAGCG TCCTCACCGTCCTGCACCAGGACTGGCTGAACGGCAAGGAGTACAAGTGCAAGG TCTCCAACAAAGGCCTCCCGTCCTCCATCGAGAAAACCATCTCCAAAGCCAAAG GGCAGCCCCGAGAGCCACAGGTGTACACCCTGCCCCCATCCCAGGAGGAGATGA CCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTACCCCAGCGACA TCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACG CCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTACAGCAGGCTCACCGTGG ACAAGAGCAGGTGGCAGGAGGGGAATGTCTTCTCATGCTCCGTGATGCATGAGG CTCTGCACAACCACTACACACAGAAGTCCCTCTCCCTGTCTCTGGGTAAATGA (SEQIDNO: 53) HC Amino Acid Sequence QVQLVQSGAEVKKPGASVKVSCKASGYTFSSHGITWVRQAPGQGLEWMGWISAYN GDTNYAQKVQGRVTMTTDTSTSTAYMELRSLRSDDTAVFYCARYRGIVGRNYNYY GMDVWGQGTTVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSW NSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRV ESKYGPPCPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNW YVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIE KTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENN YKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLG K* (SEQIDNO: 54) LC DNA Sequence GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGAGAGAG TCACCATCACTTGCCGGGCAAGTCAGGACATTAGAAATGATTTAGGCTGGTATCA GCAGAAACCAGGGAAAGCCCCTAAGCGCCTGATGTATGCTGCATCCAGTTTGCA AAGTGGGGTCCCATCAAGGTTCAGCGGCAGTGGATCTGGGACAGAATTCACTCT CACAATCAGCACCCTGCAGCCTGAAGATTTTGCAACTTATTACTGTCTACAGCAT AATAGTTACCCCCTCACTTTCGGCGGAGGGACCAAGGTGGAGATCAAACGAACT GTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTG GAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAGT ACAGTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAGGAGAGTGTCAC AGAGCAGGACAGCAAGGACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGAG CAAAGCAGACTACGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGGG CCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGTTAG (SEQIDNO: 55) LC Amino Acid Sequence DIQMTQSPSSLSASVGERVTITCRASQDIRNDLGWYQQKPGKAPKRLMYAASSLQSG VPSRFSGSGSGTEFTLTISTLQPEDFATYYCLQHNSYPLTFGGGTKVEIKRTVAAPSVF IFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTY SLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC* (SEQIDNO: 56) REGN14151 HCVR DNA Sequence CAGGTACAGCTGCAGCAGTCAGGTCCAGGACTGGTGAAGCCCTCGCAGACCCTC TCACTCACCTGTGCCTTCTCCGGGGACAGTGTCTCTAGGAACAGTGCTGCTTGGA ACTGGATCAGGCAGTCCCCATCGAGAGGCCTTGAGTGGCTGGGAAGGACATACT ACAGGTCCAAGTGGTATAATGATTATGCAGTATCTGTGAAAAGTCGAATAACCAT CAACCCAGACACAGCCAAGAACCAGTTCTCCCTGCAGCTGAAATCTGTGACTCCC GAGGACACGGCTGTGTATTACTGTGCAAGAGAGGGGCCCTATTTTGACTACTGG GGCCAGGGAACCCTGGTCACCGTCTCCTCA (SEQIDNO: 57) HCVR Amino Acid Sequence QVQLQQSGPGLVKPSQTLSLTCAFSGDSVSRNSAAWNWIRQSPSRGLEWLGRTYYR SKWYNDYAVSVKSRITINPDTAKNQFSLQLKSVTPEDTAVYYCAREGPYFDYWGQG TLVTVSS (SEQIDNO: 58) CDR1 DNA Sequence GGG GAC AGT GTC TCT AGG AAC AGT GCT GCT (SEQIDNO: 59) CDR1 Amino Acid Sequence GDSVSRNSAA (SEQIDNO: 60) CDR2 DNA Sequence ACA TAC TAC AGG TCC AAG TGG TAT AAT (SEQIDNO: 61) CDR2 Amino Acid Sequence TYYRSKWYN (SEQIDNO: 62) CDR3 DNA Sequence GCA AGA GAG GGG CCC TAT TTT GAC TAC (SEQIDNO: 63) CDR3 Amino Acid Sequence AREGPYFDY (SEQIDNO: 64) LCVR DNA Sequence GACATCGTGATGACCCAGTCTCCAGACTCCCTGGCTGTGTCTCTGGGCGAGAGGG CCACCATCAACTGCAAGTCCAGCCAGAGTGTTTTACACAGCTCCAACAATATGAA CTACTTAGCTTGGTACCAGCAGAAACCAGGACAGCCTCCTAAGTTGCTCATTTAC TGGGCATCTACCCGGAAATCCGGGGTCCCTGACCGATTCAGTGGCAGCGGGTCT GGGACAGATTTCACTCTCACCATCAGCAGCCTTCAGGCTGCTGATGTGGCAGTTT ATTACTGTCTGCAATATTATAATACTCCTCGAACGTTCGGCCAAGGGACCAAGGT GGAAATCAAA (SEQIDNO: 65) LCVR Amino Acid Sequence DIVMTQSPDSLAVSLGERATINCKSSQSVLHSSNNMNYLAWYQQKPGQPPKLLIYW ASTRKSGVPDRFSGSGSGTDFTLTISSLQAADVAVYYCLQYYNTPRTFGQGTKVEIK (SEQIDNO: 66) CDR1 DNA Sequence CAG AGT GTT TTA CAC AGC TCC AAC AAT ATG AAC TAC (SEQIDNO: 67) CDR1 Amino Acid Sequence QSVLHSSNNMNY (SEQIDNO: 68) CDR2 DNA Sequence TGG GCA TCT (SEQIDNO: 69) CDR2 Amino Acid Sequence WAS (SEQIDNO: 70) CDR3 DNA Sequence CTG CAA TAT TAT AAT ACT CCT CGA ACG (SEQIDNO: 71) CDR3 Amino Acid Sequence LQYYNTPRT (SEQIDNO: 72) HC DNA Sequence CAGGTACAGCTGCAGCAGTCAGGTCCAGGACTGGTGAAGCCCTCGCAGACCCTC TCACTCACCTGTGCCTTCTCCGGGGACAGTGTCTCTAGGAACAGTGCTGCTTGGA ACTGGATCAGGCAGTCCCCATCGAGAGGCCTTGAGTGGCTGGGAAGGACATACT ACAGGTCCAAGTGGTATAATGATTATGCAGTATCTGTGAAAAGTCGAATAACCAT CAACCCAGACACAGCCAAGAACCAGTTCTCCCTGCAGCTGAAATCTGTGACTCCC GAGGACACGGCTGTGTATTACTGTGCAAGAGAGGGGCCCTATTTTGACTACTGG GGCCAGGGAACCCTGGTCACCGTCTCCTCAGCCTCCACCAAGGGCCCATCGGTCT TCCCCCTGGCGCCCTGCTCCAGGAGCACCTCCGAGAGCACAGCCGCCCTGGGCTG CCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGC CCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTAC TCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCACGAAGACCTAC ACCTGCAACGTAGATCACAAGCCCAGCAACACCAAGGTGGACAAGAGAGTTGAG TCCAAATATGGTCCCCCATGCCCACCGTGCCCAGCACCACCTGTGGCAGGACCAT CAGTCTTCCTGTTCCCCCCAAAACCCAAGGACACTCTCATGATCTCCCGGACCCC TGAGGTCACGTGCGTGGTGGTGGACGTGAGCCAGGAAGACCCCGAGGTCCAGTT CAACTGGTACGTGGATGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGA GGAGCAGTTCAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAG GACTGGCTGAACGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGGCCTCCCG TCCTCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAGCCACAG GTGTACACCCTGCCCCCATCCCAGGAGGAGATGACCAAGAACCAGGTCAGCCTG ACCTGCCTGGTCAAAGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGC AATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGAC GGCTCCTTCTTCCTCTACAGCAGGCTCACCGTGGACAAGAGCAGGTGGCAGGAG GGGAATGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACAC AGAAGTCCCTCTCCCTGTCTCTGGGTAAATGA (SEQIDNO: 73) HC Amino Acid Sequence QVQLQQSGPGLVKPSQTLSLTCAFSGDSVSRNSAAWNWIRQSPSRGLEWLGRTYYR SKWYNDYAVSVKSRITINPDTAKNQFSLQLKSVTPEDTAVYYCAREGPYFDYWGQG TLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVH TFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPC PAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNA KTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPR EPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSD GSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK* (SEQIDNO: 74) LC DNA Sequence GACATCGTGATGACCCAGTCTCCAGACTCCCTGGCTGTGTCTCTGGGCGAGAGGG CCACCATCAACTGCAAGTCCAGCCAGAGTGTTTTACACAGCTCCAACAATATGAA CTACTTAGCTTGGTACCAGCAGAAACCAGGACAGCCTCCTAAGTTGCTCATTTAC TGGGCATCTACCCGGAAATCCGGGGTCCCTGACCGATTCAGTGGCAGCGGGTCT GGGACAGATTTCACTCTCACCATCAGCAGCCTTCAGGCTGCTGATGTGGCAGTTT ATTACTGTCTGCAATATTATAATACTCCTCGAACGTTCGGCCAAGGGACCAAGGT GGAAATCAAACGAACTGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGAT GAGCAGTTGAAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATC CCAGAGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCCAATCGGGTAACT CCCAGGAGAGTGTCACAGAGCAGGACAGCAAGGACAGCACCTACAGCCTCAGC AGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTACGCCTGC GAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGA GAGTGTTAG (SEQIDNO: 75) LC Amino Acid Sequence DIVMTQSPDSLAVSLGERATINCKSSQSVLHSSNNMNYLAWYQQKPGQPPKLLIYW ASTRKSGVPDRFSGSGSGTDFTLTISSLQAADVAVYYCLQYYNTPRTFGQGTKVEIK RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVT EQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC* (SEQIDNO: 76) REGN14152 HCVR DNA Sequence GAGGTGCAGCTGGTGGAGTCTGAGGGAGGCTGGGTACAGCCTGGGGGGTCCCTG AGACTCTCCTGTGCAGCCTCTGGAATCACCTTTAGCATCTATGCCATGGCCTGGG TCCGCCAGGCTCCAGGGAAGGGACTTGAGTGGGTCTCAACTATTAGTGGTAGTG GTGATTCCACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCAGAGA CAATTCCAAGAACACGCTGTTTCTGCAAATGAACAGCCTGAGAGCCGTGGACAC GGCCATATATTACTGTGCGAAAAGAGGATTTGCAGCTTTTGACTACTGGGGCCAG GGAACCCTGGTCACCGTCTCCTCA (SEQIDNO: 77) HCVR Amino Acid Sequence EVQLVESEGGWVQPGGSLRLSCAASGITFSIYAMAWVRQAPGKGLEWVSTISGSGDS TYYADSVKGRFTISRDNSKNTLFLQMNSLRAVDTAIYYCAKRGFAAFDYWGQGTLV TVSS (SEQIDNO: 78) CDR1 DNA Sequence GGA ATC ACC TTT AGC ATC TAT GCC (SEQIDNO: 79) CDR1 Amino Acid Sequence G I T F S I Y A (SEQIDNO: 80) CDR2 DNA Sequence ATT AGT GGT AGT GGT GAT TCC ACA (SEQIDNO: 81) CDR2 Amino Acid Sequence I S G S G D S T (SEQIDNO: 82) CDR3 DNA Sequence GCG AAA AGA GGA TTT GCA GCT TTT GAC TAC (SEQIDNO: 83) CDR3 Amino Acid Sequence AKRGFAAFDY (SEQIDNO: 84) LCVR DNA Sequence GAAATTGTGTTGACGCAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGGGAAAGAG CCACCCTCTCCTGTAGGGCCAGTCAGAGTGTTAGCAGCACCTACTTAGCCTGGTA CCAGCAGAAACCTGGCCAGTCTCCCAGGCTCCTCATCTATGGTGCATCAAACAGG GCCACTGGCATCCCAGACAGGTTCAGTGGCAGTGGGTCTGGGACAGACTTCACT CTCACCATCAGCAGACTGGAGCCTGAAGATTTTGCAGTGTATTACTGTCAGCAGT ATGGTAGCTCACGTCTGCTCAGTTTCGGCGGAGGGACCAAGGTGGAGATCAAA (SEQIDNO: 85) LCVR Amino Acid Sequence EIVLTQSPGTLSLSPGERATLSCRASQSVSSTYLAWYQQKPGQSPRLLIYGASNRATGI PDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSRLLSFGGGTKVEIK (SEQIDNO: 86) CDR1 DNA Sequence CAG AGT GTT AGC AGC ACC TAC (SEQIDNO: 87) CDR1 Amino Acid Sequence Q S V S S T Y (SEQIDNO: 88) CDR2 DNA Sequence GGT GCA TCA (SEQIDNO: 89) CDR2 Amino Acid Sequence GAS (SEQIDNO: 90) CDR3 DNA Sequence CAG CAG TAT GGT AGC TCA CGT CTG CTC AGT (SEQIDNO: 91) CDR3 Amino Acid Sequence QQYGSSRLLS (SEQIDNO: 92) HC DNA Sequence GAGGTGCAGCTGGTGGAGTCTGAGGGAGGCTGGGTACAGCCTGGGGGGTCCCTG AGACTCTCCTGTGCAGCCTCTGGAATCACCTTTAGCATCTATGCCATGGCCTGGG TCCGCCAGGCTCCAGGGAAGGGACTTGAGTGGGTCTCAACTATTAGTGGTAGTG GTGATTCCACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCAGAGA CAATTCCAAGAACACGCTGTTTCTGCAAATGAACAGCCTGAGAGCCGTGGACAC GGCCATATATTACTGTGCGAAAAGAGGATTTGCAGCTTTTGACTACTGGGGCCAG GGAACCCTGGTCACCGTCTCCTCAGCCTCCACCAAGGGCCCATCGGTCTTCCCCC TGGCGCCCTGCTCCAGGAGCACCTCCGAGAGCACAGCCGCCCTGGGCTGCCTGG TCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGA CCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCT CAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCACGAAGACCTACACCTG CAACGTAGATCACAAGCCCAGCAACACCAAGGTGGACAAGAGAGTTGAGTCCAA ATATGGTCCCCCATGCCCACCGTGCCCAGCACCACCTGTGGCAGGACCATCAGTC TTCCTGTTCCCCCCAAAACCCAAGGACACTCTCATGATCTCCCGGACCCCTGAGG TCACGTGCGTGGTGGTGGACGTGAGCCAGGAAGACCCCGAGGTCCAGTTCAACT GGTACGTGGATGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAG CAGTTCAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACT GGCTGAACGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGGCCTCCCGTCCT CCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAGCCACAGGTGT ACACCCTGCCCCCATCCCAGGAGGAGATGACCAAGAACCAGGTCAGCCTGACCT GCCTGGTCAAAGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATG GGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCT CCTTCTTCCTCTACAGCAGGCTCACCGTGGACAAGAGCAGGTGGCAGGAGGGGA ATGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACACAGAA GTCCCTCTCCCTGTCTCTGGGTAAATGA (SEQIDNO: 93) HC Amino Acid Sequence EVQLVESEGGWVQPGGSLRLSCAASGITFSIYAMAWVRQAPGKGLEWVSTISGSGDS TYYADSVKGRFTISRDNSKNTLFLQMNSLRAVDTAIYYCAKRGFAAFDYWGQGTLV TVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFP AVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAP PVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKT KPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREP QVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGS FFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK* (SEQIDNO: 94) LC DNA Sequence GAAATTGTGTTGACGCAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGGGAAAGAG CCACCCTCTCCTGTAGGGCCAGTCAGAGTGTTAGCAGCACCTACTTAGCCTGGTA CCAGCAGAAACCTGGCCAGTCTCCCAGGCTCCTCATCTATGGTGCATCAAACAGG GCCACTGGCATCCCAGACAGGTTCAGTGGCAGTGGGTCTGGGACAGACTTCACT CTCACCATCAGCAGACTGGAGCCTGAAGATTTTGCAGTGTATTACTGTCAGCAGT ATGGTAGCTCACGTCTGCTCAGTTTCGGCGGAGGGACCAAGGTGGAGATCAAAC GAACTGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAA ATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCC AAAGTACAGTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAGGAGAGT GTCACAGAGCAGGACAGCAAGGACAGCACCTACAGCCTCAGCAGCACCCTGACG CTGAGCAAAGCAGACTACGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCAT CAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGTTAG (SEQIDNO: 95) LC Amino Acid Sequence EIVLTQSPGTLSLSPGERATLSCRASQSVSSTYLAWYQQKPGQSPRLLIYGASNRATGI PDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSRLLSFGGGTKVEIKRTVAAPSVF IFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTY SLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC* (SEQIDNO: 96) REGN14153 HCVR DNA Sequence GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTG AGACTCTCCTGTGCAGCCTCTGGATTCACCTTTAGTAGTTATGCCATGAACTGGG TCCGCCAGGCTCCAGGGGAGGGCCTGGAGTGGGTCTCAACTTTGACTGGTAGTG GTGGTAGTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCAGAG ACAATTCCAAGAACACGCTGTTTCTGCACATGAGCAGCCTGAGAGCCGAGGACA CGGCCGTATATTACTGTGCGAAAGGTGGAGTGGGATCTACTAAGGTTGTCTACTA CGGTTTGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCA (SEQIDNO: 97) HCVR Amino Acid Sequence EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYAMNWVRQAPGEGLEWVSTLTGSGG STYYADSVKGRFTISRDNSKNTLFLHMSSLRAEDTAVYYCAKGGVGSTKVVYYGLD VWGQGTTVTVSS (SEQIDNO: 98) CDR1 DNA Sequence GGA TTC ACC TTT AGT AGT TAT GCC (SEQIDNO: 99) CDR1 Amino Acid Sequence GFTFSSYA (SEQIDNO: 100) CDR2 DNA Sequence TTG ACT GGT AGT GGT GGT AGT ACA (SEQIDNO: 101) CDR2 Amino Acid Sequence LTGSGGST (SEQIDNO: 102) CDR3 DNA Sequence GCG AAA GGT GGA GTG GGA TCT ACT AAG GTT GTC TAC TAC GGT TTG GAC GTC (SEQIDNO: 103) CDR3 Amino Acid Sequence AKGGVGSTKVVYYGLDV (SEQIDNO: 104) LCVR DNA Sequence GATATTGTGATGACTCAGTCTCCACTTTCCCTGCCCGTCATCCCTGGAGAGCCGG CCTCCATCTCCTGCAGGTCTAGTCAGAGCCTCCTGCATCGTAATGGATACAACTT TTTGGATTGGTACCTGCGGAAGCCAGGGCAGTCTCCACAGCTCCTGATCTATTTG GGTTCTAATCGGGCCTCCGGGGTCCCTGACAGGTTCAGTGGCAGTGGATCAGGC ACAGATTTTACACTGAAAATCAGCAGAGTGGAGGCTGAGGATGTTGGGGTTTATT ACTGCATGCAAGCTCTACAAACTCCGCTCACTTTCGGCGGAGGGACCAAGGTGG AGATCAAA (SEQIDNO: 105) LCVR Amino Acid Sequence DIVMTQSPLSLPVIPGEPASISCRSSQSLLHRNGYNFLDWYLRKPGQSPQLLIYLGSNR ASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQALQTPLTFGGGTKVEIK (SEQIDNO: 106) CDR1 DNA Sequence CAG AGC CTC CTG CAT CGT AAT GGA TAC AAC TTT (SEQIDNO: 107) CDR1 Amino Acid Sequence QSLLHRNGYNF (SEQIDNO: 108) CDR2 DNA Sequence TTG GGT TCT (SEQIDNO: 33) CDR2 Amino Acid Sequence L G S (SEQIDNO: 34) CDR3 DNA Sequence ATG CAA GCT CTA CAA ACT CCG CTC ACT (SEQIDNO: 109) CDR3 Amino Acid Sequence MQALQTPLT (SEQIDNO: 110) HC DNA Sequence GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTG AGACTCTCCTGTGCAGCCTCTGGATTCACCTTTAGTAGTTATGCCATGAACTGGG TCCGCCAGGCTCCAGGGGAGGGCCTGGAGTGGGTCTCAACTTTGACTGGTAGTG GTGGTAGTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCAGAG ACAATTCCAAGAACACGCTGTTTCTGCACATGAGCAGCCTGAGAGCCGAGGACA CGGCCGTATATTACTGTGCGAAAGGTGGAGTGGGATCTACTAAGGTTGTCTACTA CGGTTTGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCAGCCTCCACC AAGGGCCCATCGGTCTTCCCCCTGGCGCCCTGCTCCAGGAGCACCTCCGAGAGCA CAGCCGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTC GTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAG TCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGG GCACGAAGACCTACACCTGCAACGTAGATCACAAGCCCAGCAACACCAAGGTGG ACAAGAGAGTTGAGTCCAAATATGGTCCCCCATGCCCACCGTGCCCAGCACCAC CTGTGGCAGGACCATCAGTCTTCCTGTTCCCCCCAAAACCCAAGGACACTCTCAT GATCTCCCGGACCCCTGAGGTCACGTGCGTGGTGGTGGACGTGAGCCAGGAAGA CCCCGAGGTCCAGTTCAACTGGTACGTGGATGGCGTGGAGGTGCATAATGCCAA GACAAAGCCGCGGGAGGAGCAGTTCAACAGCACGTACCGTGTGGTCAGCGTCCT CACCGTCCTGCACCAGGACTGGCTGAACGGCAAGGAGTACAAGTGCAAGGTCTC CAACAAAGGCCTCCCGTCCTCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCA GCCCCGAGAGCCACAGGTGTACACCCTGCCCCCATCCCAGGAGGAGATGACCAA GAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTACCCCAGCGACATCGCC GTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCC CGTGCTGGACTCCGACGGCTCCTTCTTCCTCTACAGCAGGCTCACCGTGGACAAG AGCAGGTGGCAGGAGGGGAATGTCTTCTCATGCTCCGTGATGCATGAGGCTCTG CACAACCACTACACACAGAAGTCCCTCTCCCTGTCTCTGGGTAAATGA (SEQIDNO: 111) HC Amino Acid Sequence EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYAMNWVRQAPGEGLEWVSTLTGSGG STYYADSVKGRFTISRDNSKNTLFLHMSSLRAEDTAVYYCAKGGVGSTKVVYYGLD VWGQGTTVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGA LTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKY GPPCPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVD GVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTIS KAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKT TPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK* (SEQIDNO: 112) LC DNA Sequence GATATTGTGATGACTCAGTCTCCACTTTCCCTGCCCGTCATCCCTGGAGAGCCGG CCTCCATCTCCTGCAGGTCTAGTCAGAGCCTCCTGCATCGTAATGGATACAACTT TTTGGATTGGTACCTGCGGAAGCCAGGGCAGTCTCCACAGCTCCTGATCTATTTG GGTTCTAATCGGGCCTCCGGGGTCCCTGACAGGTTCAGTGGCAGTGGATCAGGC ACAGATTTTACACTGAAAATCAGCAGAGTGGAGGCTGAGGATGTTGGGGTTTATT ACTGCATGCAAGCTCTACAAACTCCGCTCACTTTCGGCGGAGGGACCAAGGTGG AGATCAAACGAACTGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGA GCAGTTGAAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCC AGAGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCC CAGGAGAGTGTCACAGAGCAGGACAGCAAGGACAGCACCTACAGCCTCAGCAG CACCCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTACGCCTGCGA AGTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGA GTGTTAG (SEQIDNO: 113) LC Amino Acid Sequence DIVMTQSPLSLPVIPGEPASISCRSSQSLLHRNGYNFLDWYLRKPGQSPQLLIYLGSNR ASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQALQTPLTFGGGTKVEIKRTVA APSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDS KDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC* (SEQIDNO: 114) REGN14154 HCVR DNA Sequence CAGCTGCAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCGGAGACCCTG TCCCTCACTTGCACTGTCTCGGGTGGCTCCAGCAGCAGAAGTAGTTACTACTGGG GCTGGATCCGCCAGCCCCCAGGGAAGGGACTGGAGTGGATTGGGAGTATCTATT ATAGTGGGAACACCTACTACAACCCGTCCCTCCAGAGTCGAGTCACCATATCCGT AGACACGTCCAAGAACCAGTTCTCCCTGAAACTGAACTCTGTGACCGCCGCAGA CACGGCTGTATTTTATTGTGCGAGACACAAACCTACTACGTGGGCTTTTGATATC TGGGGCCAAGGGACAATGGTCACCGTCTCTTCA (SEQIDNO: 115) HCVR Amino Acid Sequence QLQLQESGPGLVKPSETLSLTCTVSGGSSSRSSYYWGWIRQPPGKGLEWIGSIYYSGN TYYNPSLQSRVTISVDTSKNQFSLKLNSVTAADTAVFYCARHKPTTWAFDIWGQGT MVTVSS (SEQIDNO: 116) CDR1 DNA Sequence GGT GGC TCC AGC AGC AGA AGT AGT TAC TAC (SEQIDNO: 117) CDR1 Amino Acid Sequence GGSSSRSSYY (SEQIDNO: 118) CDR2 DNA Sequence ATC TAT TAT AGT GGG AAC ACC (SEQIDNO: 119) CDR2 Amino Acid Sequence I Y Y S G N T (SEQIDNO: 120) CDR3 DNA Sequence GCG AGA CAC AAA CCT ACT ACG TGG GCT TTT GAT ATC (SEQIDNO: 121) CDR3 Amino Acid Sequence ARHKPTTWAFDI (SEQIDNO: 122) LCVR DNA Sequence GACATCCAGATGACCCAGTCTCCTTCCACCCTGTCTGCATCTGTAGGAGACAGAG TCACCATCACTTGCCGGGCCAGTCAGAGTATCAGTAGTTGGTTGGCCTGGTATCA GCAGAAACCAGGGAAAGTCCCAAAGTTGCTGATCTATAAGGCGTCTAATTTAGA AAGTGGGGTCCCCTCAAGGTTCAGCGGCAGTGGATCTGGGACAGAATTCACTCT CACCATCAGCGACCTGCAGCCTGATGATTTTGCAAGTTATTACTGCCAACAGTAT AGTACTTATTCTCGGACGTTCGGCCGAGGGACCAAGGTGGAGATCAAA (SEQIDNO: 123) LCVR Amino Acid Sequence DIQMTQSPSTLSASVGDRVTITCRASQSISSWLAWYQQKPGKVPKLLIYKASNLESGV PSRFSGSGSGTEFTLTISDLQPDDFASYYCQQYSTYSRTFGRGTKVEIK (SEQIDNO: 124) CDR1 DNA Sequence CAG AGT ATC AGT AGT TGG (SEQIDNO: 125) CDR1 Amino Acid Sequence Q S I S S W (SEQIDNO: 126) CDR2 DNA Sequence AAG GCG TCT (SEQIDNO: 127) CDR2 Amino Acid Sequence KAS (SEQIDNO: 128) CDR3 DNA Sequence CAA CAG TAT AGT ACT TAT TCT CGG ACG (SEQIDNO: 129) CDR3 Amino Acid Sequence QQYSTYSRT (SEQIDNO: 130) HC DNA Sequence CAGCTGCAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCGGAGACCCTG TCCCTCACTTGCACTGTCTCGGGTGGCTCCAGCAGCAGAAGTAGTTACTACTGGG GCTGGATCCGCCAGCCCCCAGGGAAGGGACTGGAGTGGATTGGGAGTATCTATT ATAGTGGGAACACCTACTACAACCCGTCCCTCCAGAGTCGAGTCACCATATCCGT AGACACGTCCAAGAACCAGTTCTCCCTGAAACTGAACTCTGTGACCGCCGCAGA CACGGCTGTATTTTATTGTGCGAGACACAAACCTACTACGTGGGCTTTTGATATC TGGGGCCAAGGGACAATGGTCACCGTCTCTTCAGCCTCCACCAAGGGCCCATCG GTCTTCCCCCTGGCGCCCTGCTCCAGGAGCACCTCCGAGAGCACAGCCGCCCTGG GCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAG GCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACT CTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCACGAAGACC TACACCTGCAACGTAGATCACAAGCCCAGCAACACCAAGGTGGACAAGAGAGTT GAGTCCAAATATGGTCCCCCATGCCCACCGTGCCCAGCACCACCTGTGGCAGGA CCATCAGTCTTCCTGTTCCCCCCAAAACCCAAGGACACTCTCATGATCTCCCGGA CCCCTGAGGTCACGTGCGTGGTGGTGGACGTGAGCCAGGAAGACCCCGAGGTCC AGTTCAACTGGTACGTGGATGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGC GGGAGGAGCAGTTCAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGC ACCAGGACTGGCTGAACGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGGCC TCCCGTCCTCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAGC CACAGGTGTACACCCTGCCCCCATCCCAGGAGGAGATGACCAAGAACCAGGTCA GCCTGACCTGCCTGGTCAAAGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGG AGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACT CCGACGGCTCCTTCTTCCTCTACAGCAGGCTCACCGTGGACAAGAGCAGGTGGCA GGAGGGGAATGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTAC ACACAGAAGTCCCTCTCCCTGTCTCTGGGTAAATGA (SEQIDNO: 131) HC Amino Acid Sequence QLQLQESGPGLVKPSETLSLTCTVSGGSSSRSSYYWGWIRQPPGKGLEWIGSIYYSGN TYYNPSLQSRVTISVDTSKNQFSLKLNSVTAADTAVFYCARHKPTTWAFDIWGQGT MVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVH TFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPC PAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNA KTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPR EPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSD GSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK* (SEQIDNO: 132) LC DNA Sequence GACATCCAGATGACCCAGTCTCCTTCCACCCTGTCTGCATCTGTAGGAGACAGAG TCACCATCACTTGCCGGGCCAGTCAGAGTATCAGTAGTTGGTTGGCCTGGTATCA GCAGAAACCAGGGAAAGTCCCAAAGTTGCTGATCTATAAGGCGTCTAATTTAGA AAGTGGGGTCCCCTCAAGGTTCAGCGGCAGTGGATCTGGGACAGAATTCACTCT CACCATCAGCGACCTGCAGCCTGATGATTTTGCAAGTTATTACTGCCAACAGTAT AGTACTTATTCTCGGACGTTCGGCCGAGGGACCAAGGTGGAGATCAAACGAACT GTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTG GAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAGT ACAGTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAGGAGAGTGTCAC AGAGCAGGACAGCAAGGACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGAG CAAAGCAGACTACGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGGG CCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGTTAG (SEQIDNO: 133) LC Amino Acid Sequence DIQMTQSPSTLSASVGDRVTITCRASQSISSWLAWYQQKPGKVPKLLIYKASNLESGV PSRFSGSGSGTEFTLTISDLQPDDFASYYCQQYSTYSRTFGRGTKVEIKRTVAAPSVFI FPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTY SLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC* (SEQIDNO: 134) REGN14155 HCVR DNA Sequence CAGGTTCAGCTGGTGCAGTCTGGAGGTGAGGTGAAGAAGCCTGGGGACTCAGTG AAGGTCTCCTGCAAGGCTTCTGGTTACACCTTTACCAGCTATGGTATCAGCTGGG TGCGACAGGCCCCTGGACAAGGGCTTGAGTGGATGGGATGGATCAGCGTCTACA GTGGTAAAAAAAACTACGCACGGAAGGTCCAGGACAGAGTCACCATGACCACA GACACATCCACGAGCACAGCCTACATGGAGGTGAGGAGCCTGCGATCTGACGAC ACGGCCATATATTATTGTACAAGAAGGGGAGTGTCTTCGATGGTCGGTGCTTTTG AAATCTGGGGCCAAGGGACAATGGTCACCGTCTCTTCA (SEQIDNO: 135) HCVR Amino Acid Sequence QVQLVQSGGEVKKPGDSVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGWISVYS GKKNYARKVQDRVTMTTDTSTSTAYMEVRSLRSDDTAIYYCTRRGVSSMVGAFEI WGQGTMVTVSS (SEQIDNO: 136) CDR1 DNA Sequence GGT TAC ACC TTT ACC AGC TAT GGT (SEQIDNO: 137) CDR1 Amino Acid Sequence GYTFTSYG (SEQIDNO: 138) CDR2 DNA Sequence ATC AGC GTC TAC AGT GGT AAA AAA (SEQIDNO: 139) CDR2 Amino Acid Sequence I S V Y S G K K (SEQIDNO: 140) CDR3 DNA Sequence ACA AGA AGG GGA GTG TCT TCG ATG GTC GGT GCT TTT GAA ATC (SEQIDNO: 141) CDR3 Amino Acid Sequence TRRGVSSMVGAFEI (SEQIDNO: 142) LCVR DNA Sequence GAAATTGTGTTGACGCAGTCTCCAGGCATTCTGTCTTTGTCTCCAGGGGAAAGAG CCACCCTCTCCTGCAAGGCCAGTCAGAGTGTTAGCAACAGCTACTTAGCCTGGTA CCAGCAGAAACCTGGCCAGGCTCCCAGGCTCCTCATCTATGGAGCATCTAGTAG GGCCACTGGCATCCCAGACAGGTTCAGTGGCAGTGGGTCTGGGACAGACTTCAC TGTCACCATCAGCAGACTGGAGCCTGAAGATTTTGCAGTCTATTACTGTCAGCAG TATGGTAGCTCACCGCTCACTTTCGGCGGAGGGACCAAGGTGGAGATCAAA (SEQIDNO: 143) LCVR Amino Acid Sequence EIVLTQSPGILSLSPGERATLSCKASQSVSNSYLAWYQQKPGQAPRLLIYGASSRATGI PDRFSGSGSGTDFTVTISRLEPEDFAVYYCQQYGSSPLTFGGGTKVEIK (SEQIDNO: 144) CDR1 DNA Sequence CAG AGT GTT AGC AAC AGC TAC (SEQIDNO: 145) CDR1 Amino Acid Sequence Q S V S N S Y (SEQIDNO: 146) CDR2 DNA Sequence GGA GCA TCT (SEQIDNO: 147) CDR2 Amino Acid Sequence GAS (SEQIDNO: 90) CDR3 DNA Sequence CAG CAG TAT GGT AGC TCA CCG CTC ACT (SEQIDNO: 148) CDR3 Amino Acid Sequence QQYGSSPLT (SEQIDNO: 149) HC DNA Sequence CAGGTTCAGCTGGTGCAGTCTGGAGGTGAGGTGAAGAAGCCTGGGGACTCAGTG AAGGTCTCCTGCAAGGCTTCTGGTTACACCTTTACCAGCTATGGTATCAGCTGGG TGCGACAGGCCCCTGGACAAGGGCTTGAGTGGATGGGATGGATCAGCGTCTACA GTGGTAAAAAAAACTACGCACGGAAGGTCCAGGACAGAGTCACCATGACCACA GACACATCCACGAGCACAGCCTACATGGAGGTGAGGAGCCTGCGATCTGACGAC ACGGCCATATATTATTGTACAAGAAGGGGAGTGTCTTCGATGGTCGGTGCTTTTG AAATCTGGGGCCAAGGGACAATGGTCACCGTCTCTTCAGCCTCCACCAAGGGCC CATCGGTCTTCCCCCTGGCGCCCTGCTCCAGGAGCACCTCCGAGAGCACAGCCGC CCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAAC TCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCAG GACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCACGAA GACCTACACCTGCAACGTAGATCACAAGCCCAGCAACACCAAGGTGGACAAGAG AGTTGAGTCCAAATATGGTCCCCCATGCCCACCGTGCCCAGCACCACCTGTGGCA GGACCATCAGTCTTCCTGTTCCCCCCAAAACCCAAGGACACTCTCATGATCTCCC GGACCCCTGAGGTCACGTGCGTGGTGGTGGACGTGAGCCAGGAAGACCCCGAGG TCCAGTTCAACTGGTACGTGGATGGCGTGGAGGTGCATAATGCCAAGACAAAGC CGCGGGAGGAGCAGTTCAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCC TGCACCAGGACTGGCTGAACGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAG GCCTCCCGTCCTCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAG AGCCACAGGTGTACACCCTGCCCCCATCCCAGGAGGAGATGACCAAGAACCAGG TCAGCCTGACCTGCCTGGTCAAAGGCTTCTACCCCAGCGACATCGCCGTGGAGTG GGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGA CTCCGACGGCTCCTTCTTCCTCTACAGCAGGCTCACCGTGGACAAGAGCAGGTGG CAGGAGGGGAATGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACT ACACACAGAAGTCCCTCTCCCTGTCTCTGGGTAAATGA (SEQIDNO: 150) HC Amino Acid Sequence QVQLVQSGGEVKKPGDSVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGWISVYS GKKNYARKVQDRVTMTTDTSTSTAYMEVRSLRSDDTAIYYCTRRGVSSMVGAFEI WGQGTMVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGAL TSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYG PPCPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDG VEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISK AKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTP PVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK* (SEQIDNO: 151) LC DNA Sequence GAAATTGTGTTGACGCAGTCTCCAGGCATTCTGTCTTTGTCTCCAGGGGAAAGAG CCACCCTCTCCTGCAAGGCCAGTCAGAGTGTTAGCAACAGCTACTTAGCCTGGTA CCAGCAGAAACCTGGCCAGGCTCCCAGGCTCCTCATCTATGGAGCATCTAGTAG GGCCACTGGCATCCCAGACAGGTTCAGTGGCAGTGGGTCTGGGACAGACTTCAC TGTCACCATCAGCAGACTGGAGCCTGAAGATTTTGCAGTCTATTACTGTCAGCAG TATGGTAGCTCACCGCTCACTTTCGGCGGAGGGACCAAGGTGGAGATCAAACGA ACTGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAAT CTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAA AGTACAGTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAGGAGAGTGT CACAGAGCAGGACAGCAAGGACAGCACCTACAGCCTCAGCAGCACCCTGACGCT GAGCAAAGCAGACTACGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATCA GGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGTTAG (SEQIDNO: 152) LC Amino Acid Sequence EIVLTQSPGILSLSPGERATLSCKASQSVSNSYLAWYQQKPGQAPRLLIYGASSRATGI PDRFSGSGSGTDFTVTISRLEPEDFAVYYCQQYGSSPLTFGGGTKVEIKRTVAAPSVFI FPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTY SLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC* (SEQIDNO: 153) REGN14156 HCVR DNA Sequence GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGAGTCCCTG AGACTCTCCTGTGCAGCCTCTGGATTCACCTTTAGCAGCTATGCCATGACCTGGG TCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGGTCTCAACTATTAGTGGTAGTG GTGGTAACACATACTACGCAGTCTCCGTGAAGGGCCGGTTCACCATCTCCAGAG ACACTTCCAAGAACACGCTGTATCTGCAAATGAACGGCCTGAGAGCCGAGGACA CGGCCGTATATTACTGTGCGACCCTCACCAGTGGCTGGTACCTTTTTGAGTACTG GGGCCAGGGAACCCTGGTCACCGTCTCCTCA (SEQIDNO: 154) HCVR Amino Acid Sequence EVQLVESGGGLVQPGESLRLSCAASGFTFSSYAMTWVRQAPGKGLEWVSTISGSGG NTYYAVSVKGRFTISRDTSKNTLYLQMNGLRAEDTAVYYCATLTSGWYLFEYWGQ GTLVTVSS (SEQIDNO: 155) CDR1 DNA Sequence GGA TTC ACC TTT AGC AGC TAT GCC (SEQIDNO: 156) CDR1 Amino Acid Sequence GFTFSSYA (SEQIDNO: 100) CDR2 DNA Sequence ATT AGT GGT AGT GGT GGT AAC ACA (SEQIDNO: 157) CDR2 Amino Acid Sequence I S G S G G N T (SEQIDNO: 158) CDR3 DNA Sequence GCG ACC CTC ACC AGT GGC TGG TAC CTT TTT GAG TAC (SEQIDNO: 159) CDR3 Amino Acid Sequence ATLTSGWYLFEY (SEQIDNO: 160) LCVR DNA Sequence GAAATTGTGTTGACGCAGTCTCCAGGCACCCTGTCTTTGGCTCCAGGGGAAAGAG CCACCCTCTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCAGCTTCTTTGCCTGGTA CCAGCAGAAACCTGGCCAGGCTCCCAGGCTCCTCATCTATGGTGCATCCAGCAG GGCCACTGGCATCCCAGACAGGTTCAGTGGCAGTGGGTCTGGGACAGACTTCAC TCTCACCATCAGCAGACTGGAGCCTGAAGATTTTGCAGTGTATTACTGTCAGCAG TATGGAAGCTCACCTCCGTGGACGTTCGGCCAAGGGACCAAGGTGGAAATCAAA (SEQIDNO: 161) LCVR Amino Acid Sequence EIVLTQSPGTLSLAPGERATLSCRASQSVSSSFFAWYQQKPGQAPRLLIYGASSRATGI PDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPPWTFGQGTKVEIK (SEQIDNO: 162) CDR1 DNA Sequence CAG AGT GTT AGC AGC AGC TTC (SEQIDNO: 163) CDR1 Amino Acid Sequence Q S V S S S F (SEQIDNO: 164) CDR2 DNA Sequence GGT GCA TCC (SEQIDNO: 165) CDR2 Amino Acid Sequence GAS (SEQIDNO: 90) CDR3 DNA Sequence CAG CAG TAT GGA AGC TCA CCT CCG TGG ACG (SEQIDNO: 166) CDR3 Amino Acid Sequence QQYGSSPPWT (SEQIDNO: 167) HC DNA Sequence GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGAGTCCCTG AGACTCTCCTGTGCAGCCTCTGGATTCACCTTTAGCAGCTATGCCATGACCTGGG TCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGGTCTCAACTATTAGTGGTAGTG GTGGTAACACATACTACGCAGTCTCCGTGAAGGGCCGGTTCACCATCTCCAGAG ACACTTCCAAGAACACGCTGTATCTGCAAATGAACGGCCTGAGAGCCGAGGACA CGGCCGTATATTACTGTGCGACCCTCACCAGTGGCTGGTACCTTTTTGAGTACTG GGGCCAGGGAACCCTGGTCACCGTCTCCTCAGCCTCCACCAAGGGCCCATCGGTC TTCCCCCTGGCGCCCTGCTCCAGGAGCACCTCCGAGAGCACAGCCGCCCTGGGCT GCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCG CCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTA CTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCACGAAGACCTAC ACCTGCAACGTAGATCACAAGCCCAGCAACACCAAGGTGGACAAGAGAGTTGAG TCCAAATATGGTCCCCCATGCCCACCGTGCCCAGCACCACCTGTGGCAGGACCAT CAGTCTTCCTGTTCCCCCCAAAACCCAAGGACACTCTCATGATCTCCCGGACCCC TGAGGTCACGTGCGTGGTGGTGGACGTGAGCCAGGAAGACCCCGAGGTCCAGTT CAACTGGTACGTGGATGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGA GGAGCAGTTCAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAG GACTGGCTGAACGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGGCCTCCCG TCCTCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAGCCACAG GTGTACACCCTGCCCCCATCCCAGGAGGAGATGACCAAGAACCAGGTCAGCCTG ACCTGCCTGGTCAAAGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGC AATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGAC GGCTCCTTCTTCCTCTACAGCAGGCTCACCGTGGACAAGAGCAGGTGGCAGGAG GGGAATGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACAC AGAAGTCCCTCTCCCTGTCTCTGGGTAAATGA (SEQIDNO: 168) HC Amino Acid Sequence EVQLVESGGGLVQPGESLRLSCAASGFTFSSYAMTWVRQAPGKGLEWVSTISGSGG NTYYAVSVKGRFTISRDTSKNTLYLQMNGLRAEDTAVYYCATLTSGWYLFEYWGQ GTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGV HTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPP CPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHN AKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQP REPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDS DGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK* (SEQIDNO: 169) LC DNA Sequence GAAATTGTGTTGACGCAGTCTCCAGGCACCCTGTCTTTGGCTCCAGGGGAAAGAG CCACCCTCTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCAGCTTCTTTGCCTGGTA CCAGCAGAAACCTGGCCAGGCTCCCAGGCTCCTCATCTATGGTGCATCCAGCAG GGCCACTGGCATCCCAGACAGGTTCAGTGGCAGTGGGTCTGGGACAGACTTCAC TCTCACCATCAGCAGACTGGAGCCTGAAGATTTTGCAGTGTATTACTGTCAGCAG TATGGAAGCTCACCTCCGTGGACGTTCGGCCAAGGGACCAAGGTGGAAATCAAA CGAACTGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGA AATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGC CAAAGTACAGTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAGGAGAG TGTCACAGAGCAGGACAGCAAGGACAGCACCTACAGCCTCAGCAGCACCCTGAC GCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCA TCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGTTAG (SEQIDNO: 170) LC Amino Acid Sequence EIVLTQSPGTLSLAPGERATLSCRASQSVSSSFFAWYQQKPGQAPRLLIYGASSRATGI PDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPPWTFGQGTKVEIKRTVAAPSV FIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDST YSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC* (SEQIDNO: 171) REGN14157 HCVR DNA Sequence GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTG AGACTCTCCTGTGCAGCCTCTGGATTCACCTTTAGCAGCTATGCCATGAGCTGGG TCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGGTCTCAGCTATTAGTGGTAGTG GTGATAACACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCAGAG ACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGAGAGTCGAGGATA CGGCCGTATATTATTGTGCGAAAGAGAAGAGCAGTGGCTGGTACGAATACTGGG GCCAGGGAACCCTGGTCACCGTCTCCTCA (SEQIDNO: 172) HCVR Amino Acid Sequence EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGD NTYYADSVKGRFTISRDNSKNTLYLQMNSLRVEDTAVYYCAKEKSSGWYEYWGQG TLVTVSS (SEQIDNO: 173) CDR1 DNA Sequence GGA TTC ACC TTT AGC AGC TAT GCC (SEQIDNO: 156) CDR1 Amino Acid Sequence GFTFSSYA (SEQIDNO: 100) CDR2 DNA Sequence ATT AGT GGT AGT GGT GAT AAC ACA (SEQIDNO: 174) CDR2 Amino Acid Sequence I S G S G D N T (SEQIDNO: 175) CDR3 DNA Sequence GCG AAA GAG AAG AGC AGT GGC TGG TAC GAA TAC (SEQIDNO: 176) CDR3 Amino Acid Sequence AKEKSSGWYEY (SEQIDNO: 177) LCVR DNA Sequence GACATCGTGATGACCCAGTCTCCAGACTCCCTGGCTGTGTCTCTGGGCGAGAGGG CCACCATCAACTGCAAGTCCAGCCAGAGTGTTTTATACAGTTCCAACAATAAGAA TTACTTAGCTTGGTACCAGCAGAAACCAGGACAGACTCCTAAACTGCTCATTTAC TGGGCATCTACCCGGGAATCCGGGGTCCCTGACCGATTCAGTGGCAGCGGGTCT GGGACAGATTTCACTCTCACCATCAGCAGCCTGCAGGCTGAAGATGTGGCAGTTT ATTACTGTCAGCAATATTATTTTATTCCGTACACTTTTGGCCAGGGGACCAAGCT GGAGATCAAA (SEQIDNO: 178) LCVR Amino Acid Sequence DIVMTQSPDSLAVSLGERATINCKSSQSVLYSSNNKNYLAWYQQKPGQTPKLLIYWA STRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYFIPYTFGQGTKLEIK (SEQIDNO: 179) CDR1 DNA Sequence CAG AGT GTT TTA TAC AGT TCC AAC AAT AAG AAT TAC (SEQIDNO: 180) CDR1 Amino Acid Sequence QSVLYSSNNKNY (SEQIDNO: 181) CDR3 DNA Sequence CAG CAA TAT TAT TTT ATT CCG TAC ACT (SEQIDNO: 182) CDR3 Amino Acid Sequence QQYYFIPYT (SEQIDNO: 183) HC DNA Sequence GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTG AGACTCTCCTGTGCAGCCTCTGGATTCACCTTTAGCAGCTATGCCATGAGCTGGG TCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGGTCTCAGCTATTAGTGGTAGTG GTGATAACACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCAGAG ACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGAGAGTCGAGGATA CGGCCGTATATTATTGTGCGAAAGAGAAGAGCAGTGGCTGGTACGAATACTGGG GCCAGGGAACCCTGGTCACCGTCTCCTCAGCCTCCACCAAGGGCCCATCGGTCTT CCCCCTGGCGCCCTGCTCCAGGAGCACCTCCGAGAGCACAGCCGCCCTGGGCTG CCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGC CCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTAC TCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCACGAAGACCTAC ACCTGCAACGTAGATCACAAGCCCAGCAACACCAAGGTGGACAAGAGAGTTGAG TCCAAATATGGTCCCCCATGCCCACCGTGCCCAGCACCACCTGTGGCAGGACCAT CAGTCTTCCTGTTCCCCCCAAAACCCAAGGACACTCTCATGATCTCCCGGACCCC TGAGGTCACGTGCGTGGTGGTGGACGTGAGCCAGGAAGACCCCGAGGTCCAGTT CAACTGGTACGTGGATGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGA GGAGCAGTTCAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAG GACTGGCTGAACGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGGCCTCCCG TCCTCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAGCCACAG GTGTACACCCTGCCCCCATCCCAGGAGGAGATGACCAAGAACCAGGTCAGCCTG ACCTGCCTGGTCAAAGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGC AATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGAC GGCTCCTTCTTCCTCTACAGCAGGCTCACCGTGGACAAGAGCAGGTGGCAGGAG GGGAATGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACAC AGAAGTCCCTCTCCCTGTCTCTGGGTAAATGA (SEQIDNO: 184) HC Amino Acid Sequence EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGD NTYYADSVKGRFTISRDNSKNTLYLQMNSLRVEDTAVYYCAKEKSSGWYEYWGQG TLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVH TFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPC PAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNA KTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPR EPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSD GSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK* (SEQIDNO: 185) LC DNA Sequence GACATCGTGATGACCCAGTCTCCAGACTCCCTGGCTGTGTCTCTGGGCGAGAGGG CCACCATCAACTGCAAGTCCAGCCAGAGTGTTTTATACAGTTCCAACAATAAGAA TTACTTAGCTTGGTACCAGCAGAAACCAGGACAGACTCCTAAACTGCTCATTTAC TGGGCATCTACCCGGGAATCCGGGGTCCCTGACCGATTCAGTGGCAGCGGGTCT GGGACAGATTTCACTCTCACCATCAGCAGCCTGCAGGCTGAAGATGTGGCAGTTT ATTACTGTCAGCAATATTATTTTATTCCGTACACTTTTGGCCAGGGGACCAAGCT GGAGATCAAACGAACTGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGAT GAGCAGTTGAAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATC CCAGAGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCCAATCGGGTAACT CCCAGGAGAGTGTCACAGAGCAGGACAGCAAGGACAGCACCTACAGCCTCAGC AGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTACGCCTGC GAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGA GAGTGTTAG (SEQIDNO: 186) LC Amino Acid Sequence DIVMTQSPDSLAVSLGERATINCKSSQSVLYSSNNKNYLAWYQQKPGQTPKLLIYWA STRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYFIPYTFGQGTKLEIKRT VAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQ DSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC* (SEQIDNO: 187) REGN14158 HCVR DNA Sequence CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTG AGACTCTCCTGTGCAGCCTCTGGATTCACCTTCAGTCACTATGGCATGCACTGGG TCCGCCAGGCTCCAGGCAAGGGGCTGGAGTGGATGGCAGTTATATCATATGATG GAAGTAACAAATATTATGCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAG ACAATTCCAGGAACACGCTGTATCTGCAAATGAACAGCCTGAGAACTGAGGACA CGGCTGTGTTTTATTGTGCGAAAGAGTCGAGTATAACAGCCCGTCCGAGAGACTA CAACTACGGTATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCA (SEQIDNO: 188) HCVR Amino Acid Sequence QVQLVESGGGVVQPGRSLRLSCAASGFTFSHYGMHWVRQAPGKGLEWMAVISYDG SNKYYADSVKGRFTISRDNSRNTLYLQMNSLRTEDTAVFYCAKESSITARPRDYNYG MDVWGQGTTVTVSS (SEQIDNO: 189) CDR1 DNA Sequence GGA TTC ACC TTC AGT CAC TAT GGC (SEQIDNO: 190) CDR1 Amino Acid Sequence GFTFSHYG (SEQIDNO: 191) CDR2 DNA Sequence ATA TCA TAT GAT GGA AGT AAC AAA (SEQIDNO: 192) CDR2 Amino Acid Sequence I S Y D G S N K (SEQIDNO: 193) CDR3 DNA Sequence GCG AAA GAG TCG AGT ATA ACA GCC CGT CCG AGA GAC TAC AAC TAC GGT ATG GAC GTC (SEQIDNO: 194) CDR3 Amino Acid Sequence AKESSITARPRDYNYGMDV (SEQIDNO: 195) LCVR DNA Sequence GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAG TCACCATCACTTGCCGGGCAAGTCAGAGCATTAGCGGCTATTTAAATTGGTTTCA GCAGAAACCAGGGAAAGCCCCTAAACTCCTAATCTATGCTGCATCCACTTTGCAA ACTGGGGTCCCATCAAGGTTCAGCGGCAGTGGATCTGGGACAGATTTCACTCTCA TCATCAGCAGTCTGCAGCCTGACGATTTTGCAACTTACCACTGTCAACAGAGTTA CACTTCCCCTTTCACTTTCGGCCCTGGGACCAAAGTGGATATCAAA (SEQIDNO: 196) LCVR Amino Acid Sequence DIQMTQSPSSLSASVGDRVTITCRASQSISGYLNWFQQKPGKAPKLLIYAASTLQTGV PSRFSGSGSGTDFTLIISSLQPDDFATYHCQQSYTSPFTFGPGTKVDIK (SEQIDNO: 197) CDR1 DNA Sequence CAG AGC ATT AGC GGC TAT (SEQIDNO: 198) CDR1 Amino Acid Sequence Q S I S G Y (SEQIDNO: 199) CDR2 DNA Sequence GCT GCA TCC (SEQIDNO: 13) CDR2 Amino Acid Sequence A A S (SEQIDNO: 14) CDR3 DNA Sequence CAA CAG AGT TAC ACT TCC CCT TTC ACT (SEQIDNO: 200) CDR3 Amino Acid Sequence QQSYTSPFT (SEQIDNO: 201) HC DNA Sequence CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTG AGACTCTCCTGTGCAGCCTCTGGATTCACCTTCAGTCACTATGGCATGCACTGGG TCCGCCAGGCTCCAGGCAAGGGGCTGGAGTGGATGGCAGTTATATCATATGATG GAAGTAACAAATATTATGCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAG ACAATTCCAGGAACACGCTGTATCTGCAAATGAACAGCCTGAGAACTGAGGACA CGGCTGTGTTTTATTGTGCGAAAGAGTCGAGTATAACAGCCCGTCCGAGAGACTA CAACTACGGTATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCAGC CTCCACCAAGGGCCCATCGGTCTTCCCCCTGGCGCCCTGCTCCAGGAGCACCTCC GAGAGCACAGCCGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTG ACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCT GTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCA GCAGCTTGGGCACGAAGACCTACACCTGCAACGTAGATCACAAGCCCAGCAACA CCAAGGTGGACAAGAGAGTTGAGTCCAAATATGGTCCCCCATGCCCACCGTGCC CAGCACCACCTGTGGCAGGACCATCAGTCTTCCTGTTCCCCCCAAAACCCAAGGA CACTCTCATGATCTCCCGGACCCCTGAGGTCACGTGCGTGGTGGTGGACGTGAGC CAGGAAGACCCCGAGGTCCAGTTCAACTGGTACGTGGATGGCGTGGAGGTGCAT AATGCCAAGACAAAGCCGCGGGAGGAGCAGTTCAACAGCACGTACCGTGTGGTC AGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAACGGCAAGGAGTACAAGTGC AAGGTCTCCAACAAAGGCCTCCCGTCCTCCATCGAGAAAACCATCTCCAAAGCC AAAGGGCAGCCCCGAGAGCCACAGGTGTACACCCTGCCCCCATCCCAGGAGGAG ATGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTACCCCAGC GACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGAC CACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTACAGCAGGCTCACC GTGGACAAGAGCAGGTGGCAGGAGGGGAATGTCTTCTCATGCTCCGTGATGCAT GAGGCTCTGCACAACCACTACACACAGAAGTCCCTCTCCCTGTCTCTGGGTAAAT GA (SEQIDNO: 202) HC Amino Acid Sequence QVQLVESGGGVVQPGRSLRLSCAASGFTFSHYGMHWVRQAPGKGLEWMAVISYDG SNKYYADSVKGRFTISRDNSRNTLYLQMNSLRTEDTAVFYCAKESSITARPRDYNYG MDVWGQGTTVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNS GALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVES KYGPPCPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWY VDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEK TISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNY KTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK* (SEQIDNO: 203) LC DNA Sequence GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAG TCACCATCACTTGCCGGGCAAGTCAGAGCATTAGCGGCTATTTAAATTGGTTTCA GCAGAAACCAGGGAAAGCCCCTAAACTCCTAATCTATGCTGCATCCACTTTGCAA ACTGGGGTCCCATCAAGGTTCAGCGGCAGTGGATCTGGGACAGATTTCACTCTCA TCATCAGCAGTCTGCAGCCTGACGATTTTGCAACTTACCACTGTCAACAGAGTTA CACTTCCCCTTTCACTTTCGGCCCTGGGACCAAAGTGGATATCAAACGAACTGTG GCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGAA CTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAGTACA GTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAGGAGAGTGTCACAGA GCAGGACAGCAAGGACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAA AGCAGACTACGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGGGCCT GAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGTTAG (SEQIDNO: 204) LC Amino Acid Sequence DIQMTQSPSSLSASVGDRVTITCRASQSISGYLNWFQQKPGKAPKLLIYAASTLQTGV PSRFSGSGSGTDFTLIISSLQPDDFATYHCQQSYTSPFTFGPGTKVDIKRTVAAPSVFIF PPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYS LSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC* (SEQIDNO: 205) REGN14159 HCVR DNA Sequence GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGCACAGCGGGGGGGGTCCCTG AGACTCTCCTGTGCAGCCTCTGGATTCACCTTTAGCGACTATGCCGTGAGCTGGG TCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGGTCTCAGGTATTAGCCGTGGTG GTGATTACACGTACTACGCAGACTCCGTGAAGGGCCGGTTCATCATCTCCAGAGA CAATTCCAAGAATATGTTGTATCTGCAAATGAACAGCCTGAGAGCCGAGGACAC GGCCGTATATTATTGTGCGAAAAACTGGGGATCACTTGACTACTGGGGCCAGGG AACCCTGGTCACCGTCTCCTCA (SEQIDNO: 206) HCVR Amino Acid Sequence EVQLVESGGGLAQRGGSLRLSCAASGFTFSDYAVSWVRQAPGKGLEWVSGISRGGD YTYYADSVKGRFIISRDNSKNMLYLQMNSLRAEDTAVYYCAKNWGSLDYWGQGTL VTVSS (SEQIDNO: 207) CDR1 DNA Sequence GGA TTC ACC TTT AGC GAC TAT GCC (SEQIDNO: 208) CDR1 Amino Acid Sequence GFTFSDYA (SEQIDNO: 209) CDR2 DNA Sequence ATT AGC CGT GGT GGT GAT TAC ACG (SEQIDNO: 210) CDR2 Amino Acid Sequence I S R G G D Y T (SEQIDNO: 211) CDR3 DNA Sequence GCG AAA AAC TGG GGA TCA CTT GAC TAC (SEQIDNO: 212) CDR3 Amino Acid Sequence AKNWGSLDY (SEQIDNO: 213) LCVR DNA Sequence GAAATTGTGTTGACACAGTCTCCAGCCACCCTGTCTTTGTCTCCAGGGGAAAGAG CCACCCTCTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCTACTTAGCCTGGTACCA ACAGAAACCTGGCCAGGCTCCCAGACTCCTCATCTATGATGCATCCAACAGGGTC ACTGGCATCCCAGCCAGGTTCAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCA CCATCAGCAGCCTAGAGCCTGAAGATTTTGCAGTTTATTACTGTCAGCAGCGTAG CAACTGGCCTCGAACTTTTGGCCAGGGGACCAAGCTGGAGATCAAA (SEQIDNO: 214) LCVR Amino Acid Sequence EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRVTGI PARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPRTFGQGTKLEIK (SEQIDNO: 215) CDR1 DNA Sequence CAG AGT GTT AGC AGC TAC (SEQIDNO: 216) CDR1 Amino Acid Sequence Q S V S S Y (SEQIDNO: 217) CDR2 DNA Sequence GAT GCA TCC (SEQIDNO: 218) CDR2 Amino Acid Sequence DAS (SEQIDNO. 219) CDR3 DNA Sequence CAG CAG CGT AGC AAC TGG CCT CGA ACT (SEQIDNO: 220) CDR3 Amino Acid Sequence QQRSNWPRT (SEQIDNO: 221) HC DNA Sequence GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGCACAGCGGGGGGGGTCCCTG AGACTCTCCTGTGCAGCCTCTGGATTCACCTTTAGCGACTATGCCGTGAGCTGGG TCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGGTCTCAGGTATTAGCCGTGGTG GTGATTACACGTACTACGCAGACTCCGTGAAGGGCCGGTTCATCATCTCCAGAGA CAATTCCAAGAATATGTTGTATCTGCAAATGAACAGCCTGAGAGCCGAGGACAC GGCCGTATATTATTGTGCGAAAAACTGGGGATCACTTGACTACTGGGGCCAGGG AACCCTGGTCACCGTCTCCTCAGCCTCCACCAAGGGCCCATCGGTCTTCCCCCTG GCGCCCTGCTCCAGGAGCACCTCCGAGAGCACAGCCGCCCTGGGCTGCCTGGTC AAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACC AGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCA GCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCACGAAGACCTACACCTGCA ACGTAGATCACAAGCCCAGCAACACCAAGGTGGACAAGAGAGTTGAGTCCAAAT ATGGTCCCCCATGCCCACCGTGCCCAGCACCACCTGTGGCAGGACCATCAGTCTT CCTGTTCCCCCCAAAACCCAAGGACACTCTCATGATCTCCCGGACCCCTGAGGTC ACGTGCGTGGTGGTGGACGTGAGCCAGGAAGACCCCGAGGTCCAGTTCAACTGG TACGTGGATGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCA GTTCAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGG CTGAACGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGGCCTCCCGTCCTCC ATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAGCCACAGGTGTAC ACCCTGCCCCCATCCCAGGAGGAGATGACCAAGAACCAGGTCAGCCTGACCTGC CTGGTCAAAGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGG CAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCC TTCTTCCTCTACAGCAGGCTCACCGTGGACAAGAGCAGGTGGCAGGAGGGGAAT GTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACACAGAAGT CCCTCTCCCTGTCTCTGGGTAAATGA (SEQIDNO: 222) HC Amino Acid Sequence EVQLVESGGGLAQRGGSLRLSCAASGFTFSDYAVSWVRQAPGKGLEWVSGISRGGD YTYYADSVKGRFIISRDNSKNMLYLQMNSLRAEDTAVYYCAKNWGSLDYWGQGTL VTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTF PAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPA PPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAK TKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPRE PQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDG SFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK* (SEQIDNO: 223) LC DNA Sequence GAAATTGTGTTGACACAGTCTCCAGCCACCCTGTCTTTGTCTCCAGGGGAAAGAG CCACCCTCTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCTACTTAGCCTGGTACCA ACAGAAACCTGGCCAGGCTCCCAGACTCCTCATCTATGATGCATCCAACAGGGTC ACTGGCATCCCAGCCAGGTTCAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCA CCATCAGCAGCCTAGAGCCTGAAGATTTTGCAGTTTATTACTGTCAGCAGCGTAG CAACTGGCCTCGAACTTTTGGCCAGGGGACCAAGCTGGAGATCAAACGAACTGT GGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGA ACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAGTAC AGTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAGGAGAGTGTCACAG AGCAGGACAGCAAGGACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGAGCA AAGCAGACTACGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGGGCC TGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGTTAG (SEQIDNO: 224) LC Amino Acid Sequence EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRVTGI PARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPRTFGQGTKLEIKRTVAAPSVFI FPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTY SLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC* (SEQIDNO: 225) REGN14160 HCVR DNA Sequence CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTG AGACTCTCCTGTGCAGCCTCTGGATTCACCTTCAGTTACTATGTCATGCACTGGGT CCGCCAGGCTCCAGGCAAGGGGCTGGAATGGGTGACAGTTATATCATATGATGG AACTAAGAAACACTATGCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGA CAATTCCAAGAACACCTTGTATCTGCAAATGAACAGCCTGAGAGCTGACGACAC GGCTGTGTATTACTGTGCGAAAACGCATAGTACGTCATCCAGGGCCGACTACTTC TACGGTATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCA (SEQIDNO: 226) HCVR Amino Acid Sequence QVQLVESGGGVVQPGRSLRLSCAASGFTFSYYVMHWVRQAPGKGLEWVTVISYDG TKKHYADSVKGRFTISRDNSKNTLYLQMNSLRADDTAVYYCAKTHSTSSRADYFYG MDVWGQGTTVTVSS (SEQIDNO: 227) CDR1 DNA Sequence GGA TTC ACC TTC AGT TAC TAT GTC (SEQIDNO: 228) CDR1 Amino Acid Sequence GFTFSYYV (SEQIDNO: 229) CDR2 DNA Sequence ATA TCA TAT GAT GGA ACT AAG AAA (SEQIDNO: 230) CDR2 Amino Acid Sequence I S Y D G T K K (SEQIDNO: 231) CDR3 DNA Sequence GCG AAA ACG CAT AGT ACG TCA TCC AGG GCC GAC TAC TTC TAC GGT ATG GAC GTC (SEQIDNO: 232) CDR3 Amino Acid Sequence AKTHSTSSRADYFYGMDV (SEQIDNO: 233) LCVR DNA Sequence GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAG TCACCATCACTTGCCGGGCAAGTCAGAGCATTAGCAGCTATTTAAATTGGTATCA GCAGAAACCAGGGAAAGCCCCTCAGTTCCTGATCTATGCTGCATCCAGTTTGCAA AGTGGGGTCCCATCAAGGTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCA CCATCAGCAGTCTGCAACCTGAAGATTTTGCAACTTACTACTGTCAACAGAGTTA CAGTACCCTCCTCACTTTCGGCGGAGGGACCAAGGTGGAGATCAAA (SEQIDNO: 234) LCVR Amino Acid Sequence DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPQFLIYAASSLQSGV PSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTLLTFGGGTKVEIK (SEQIDNO: 235) CDR1 DNA Sequence CAG AGC ATT AGC AGC TAT (SEQIDNO: 236) CDR1 Amino Acid Sequence Q S I S S Y (SEQIDNO: 237) CDR2 DNA Sequence GCT GCA TCC (SEQIDNO: 13) CDR2 Amino Acid Sequence A A S (SEQIDNO: 14) CDR3 DNA Sequence CAA CAG AGT TAC AGT ACC CTC CTC ACT (SEQIDNO: 238) CDR3 Amino Acid Sequence QQSYSTLLT (SEQIDNO: 239) HC DNA Sequence CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTG AGACTCTCCTGTGCAGCCTCTGGATTCACCTTCAGTTACTATGTCATGCACTGGGT CCGCCAGGCTCCAGGCAAGGGGCTGGAATGGGTGACAGTTATATCATATGATGG AACTAAGAAACACTATGCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGA CAATTCCAAGAACACCTTGTATCTGCAAATGAACAGCCTGAGAGCTGACGACAC GGCTGTGTATTACTGTGCGAAAACGCATAGTACGTCATCCAGGGCCGACTACTTC TACGGTATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCAGCCTCCA CCAAGGGCCCATCGGTCTTCCCCCTGGCGCCCTGCTCCAGGAGCACCTCCGAGAG CACAGCCGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGT GTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTA CAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCT TGGGCACGAAGACCTACACCTGCAACGTAGATCACAAGCCCAGCAACACCAAGG TGGACAAGAGAGTTGAGTCCAAATATGGTCCCCCATGCCCACCGTGCCCAGCAC CACCTGTGGCAGGACCATCAGTCTTCCTGTTCCCCCCAAAACCCAAGGACACTCT CATGATCTCCCGGACCCCTGAGGTCACGTGCGTGGTGGTGGACGTGAGCCAGGA AGACCCCGAGGTCCAGTTCAACTGGTACGTGGATGGCGTGGAGGTGCATAATGC CAAGACAAAGCCGCGGGAGGAGCAGTTCAACAGCACGTACCGTGTGGTCAGCGT CCTCACCGTCCTGCACCAGGACTGGCTGAACGGCAAGGAGTACAAGTGCAAGGT CTCCAACAAAGGCCTCCCGTCCTCCATCGAGAAAACCATCTCCAAAGCCAAAGG GCAGCCCCGAGAGCCACAGGTGTACACCCTGCCCCCATCCCAGGAGGAGATGAC CAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTACCCCAGCGACAT CGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGC CTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTACAGCAGGCTCACCGTGGA CAAGAGCAGGTGGCAGGAGGGGAATGTCTTCTCATGCTCCGTGATGCATGAGGC TCTGCACAACCACTACACACAGAAGTCCCTCTCCCTGTCTCTGGGTAAATGA (SEQIDNO: 240) HC Amino Acid Sequence QVQLVESGGGVVQPGRSLRLSCAASGFTFSYYVMHWVRQAPGKGLEWVTVISYDG TKKHYADSVKGRFTISRDNSKNTLYLQMNSLRADDTAVYYCAKTHSTSSRADYFYG MDVWGQGTTVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNS GALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVES KYGPPCPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWY VDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEK TISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNY KTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK* (SEQIDNO: 241) LC DNA Sequence GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAG TCACCATCACTTGCCGGGCAAGTCAGAGCATTAGCAGCTATTTAAATTGGTATCA GCAGAAACCAGGGAAAGCCCCTCAGTTCCTGATCTATGCTGCATCCAGTTTGCAA AGTGGGGTCCCATCAAGGTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCA CCATCAGCAGTCTGCAACCTGAAGATTTTGCAACTTACTACTGTCAACAGAGTTA CAGTACCCTCCTCACTTTCGGCGGAGGGACCAAGGTGGAGATCAAACGAACTGT GGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGA ACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAGTAC AGTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAGGAGAGTGTCACAG AGCAGGACAGCAAGGACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGAGCA AAGCAGACTACGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGGGCC TGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGTTAG (SEQIDNO: 242) LC Amino Acid Sequence DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPQFLIYAASSLQSGV PSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTLLTFGGGTKVEIKRTVAAPSVFIF PPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYS LSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC* (SEQIDNO: 243) REGN14161 HCVR DNA Sequence GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTG AGACTCTCCTGTGCAGCCTCTGGATTCACCTTTAGCAGCTATGCCATGACCTGGG TCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGGTCTCAACTATTAATACTAATG GTGGTAGCACATTCTTCGCAGACTCCGTGAAGGGCCGTTTCACCATCTCCAGAGA CAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGAGAGCCGAGGACAC GGCCATATATTACTGTGCGAAAGAAAAACGGGGCGGTATGGACGTCTGGGGCCA AGGGACCACGGTCACCGTCTCCTCA (SEQIDNO: 244) HCVR Amino Acid Sequence EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYAMTWVRQAPGKGLEWVSTINTNGG STFFADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAIYYCAKEKRGGMDVWGQGTT VTVSS (SEQIDNO: 245) CDR1 DNA Sequence GGA TTC ACC TTT AGC AGC TAT GCC (SEQIDNO: 156) CDR1 Amino Acid Sequence GFTFSSYA (SEQIDNO: 100) CDR2 DNA Sequence ATT AAT ACT AAT GGT GGT AGC ACA (SEQIDNO: 246) CDR2 Amino Acid Sequence I N T N G G S T (SEQIDNO: 247) CDR3 DNA Sequence GCG AAA GAA AAA CGG GGC GGT ATG GAC GTC (SEQIDNO: 248) CDR3 Amino Acid Sequence AKEKRGGMDV (SEQIDNO: 249) LCVR DNA Sequence GACATCGTGATGACCCAGTCTCCAGACTCCCTGGCTGTGTCTCTGGGCGAGAGGG CCACCATCAACTGCAAGTCCAGCCAGAGTGTTTTATATGGCTCCAACAAAAAGA ACTACTTAGCTTGGTACCAACAGAAACCAGGACAGCCTCCTAAGCTGCTCATTTA CTGGGCATCTACCCGGGAATCCGGGGTCCCTGACCGATTCAGTGGCAGCGGGTCT GGGACAGATTTCACTCTCACCATCAGTAGCCTGCAGGCTGAAGATGTGGCAGTTT ATTACTGTCAGCAATATTATAGTACTCTCACGTGGACGTTCGGCCAAGGGACCAA GGTGGAAATCAAA (SEQIDNO: 250) LCVR Amino Acid Sequence DIVMTQSPDSLAVSLGERATINCKSSQSVLYGSNKKNYLAWYQQKPGQPPKLLIYW ASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYSTLTWTFGQGTKVEI K (SEQIDNO: 251) CDR1 DNA Sequence CAG AGT GTT TTA TAT GGC TCC AAC AAA AAG AAC TAC (SEQIDNO: 252) CDR1 Amino Acid Sequence QSVLYGSNKKNY (SEQIDNO: 253) CDR2 DNA Sequence TGG GCA TCT (SEQIDNO: 69) CDR2 Amino Acid Sequence WAS (SEQIDNO: 70) CDR3 DNA Sequence CAG CAA TAT TAT AGT ACT CTC ACG TGG ACG (SEQIDNO: 254) CDR3 Amino Acid Sequence QQYYSTLTWT (SEQIDNO: 255) HC DNA Sequence GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTG AGACTCTCCTGTGCAGCCTCTGGATTCACCTTTAGCAGCTATGCCATGACCTGGG TCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGGTCTCAACTATTAATACTAATG GTGGTAGCACATTCTTCGCAGACTCCGTGAAGGGCCGTTTCACCATCTCCAGAGA CAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGAGAGCCGAGGACAC GGCCATATATTACTGTGCGAAAGAAAAACGGGGCGGTATGGACGTCTGGGGCCA AGGGACCACGGTCACCGTCTCCTCAGCCTCCACCAAGGGCCCATCGGTCTTCCCC CTGGCGCCCTGCTCCAGGAGCACCTCCGAGAGCACAGCCGCCCTGGGCTGCCTG GTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTG ACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCC TCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCACGAAGACCTACACCT GCAACGTAGATCACAAGCCCAGCAACACCAAGGTGGACAAGAGAGTTGAGTCCA AATATGGTCCCCCATGCCCACCGTGCCCAGCACCACCTGTGGCAGGACCATCAGT CTTCCTGTTCCCCCCAAAACCCAAGGACACTCTCATGATCTCCCGGACCCCTGAG GTCACGTGCGTGGTGGTGGACGTGAGCCAGGAAGACCCCGAGGTCCAGTTCAAC TGGTACGTGGATGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGA GCAGTTCAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGAC TGGCTGAACGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGGCCTCCCGTCC TCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAGCCACAGGTG TACACCCTGCCCCCATCCCAGGAGGAGATGACCAAGAACCAGGTCAGCCTGACC TGCCTGGTCAAAGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAAT GGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGC TCCTTCTTCCTCTACAGCAGGCTCACCGTGGACAAGAGCAGGTGGCAGGAGGGG AATGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACACAGA AGTCCCTCTCCCTGTCTCTGGGTAAATGA (SEQIDNO: 256) HC Amino Acid Sequence EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYAMTWVRQAPGKGLEWVSTINTNGG STFFADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAIYYCAKEKRGGMDVWGQGTT VTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTF PAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPA PPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAK TKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPRE PQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDG SFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK* (SEQIDNO: 257) LC DNA Sequence GACATCGTGATGACCCAGTCTCCAGACTCCCTGGCTGTGTCTCTGGGCGAGAGGG CCACCATCAACTGCAAGTCCAGCCAGAGTGTTTTATATGGCTCCAACAAAAAGA ACTACTTAGCTTGGTACCAACAGAAACCAGGACAGCCTCCTAAGCTGCTCATTTA CTGGGCATCTACCCGGGAATCCGGGGTCCCTGACCGATTCAGTGGCAGCGGGTCT GGGACAGATTTCACTCTCACCATCAGTAGCCTGCAGGCTGAAGATGTGGCAGTTT ATTACTGTCAGCAATATTATAGTACTCTCACGTGGACGTTCGGCCAAGGGACCAA GGTGGAAATCAAACGAACTGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCT GATGAGCAGTTGAAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCT ATCCCAGAGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCCAATCGGGTA ACTCCCAGGAGAGTGTCACAGAGCAGGACAGCAAGGACAGCACCTACAGCCTCA GCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTACGCCT GCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGG GAGAGTGTTAG (SEQIDNO: 258) LC Amino Acid Sequence DIVMTQSPDSLAVSLGERATINCKSSQSVLYGSNKKNYLAWYQQKPGQPPKLLIYW ASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYSTLTWTFGQGTKVEI KRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESV TEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC* (SEQIDNO: 259) REGN14162 HCVRDNA Sequence CAGGTGCAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCGGAGACCCTG TCCCTCACCTGCACTGTTTCTGGTGACTCCATCAGTACTTACTACTGGAGCTGGAT CCGGCAGCCCCCAGGAAAGGGACTGGAGTGGATTGGGTTTTTCCATTACAGTGG GAGCAGCAAATACAAGCCCTCCCTCAAGAGTCGAGTCACCATATCACTAGACAC GTCCAAGAATCAGTTCTCCCTGAACCTGCGGTCTGTGACCGCTGCGGACACGGCC GTGTATTATTGTGCGAGATTAGGCTGGGGATTTGACTACTGGGGCCAGGGAACCC TGGTCACCGTCTCCTCA (SEQIDNO: 260) HCVR Amino Acid Sequence QVQLQESGPGLVKPSETLSLTCTVSGDSISTYYWSWIRQPPGKGLEWIGFFHYSGSSK YKPSLKSRVTISLDTSKNQFSLNLRSVTAADTAVYYCARLGWGFDYWGQGTLVTVS S (SEQIDNO: 261) CDR1 DNA Sequence GGT GAC TCC ATC AGT ACT TAC TAC (SEQIDNO: 262) CDR1 Amino Acid Sequence G D S I S T Y Y (SEQIDNO: 263) CDR2 DNA Sequence TTC CAT TAC AGT GGG AGC AGC (SEQIDNO: 264) CDR2 Amino Acid Sequence F H Y S G S S (SEQIDNO: 265) CDR3 DNA Sequence GCG AGA TTA GGC TGG GGA TTT GAC TAC (SEQIDNO: 266) CDR3 Amino Acid Sequence ARLGWGFDY (SEQIDNO: 267) LCVR DNA Sequence GAAATTGTGTTGACGCAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGGGAAAGAG CCACCCTCTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCAACTACTTAGCCTGGTA CCAGCAGAAACCTGGCCAGGCTCCCAGGCTCCTCATCTATGGTGCATCCAGCAG GGCCACTGGCATCCCAGACAGGTTCAGTGGCAGTGGGTCTGGGACAGACTTCAC TCTCACCATCAGCAGACTGGAGCCTGAAGATTTTGCAGTGTATTACTGTCAGCAG TATGGTAGCTCAGCATTCACTTTCGGCCCTGGGACCAAAGTGGATATCAAA (SEQIDNO: 268) LCVR Amino Acid Sequence EIVLTQSPGTLSLSPGERATLSCRASQSVSSNYLAWYQQKPGQAPRLLIYGASSRATG IPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSAFTFGPGTKVDIK (SEQIDNO: 269) CDR1 DNA Sequence CAG AGT GTT AGC AGC AAC TAC (SEQIDNO: 270) CDR1 Amino Acid Sequence Q S V S S N Y (SEQIDNO: 271) CDR2 DNA Sequence GGT GCA TCC (SEQIDNO: 165) CDR2 Amino Acid Sequence GAS (SEQIDNO: 90) CDR3 DNA Sequence CAG CAG TAT GGT AGC TCA GCA TTC ACT (SEQIDNO: 272) CDR3 Amino Acid Sequence QQYGSSAFT (SEQIDNO: 273) HC DNA Sequence CAGGTGCAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCGGAGACCCTG TCCCTCACCTGCACTGTTTCTGGTGACTCCATCAGTACTTACTACTGGAGCTGGAT CCGGCAGCCCCCAGGAAAGGGACTGGAGTGGATTGGGTTTTTCCATTACAGTGG GAGCAGCAAATACAAGCCCTCCCTCAAGAGTCGAGTCACCATATCACTAGACAC GTCCAAGAATCAGTTCTCCCTGAACCTGCGGTCTGTGACCGCTGCGGACACGGCC GTGTATTATTGTGCGAGATTAGGCTGGGGATTTGACTACTGGGGCCAGGGAACCC TGGTCACCGTCTCCTCAGCCTCCACCAAGGGCCCATCGGTCTTCCCCCTGGCGCC CTGCTCCAGGAGCACCTCCGAGAGCACAGCCGCCCTGGGCTGCCTGGTCAAGGA CTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGG CGTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGC GTGGTGACCGTGCCCTCCAGCAGCTTGGGCACGAAGACCTACACCTGCAACGTA GATCACAAGCCCAGCAACACCAAGGTGGACAAGAGAGTTGAGTCCAAATATGGT CCCCCATGCCCACCGTGCCCAGCACCACCTGTGGCAGGACCATCAGTCTTCCTGT TCCCCCCAAAACCCAAGGACACTCTCATGATCTCCCGGACCCCTGAGGTCACGTG CGTGGTGGTGGACGTGAGCCAGGAAGACCCCGAGGTCCAGTTCAACTGGTACGT GGATGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTTCA ACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAA CGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGGCCTCCCGTCCTCCATCGA GAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAGCCACAGGTGTACACCCT GCCCCCATCCCAGGAGGAGATGACCAAGAACCAGGTCAGCCTGACCTGCCTGGT CAAAGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCC GGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTC CTCTACAGCAGGCTCACCGTGGACAAGAGCAGGTGGCAGGAGGGGAATGTCTTC TCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACACAGAAGTCCCTCT CCCTGTCTCTGGGTAAATGA (SEQIDNO: 274) HC Amino Acid Sequence QVQLQESGPGLVKPSETLSLTCTVSGDSISTYYWSWIRQPPGKGLEWIGFFHYSGSSK YKPSLKSRVTISLDTSKNQFSLNLRSVTAADTAVYYCARLGWGFDYWGQGTLVTVS SASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVL QSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPPVA GPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPR EEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVY TLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFL YSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK* (SEQIDNO: 275) LC DNA Sequence GAAATTGTGTTGACGCAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGGGAAAGAG CCACCCTCTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCAACTACTTAGCCTGGTA CCAGCAGAAACCTGGCCAGGCTCCCAGGCTCCTCATCTATGGTGCATCCAGCAG GGCCACTGGCATCCCAGACAGGTTCAGTGGCAGTGGGTCTGGGACAGACTTCAC TCTCACCATCAGCAGACTGGAGCCTGAAGATTTTGCAGTGTATTACTGTCAGCAG TATGGTAGCTCAGCATTCACTTTCGGCCCTGGGACCAAAGTGGATATCAAACGAA CTGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCT GGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAG TACAGTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAGGAGAGTGTCA CAGAGCAGGACAGCAAGGACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGA GCAAAGCAGACTACGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGG GCCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGTTAG (SEQIDNO: 276) LC Amino Acid Sequence EIVLTQSPGTLSLSPGERATLSCRASQSVSSNYLAWYQQKPGQAPRLLIYGASSRATG IPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSAFTFGPGTKVDIKRTVAAPSVF IFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTY SLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC* (SEQIDNO: 277) REGN14163 HCVR DNA Sequence GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTCCAGCCTGGGGGGTCCCTG AGACTCTCCTGTGCAGCCTCTGGATTCACCTTTAGTAACTATTGGATGAACTGGG TCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGGTGGCCAACATAAAGCAAGATG GAAGTGAGAAGTACTATGTGGACTCTGTGAAGGGCCGATTCACCATCTCCAGAG ACAACGCCAAGAACTCACTGTATCTGCAAATGAACAGCCTGAGAGCCGAGGACA CGGCTGTGTATTACTGTGCGAGACGTGGATACACCTATGGCAGCTTTGACTACTG GGGCCAGGGAACCCTGGTCACCGTCTCCTCA (SEQIDNO: 278) HCVR Amino Acid Sequence EVQLVESGGGLVQPGGSLRLSCAASGFTFSNYWMNWVRQAPGKGLEWVANIKQDG SEKYYVDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARRGYTYGSFDYWG QGTLVTVSS (SEQIDNO: 279) CDR1 DNA Sequence GGA TTC ACC TTT AGT AAC TAT TGG (SEQIDNO: 280) CDR1 Amino Acid Sequence GFTFSNYW (SEQIDNO: 281) CDR2 DNA Sequence ATA AAG CAA GAT GGA AGT GAG AAG (SEQIDNO: 282) CDR2 Amino Acid Sequence I K Q D G S E K (SEQIDNO: 283) CDR3 DNA Sequence GCG AGA CGT GGA TAC ACC TAT GGC AGC TTT GAC TAC (SEQIDNO: 284) CDR3 Amino Acid Sequence ARRGYTYGSFDY (SEQIDNO: 285) LCVR DNA Sequence GACATCCAGATGACCCAGTCTCCATCTTCCGTGTCTGCATCTGTAGGAGACAGAG TCACCATCACTTGTCGGGCGCGTCAGGGTTTTAGCATCTGGTTAGCCTGGTATCA GCAGAAACCAGGGAAAGCCCCTAAGGTCCTGATCTATGCTGCATCCACTTTGCA GAGTGGGGTCCCATCAAGGTTCAGCGGCAGTGGATCTGGGACAGATTTCACTCTC ACCATCAGCAGCCTGCAGCCTGAAGATTTTGCAACTTACTTTTGTCAACAGGCTA ACAGTTTCCCTCCCACTTTCGGCGGAGGGACCAAGGTGGAGATCAAA (SEQIDNO: 286) LCVR Amino Acid Sequence DIQMTQSPSSVSASVGDRVTITCRARQGFSIWLAWYQQKPGKAPKVLIYAASTLQSG VPSRFSGSGSGTDFTLTISSLQPEDFATYFCQQANSFPPTFGGGTKVEIK (SEQIDNO: 287) CDR1 DNA Sequence CAG GGT TTT AGC ATC TGG (SEQIDNO: 288) CDR1 Amino Acid Sequence Q G F S I W (SEQIDNO: 289) CDR2 DNA Sequence GCT GCA TCC (SEQIDNO: 13) CDR2 Amino Acid Sequence A A S (SEQIDNO: 14) CDR3 DNA Sequence CAA CAG GCT AAC AGT TTC CCT CCC ACT (SEQIDNO: 290) CDR3 Amino Acid Sequence QQANSFPPT (SEQIDNO: 291) HC DNA Sequence GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTCCAGCCTGGGGGGTCCCTG AGACTCTCCTGTGCAGCCTCTGGATTCACCTTTAGTAACTATTGGATGAACTGGG TCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGGTGGCCAACATAAAGCAAGATG GAAGTGAGAAGTACTATGTGGACTCTGTGAAGGGCCGATTCACCATCTCCAGAG ACAACGCCAAGAACTCACTGTATCTGCAAATGAACAGCCTGAGAGCCGAGGACA CGGCTGTGTATTACTGTGCGAGACGTGGATACACCTATGGCAGCTTTGACTACTG GGGCCAGGGAACCCTGGTCACCGTCTCCTCAGCCTCCACCAAGGGCCCATCGGTC TTCCCCCTGGCGCCCTGCTCCAGGAGCACCTCCGAGAGCACAGCCGCCCTGGGCT GCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCG CCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTA CTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCACGAAGACCTAC ACCTGCAACGTAGATCACAAGCCCAGCAACACCAAGGTGGACAAGAGAGTTGAG TCCAAATATGGTCCCCCATGCCCACCGTGCCCAGCACCACCTGTGGCAGGACCAT CAGTCTTCCTGTTCCCCCCAAAACCCAAGGACACTCTCATGATCTCCCGGACCCC TGAGGTCACGTGCGTGGTGGTGGACGTGAGCCAGGAAGACCCCGAGGTCCAGTT CAACTGGTACGTGGATGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGA GGAGCAGTTCAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAG GACTGGCTGAACGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGGCCTCCCG TCCTCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAGCCACAG GTGTACACCCTGCCCCCATCCCAGGAGGAGATGACCAAGAACCAGGTCAGCCTG ACCTGCCTGGTCAAAGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGC AATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGAC GGCTCCTTCTTCCTCTACAGCAGGCTCACCGTGGACAAGAGCAGGTGGCAGGAG GGGAATGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACAC AGAAGTCCCTCTCCCTGTCTCTGGGTAAATGA (SEQIDNO: 292) HC Amino Acid Sequence EVQLVESGGGLVQPGGSLRLSCAASGFTFSNYWMNWVRQAPGKGLEWVANIKQDG SEKYYVDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARRGYTYGSFDYWG QGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSG VHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPC PPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEV HNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAK GQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPV LDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK* (SEQIDNO: 293) LC DNA Sequence GACATCCAGATGACCCAGTCTCCATCTTCCGTGTCTGCATCTGTAGGAGACAGAG TCACCATCACTTGTCGGGCGCGTCAGGGTTTTAGCATCTGGTTAGCCTGGTATCA GCAGAAACCAGGGAAAGCCCCTAAGGTCCTGATCTATGCTGCATCCACTTTGCA GAGTGGGGTCCCATCAAGGTTCAGCGGCAGTGGATCTGGGACAGATTTCACTCTC ACCATCAGCAGCCTGCAGCCTGAAGATTTTGCAACTTACTTTTGTCAACAGGCTA ACAGTTTCCCTCCCACTTTCGGCGGAGGGACCAAGGTGGAGATCAAACGAACTG TGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGG AACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAGTA CAGTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAGGAGAGTGTCACA GAGCAGGACAGCAAGGACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGAGC AAAGCAGACTACGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGGGC CTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGTTAG (SEQIDNO: 294) LC Amino Acid Sequence DIQMTQSPSSVSASVGDRVTITCRARQGFSIWLAWYQQKPGKAPKVLIYAASTLQSG VPSRFSGSGSGTDFTLTISSLQPEDFATYFCQQANSFPPTFGGGTKVEIKRTVAAPSVFI FPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTY SLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC* (SEQIDNO: 295) REGN14164 HCVR DNA Sequence CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTG AGACTCTCCTGTGCAGCCTCTGGATTCACCTTCAGTAACTATGGCATGTACTGGG TCCGCCAGGCTCCAGGCAAGGGTCTGGAGTGGGTGTCAATTATATCATATGATGG AAGTAATAAATACTATGCAGACTCCGTGAAGGGCCGATTCACCAGCTCCAGAGA CAATTCCAAGAACACGCTGTATCTTCAAATGAACAGCCTGAGAGGTGAGGACAC GGCTGTGTATTACTGTGCGAAAGATAGAGGAGCTGGAACTACAGCCTTCCACTA CGGTATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCA (SEQIDNO: 296) HCVR Amino Acid Sequence QVQLVESGGGVVQPGRSLRLSCAASGFTFSNYGMYWVRQAPGKGLEWVSIISYDGS NKYYADSVKGRFTSSRDNSKNTLYLQMNSLRGEDTAVYYCAKDRGAGTTAFHYG MDVWGQGTTVTVSS (SEQIDNO: 297) CDR1 DNA Sequence GGA TTC ACC TTC AGT AAC TAT GGC (SEQIDNO: 298) CDR1 Amino Acid Sequence GFTFSNYG (SEQIDNO: 299) CDR2 DNA Sequence ATA TCA TAT GAT GGA AGT AAT AAA (SEQIDNO: 300) CDR2 Amino Acid Sequence I S Y D G S N K (SEQIDNO: 193) CDR3 DNA Sequence GCG AAA GAT AGA GGA GCT GGA ACT ACA GCC TTC CAC TAC GGT ATG GAC GTC (SEQIDNO: 301) CDR3 Amino Acid Sequence AKDRGAGTTAFHYGMDV (SEQIDNO: 302) LCVR DNA Sequence GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAG TCACCATCACTTGCCGGGCAAGTCAGAGCATTAGCAGTTATTTAAATTGGTATCA GCAGAAACCAGGGAAAGCCCCTAAGGTCCTGATCTATGCTGCATTCAGTTTGCA AAGTGGGGTCCCTTCAAGGTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTA ACTATCAGTAGCCTGCAACCTGAGGATTTCGCAACTTACTATTGTCACCAGACTT ATAGTGTTCCTCCGATCACCTTCGGCCAAGGGACCAAGCTGGAGATCAAA (SEQIDNO: 303) LCVR Amino Acid Sequence DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKVLIYAAFSLQSGV PSRFSGSGSGTDFTLTISSLQPEDFATYYCHQTYSVPPITFGQGTKLEIK (SEQIDNO: 304) CDR1 DNA Sequence CAG AGC ATT AGC AGT TAT (SEQIDNO: 305) CDR1 Amino Acid Sequence Q S I S S Y (SEQIDNO: 237) CDR2 DNA Sequence GCT GCA TTC (SEQIDNO: 306) CDR2 Amino Acid Sequence A A F (SEQIDNO: 307) CDR3 DNA Sequence CAC CAG ACT TAT AGT GTT CCT CCG ATC ACC (SEQIDNO: 308) CDR3 Amino Acid Sequence HQTYSVPPIT (SEQIDNO: 309) HC DNA Sequence CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTG AGACTCTCCTGTGCAGCCTCTGGATTCACCTTCAGTAACTATGGCATGTACTGGG TCCGCCAGGCTCCAGGCAAGGGTCTGGAGTGGGTGTCAATTATATCATATGATGG AAGTAATAAATACTATGCAGACTCCGTGAAGGGCCGATTCACCAGCTCCAGAGA CAATTCCAAGAACACGCTGTATCTTCAAATGAACAGCCTGAGAGGTGAGGACAC GGCTGTGTATTACTGTGCGAAAGATAGAGGAGCTGGAACTACAGCCTTCCACTA CGGTATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCAGCCTCCACC AAGGGCCCATCGGTCTTCCCCCTGGCGCCCTGCTCCAGGAGCACCTCCGAGAGCA CAGCCGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTC GTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAG TCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGG GCACGAAGACCTACACCTGCAACGTAGATCACAAGCCCAGCAACACCAAGGTGG ACAAGAGAGTTGAGTCCAAATATGGTCCCCCATGCCCACCGTGCCCAGCACCAC CTGTGGCAGGACCATCAGTCTTCCTGTTCCCCCCAAAACCCAAGGACACTCTCAT GATCTCCCGGACCCCTGAGGTCACGTGCGTGGTGGTGGACGTGAGCCAGGAAGA CCCCGAGGTCCAGTTCAACTGGTACGTGGATGGCGTGGAGGTGCATAATGCCAA GACAAAGCCGCGGGAGGAGCAGTTCAACAGCACGTACCGTGTGGTCAGCGTCCT CACCGTCCTGCACCAGGACTGGCTGAACGGCAAGGAGTACAAGTGCAAGGTCTC CAACAAAGGCCTCCCGTCCTCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCA GCCCCGAGAGCCACAGGTGTACACCCTGCCCCCATCCCAGGAGGAGATGACCAA GAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTACCCCAGCGACATCGCC GTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCC CGTGCTGGACTCCGACGGCTCCTTCTTCCTCTACAGCAGGCTCACCGTGGACAAG AGCAGGTGGCAGGAGGGGAATGTCTTCTCATGCTCCGTGATGCATGAGGCTCTG CACAACCACTACACACAGAAGTCCCTCTCCCTGTCTCTGGGTAAATGA (SEQIDNO: 310) HC Amino Acid Sequence QVQLVESGGGVVQPGRSLRLSCAASGFTFSNYGMYWVRQAPGKGLEWVSIISYDGS NKYYADSVKGRFTSSRDNSKNTLYLQMNSLRGEDTAVYYCAKDRGAGTTAFHYG MDVWGQGTTVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNS GALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVES KYGPPCPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWY VDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEK TISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNY KTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK* (SEQIDNO: 311) LC DNA Sequence GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAG TCACCATCACTTGCCGGGCAAGTCAGAGCATTAGCAGTTATTTAAATTGGTATCA GCAGAAACCAGGGAAAGCCCCTAAGGTCCTGATCTATGCTGCATTCAGTTTGCA AAGTGGGGTCCCTTCAAGGTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTA ACTATCAGTAGCCTGCAACCTGAGGATTTCGCAACTTACTATTGTCACCAGACTT ATAGTGTTCCTCCGATCACCTTCGGCCAAGGGACCAAGCTGGAGATCAAACGAA CTGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCT GGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAG TACAGTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAGGAGAGTGTCA CAGAGCAGGACAGCAAGGACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGA GCAAAGCAGACTACGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGG GCCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGTTAG (SEQIDNO: 312) LC Amino Acid Sequence DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKVLIYAAFSLQSGV PSRFSGSGSGTDFTLTISSLQPEDFATYYCHQTYSVPPITFGQGTKLEIKRTVAAPSVFI FPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTY SLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC* (SEQIDNO: 313) REGN14165 HCVR DNA Sequence CAGGTTCAGCTGGTGCAGTCTGGAGGTGAGGTGAAGAAGCCTGGGGCCTCAGTG AAGGTCTCCTGCAAGGCTTCTGGTTACACCTTTACCAACTATGGAATCAGCTGGA TACGACAGGCCCCTGGACAAGGGCTTGAGTGGATGGGATGGATCAGCGCTTACA ATGGTAACACAAACTATGCACAGAAGGTCCAGGGCAGAGTCACCATGACCACAG ACACATCCACGACCACAGCCTACATGGAGCTGAGGAGCCTGAGATCTGACGACA CGGCCGTATATTTCTGTGCGAGAGATCGGGGACAACTGGATCGAGGAGGAAACT ACTACTTCTACATTATGAGCGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTC A (SEQIDNO: 314) HCVR Amino Acid Sequence QVQLVQSGGEVKKPGASVKVSCKASGYTFTNYGISWIRQAPGQGLEWMGWISAYN GNTNYAQKVQGRVTMTTDTSTTTAYMELRSLRSDDTAVYFCARDRGQLDRGGNYY FYIMSVWGQGTTVTVSS (SEQIDNO: 315) CDR1 DNA Sequence GGT TAC ACC TTT ACC AAC TAT GGA (SEQIDNO: 316) CDR1 Amino Acid Sequence GYTFTNYG (SEQIDNO: 317) CDR2 DNA Sequence ATC AGC GCT TAC AAT GGT AAC ACA (SEQIDNO: 318) CDR2 Amino Acid Sequence I S A Y N G N T (SEQIDNO: 319) CDR3 DNA Sequence GCG AGA GAT CGG GGA CAA CTG GAT CGA GGA GGA AAC TAC TAC TTC TAC ATT ATG AGC GTC (SEQIDNO: 320) CDR3 Amino Acid Sequence ARDRGQLDRGGNYYFYIMSV (SEQIDNO: 321) LCVR DNA Sequence GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAG TCACCATCACTTGCCGGGCAAGTCAGGACATTAGAAATGATTTAGGCTGGTATCA GCAGAAACCAGGGAAAGCCCCTAAGCGCCTAATCTATGCTGCATCCAATTTGCA AAGTGGGGTCCCATCAAGGTTCAGCGGCAGTGGATCTGGGACAGAATTCACTCT CACAATCAGCAGCCTGCAGCCTGAAGATTTTGCAACTTATTACTGTCTACAGCAT AGTAGTTACCCGTGGACGTTCGGCCAAGGGACCAAGGTGGAAATCAAA (SEQIDNO: 322) LCVR Amino Acid Sequence DIQMTQSPSSLSASVGDRVTITCRASQDIRNDLGWYQQKPGKAPKRLIYAASNLQSG VPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHSSYPWTFGQGTKVEIK (SEQIDNO: 323) CDR1 DNA Sequence CAG GAC ATT AGA AAT GAT (SEQIDNO: 11) CDR1 Amino Acid Sequence Q D I R N D (SEQIDNO: 12) CDR2 DNA Sequence GCT GCA TCC (SEQIDNO: 13) CDR2 Amino Acid Sequence A A S (SEQIDNO: 14) CDR3 DNA Sequence CTA CAG CAT AGT AGT TAC CCG TGG ACG (SEQIDNO: 324) CDR3 Amino Acid Sequence LQHSSYPWT (SEQIDNO: 325) HC DNA Sequence CAGGTTCAGCTGGTGCAGTCTGGAGGTGAGGTGAAGAAGCCTGGGGCCTCAGTG AAGGTCTCCTGCAAGGCTTCTGGTTACACCTTTACCAACTATGGAATCAGCTGGA TACGACAGGCCCCTGGACAAGGGCTTGAGTGGATGGGATGGATCAGCGCTTACA ATGGTAACACAAACTATGCACAGAAGGTCCAGGGCAGAGTCACCATGACCACAG ACACATCCACGACCACAGCCTACATGGAGCTGAGGAGCCTGAGATCTGACGACA CGGCCGTATATTTCTGTGCGAGAGATCGGGGACAACTGGATCGAGGAGGAAACT ACTACTTCTACATTATGAGCGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTC AGCCTCCACCAAGGGCCCATCGGTCTTCCCCCTGGCGCCCTGCTCCAGGAGCACC TCCGAGAGCACAGCCGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCG GTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCG GCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCT CCAGCAGCTTGGGCACGAAGACCTACACCTGCAACGTAGATCACAAGCCCAGCA ACACCAAGGTGGACAAGAGAGTTGAGTCCAAATATGGTCCCCCATGCCCACCGT GCCCAGCACCACCTGTGGCAGGACCATCAGTCTTCCTGTTCCCCCCAAAACCCAA GGACACTCTCATGATCTCCCGGACCCCTGAGGTCACGTGCGTGGTGGTGGACGTG AGCCAGGAAGACCCCGAGGTCCAGTTCAACTGGTACGTGGATGGCGTGGAGGTG CATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTTCAACAGCACGTACCGTGTG GTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAACGGCAAGGAGTACAAG TGCAAGGTCTCCAACAAAGGCCTCCCGTCCTCCATCGAGAAAACCATCTCCAAA GCCAAAGGGCAGCCCCGAGAGCCACAGGTGTACACCCTGCCCCCATCCCAGGAG GAGATGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTACCCC AGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAA GACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTACAGCAGGCTC ACCGTGGACAAGAGCAGGTGGCAGGAGGGGAATGTCTTCTCATGCTCCGTGATG CATGAGGCTCTGCACAACCACTACACACAGAAGTCCCTCTCCCTGTCTCTGGGTA AATGA (SEQIDNO: 326) HC Amino Acid Sequence QVQLVQSGGEVKKPGASVKVSCKASGYTFTNYGISWIRQAPGQGLEWMGWISAYN GNTNYAQKVQGRVTMTTDTSTTTAYMELRSLRSDDTAVYFCARDRGQLDRGGNYY FYIMSVWGQGTTVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVS WNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKR VESKYGPPCPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFN WYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSS IEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPEN NYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSL GK* (SEQIDNO: 327) LC DNA Sequence GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAG TCACCATCACTTGCCGGGCAAGTCAGGACATTAGAAATGATTTAGGCTGGTATCA GCAGAAACCAGGGAAAGCCCCTAAGCGCCTAATCTATGCTGCATCCAATTTGCA AAGTGGGGTCCCATCAAGGTTCAGCGGCAGTGGATCTGGGACAGAATTCACTCT CACAATCAGCAGCCTGCAGCCTGAAGATTTTGCAACTTATTACTGTCTACAGCAT AGTAGTTACCCGTGGACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGAACT GTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTG GAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAGT ACAGTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAGGAGAGTGTCAC AGAGCAGGACAGCAAGGACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGAG CAAAGCAGACTACGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGGG CCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGTTAG (SEQIDNO: 328) LC Amino Acid Sequence DIQMTQSPSSLSASVGDRVTITCRASQDIRNDLGWYQQKPGKAPKRLIYAASNLQSG VPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHSSYPWTFGQGTKVEIKRTVAAPSVF IFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTY SLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC* (SEQIDNO: 329) REGN14175 HCVR DNA Sequence CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTG AGACTCTCCTGTGCAGCCTCTGGATTCAGATTCAGTAGTTATGGCATGCACTGGG TCCGCCAGGCTCCAGGCAAGGGGCTGGAGTGGGTGGCAGTCATTTCATATGATG GAAGTGATAAATATTATGCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAG ACAATTCCAAGAACACGCTTTATATGCAAATGAACAGACTGAAAAGTGAGGACA CGGCTGTTTATTATTGTGCGAAAGAGAGAAGTACAGCAGCTCGTCGGGGGGACT ACTACGACTACGGTATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCT CA (SEQIDNO: 330) HCVR Amino Acid Sequence QVQLVESGGGVVQPGRSLRLSCAASGFRFSSYGMHWVRQAPGKGLEWVAVISYDG SDKYYADSVKGRFTISRDNSKNTLYMQMNRLKSEDTAVYYCAKERSTAARRGDYY DYGMDVWGQGTTVTVS S (SEQIDNO: 331) CDR1 DNA Sequence GGA TTC AGA TTC AGT AGT TAT GGC (SEQIDNO: 332) CDR1 Amino Acid Sequence GFRFSSYG (SEQIDNO: 333) CDR2 DNA Sequence ATT TCA TAT GAT GGA AGT GAT AAA (SEQIDNO: 334) CDR2 Amino Acid Sequence I S Y D G S D K (SEQIDNO: 335) CDR3 DNA Sequence GCG AAA GAG AGA AGT ACA GCA GCT CGT CGG GGG GAC TAC TAC GAC TAC GGT ATG GAC GTC (SEQIDNO: 336) CDR3 Amino Acid Sequence AKERSTAARRGDYYDYGMDV (SEQIDNO: 337) LCVR DNA Sequence GACATCCAGATGACCCAGTCTCCATCCTCCCTGTTTGCATCTGTGGGAGACAGAG TCACCATCACTTGCCGGGCAAGTCAGAGCATTAGCAGCTATTTAAATTGGTATCA CCAGAAACCAGGGAGAGCCCCTAAACTCCTGATCTTTGCTTCATTCAGTTTGCAA AGTGGGGTCCCGTCAAGGTTCAGTGGCAGTGGATCTGGAACAGATTTCACTCTCA CCATCAGCAGTGTGGAACCTGAAGATTTTGCATCTTACTACTGTCAACAGAGTTA CAGTACCCCATTCACTTTCGGCCCTGGGACCAAAGTGGATATCAAA (SEQIDNO: 338) LCVR Amino Acid Sequence DIQMTQSPSSLFASVGDRVTITCRASQSISSYLNWYHQKPGRAPKLLIFASFSLQSGVP SRFSGSGSGTDFTLTISSVEPEDFASYYCQQSYSTPFTFGPGTKVDIK (SEQIDNO: 339) CDR1 DNA Sequence CAG AGC ATT AGC AGC TAT (SEQIDNO: 236) CDR1 Amino Acid Sequence Q S I S S Y (SEQIDNO: 237) CDR2 DNA Sequence GCT TCA TTC (SEQIDNO: 340) CDR2 Amino Acid Sequence ASF (SEQIDNO: 341) CDR3 DNA Sequence CAA CAG AGT TAC AGT ACC CCA TTC ACT (SEQIDNO: 342) CDR3 Amino Acid Sequence QQSYSTPFT (SEQIDNO: 343) HC DNA Sequence CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTG AGACTCTCCTGTGCAGCCTCTGGATTCAGATTCAGTAGTTATGGCATGCACTGGG TCCGCCAGGCTCCAGGCAAGGGGCTGGAGTGGGTGGCAGTCATTTCATATGATG GAAGTGATAAATATTATGCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAG ACAATTCCAAGAACACGCTTTATATGCAAATGAACAGACTGAAAAGTGAGGACA CGGCTGTTTATTATTGTGCGAAAGAGAGAAGTACAGCAGCTCGTCGGGGGGACT ACTACGACTACGGTATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCT CAGCCTCCACCAAGGGCCCATCGGTCTTCCCCCTGGCGCCCTGCTCCAGGAGCAC CTCCGAGAGCACAGCCGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACC GGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCC GGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCC TCCAGCAGCTTGGGCACGAAGACCTACACCTGCAACGTAGATCACAAGCCCAGC AACACCAAGGTGGACAAGAGAGTTGAGTCCAAATATGGTCCCCCATGCCCACCG TGCCCAGCACCACCTGTGGCAGGACCATCAGTCTTCCTGTTCCCCCCAAAACCCA AGGACACTCTCATGATCTCCCGGACCCCTGAGGTCACGTGCGTGGTGGTGGACGT GAGCCAGGAAGACCCCGAGGTCCAGTTCAACTGGTACGTGGATGGCGTGGAGGT GCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTTCAACAGCACGTACCGTGT GGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAACGGCAAGGAGTACAA GTGCAAGGTCTCCAACAAAGGCCTCCCGTCCTCCATCGAGAAAACCATCTCCAA AGCCAAAGGGCAGCCCCGAGAGCCACAGGTGTACACCCTGCCCCCATCCCAGGA GGAGATGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTACCC CAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACA AGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTACAGCAGGCT CACCGTGGACAAGAGCAGGTGGCAGGAGGGGAATGTCTTCTCATGCTCCGTGAT GCATGAGGCTCTGCACAACCACTACACACAGAAGTCCCTCTCCCTGTCTCTGGGT AAATGA (SEQIDNO: 344) HC Amino Acid Sequence QVQLVESGGGVVQPGRSLRLSCAASGFRFSSYGMHWVRQAPGKGLEWVAVISYDG SDKYYADSVKGRFTISRDNSKNTLYMQMNRLKSEDTAVYYCAKERSTAARRGDYY DYGMDVWGQGTTVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVS WNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKR VESKYGPPCPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFN WYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSS IEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPEN NYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSL GK* (SEQIDNO: 345) LC DNA Sequence GACATCCAGATGACCCAGTCTCCATCCTCCCTGTTTGCATCTGTGGGAGACAGAG TCACCATCACTTGCCGGGCAAGTCAGAGCATTAGCAGCTATTTAAATTGGTATCA CCAGAAACCAGGGAGAGCCCCTAAACTCCTGATCTTTGCTTCATTCAGTTTGCAA AGTGGGGTCCCGTCAAGGTTCAGTGGCAGTGGATCTGGAACAGATTTCACTCTCA CCATCAGCAGTGTGGAACCTGAAGATTTTGCATCTTACTACTGTCAACAGAGTTA CAGTACCCCATTCACTTTCGGCCCTGGGACCAAAGTGGATATCAAACGAACTGTG GCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGAA CTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAGTACA GTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAGGAGAGTGTCACAGA GCAGGACAGCAAGGACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAA AGCAGACTACGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGGGCCT GAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGTTAG (SEQIDNO: 346) LC Amino Acid Sequence DIQMTQSPSSLFASVGDRVTITCRASQSISSYLNWYHQKPGRAPKLLIFASFSLQSGVP SRFSGSGSGTDFTLTISSVEPEDFASYYCQQSYSTPFTFGPGTKVDIKRTVAAPSVFIFP PSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSL SSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC* (SEQIDNO: 347) REGN14176 HCVR DNA Sequence CAGGTTCAGCTGGTGCAGTCTGGAACTGAGGTGAAGAAGCCTGGGGCCTCAGTG ACGGTCTCCTGCAAGGCTTCTGGTTACACTTTTACCAGCTATAGTGTCAGCTGGG TGCGACAGGCCCCTGGACAAGGGCTTGAGTGGATGGGATGGATCAACGCTTACA ATGGTGACACAAACTATGCACAGAGGTTCCACGGCAGAGTCACCATGACCACAG ACACATCCACGAGCACAGCCTATATGGACTTGAGGAGCCTGAGATCTGACGACA CGGCCGTGTATTACTGTGCGAGAGATCGGATAAGTGGAACCTTAGACTACTGGG GCCAGGGAACCCTGGTCACCGTCTCCTCA (SEQIDNO: 348) HCVR Amino Acid Sequence QVQLVQSGTEVKKPGASVTVSCKASGYTFTSYSVSWVRQAPGQGLEWMGWINAYN GDTNYAQRFHGRVTMTTDTSTSTAYMDLRSLRSDDTAVYYCARDRISGTLDYWGQ GTLVTVSS (SEQIDNO: 349) CDR1 DNA Sequence GGT TAC ACT TTT ACC AGC TAT AGT (SEQIDNO: 350) CDR1 Amino Acid Sequence GYTFTSYS (SEQIDNO: 351) CDR2 DNA Sequence ATC AAC GCT TAC AAT GGT GAC ACA (SEQIDNO: 352) CDR2 Amino Acid Sequence I N A Y N G D T (SEQIDNO: 353) CDR3 DNA Sequence GCG AGA GAT CGG ATA AGT GGA ACC TTA GAC TAC (SEQIDNO: 354) CDR3 Amino Acid Sequence ARDRISGTLDY (SEQIDNO: 355) LCVR DNA Sequence GATGTTGTGATGACTCAGTCTCCACTCTCCCTGCCCGTCACCCTTGGACAGTCGG CCTCCATCTCCTGCAGGTCTAGTCAAAGCCTCGTATACAGTAATGGAAACACCTA CTTGAATTGGTTTCAGCAGAGGCCAGGCCAATCTCCACGGCGCCTATTTTATAAG GTTTCTAACCGGGACTCTGGGGTCCCAGACAGATTCAGCGGCATTGGGTCAGGC ACTGATTTCACACTGAAAATCAGCAGGGTGGAGGCTGAGGATGTTGGATTTTATT ACTGCATGCAAGGTACACACTGGCCTCGGACTTTTGGCCAGGGGACCAAGCTGG AGATCAAA (SEQIDNO: 356) LCVR Amino Acid Sequence DVVMTQSPLSLPVTLGQSASISCRSSQSLVYSNGNTYLNWFQQRPGQSPRRLFYKVS NRDSGVPDRFSGIGSGTDFTLKISRVEAEDVGFYYCMQGTHWPRTFGQGTKLEIK (SEQIDNO: 357) CDR1 DNA Sequence CAA AGC CTC GTA TAC AGT AAT GGA AAC ACC TAC (SEQIDNO: 358) CDR1 Amino Acid Sequence QSLVYSNGNTY (SEQIDNO: 359) CDR2 DNA Sequence AAG GTT TCT (SEQIDNO: 360) CDR2 Amino Acid Sequence K V S (SEQIDNO: 361) CDR3 DNA Sequence ATG CAA GGT ACA CAC TGG CCT CGG ACT (SEQIDNO: 362) CDR3 Amino Acid Sequence MQGTHWPRT (SEQIDNO: 363) HC DNA Sequence CAGGTTCAGCTGGTGCAGTCTGGAACTGAGGTGAAGAAGCCTGGGGCCTCAGTG ACGGTCTCCTGCAAGGCTTCTGGTTACACTTTTACCAGCTATAGTGTCAGCTGGG TGCGACAGGCCCCTGGACAAGGGCTTGAGTGGATGGGATGGATCAACGCTTACA ATGGTGACACAAACTATGCACAGAGGTTCCACGGCAGAGTCACCATGACCACAG ACACATCCACGAGCACAGCCTATATGGACTTGAGGAGCCTGAGATCTGACGACA CGGCCGTGTATTACTGTGCGAGAGATCGGATAAGTGGAACCTTAGACTACTGGG GCCAGGGAACCCTGGTCACCGTCTCCTCAGCCTCCACCAAGGGCCCATCGGTCTT CCCCCTGGCGCCCTGCTCCAGGAGCACCTCCGAGAGCACAGCCGCCCTGGGCTG CCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGC CCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTAC TCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCACGAAGACCTAC ACCTGCAACGTAGATCACAAGCCCAGCAACACCAAGGTGGACAAGAGAGTTGAG TCCAAATATGGTCCCCCATGCCCACCGTGCCCAGCACCACCTGTGGCAGGACCAT CAGTCTTCCTGTTCCCCCCAAAACCCAAGGACACTCTCATGATCTCCCGGACCCC TGAGGTCACGTGCGTGGTGGTGGACGTGAGCCAGGAAGACCCCGAGGTCCAGTT CAACTGGTACGTGGATGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGA GGAGCAGTTCAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAG GACTGGCTGAACGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGGCCTCCCG TCCTCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAGCCACAG GTGTACACCCTGCCCCCATCCCAGGAGGAGATGACCAAGAACCAGGTCAGCCTG ACCTGCCTGGTCAAAGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGC AATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGAC GGCTCCTTCTTCCTCTACAGCAGGCTCACCGTGGACAAGAGCAGGTGGCAGGAG GGGAATGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACAC AGAAGTCCCTCTCCCTGTCTCTGGGTAAATGA (SEQIDNO: 364) HC Amino Acid Sequence QVQLVQSGTEVKKPGASVTVSCKASGYTFTSYSVSWVRQAPGQGLEWMGWINAYN GDTNYAQRFHGRVTMTTDTSTSTAYMDLRSLRSDDTAVYYCARDRISGTLDYWGQ GTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGV HTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPP CPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHN AKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQP REPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDS DGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK* (SEQIDNO: 365) LC DNA Sequence GATGTTGTGATGACTCAGTCTCCACTCTCCCTGCCCGTCACCCTTGGACAGTCGG CCTCCATCTCCTGCAGGTCTAGTCAAAGCCTCGTATACAGTAATGGAAACACCTA CTTGAATTGGTTTCAGCAGAGGCCAGGCCAATCTCCACGGCGCCTATTTTATAAG GTTTCTAACCGGGACTCTGGGGTCCCAGACAGATTCAGCGGCATTGGGTCAGGC ACTGATTTCACACTGAAAATCAGCAGGGTGGAGGCTGAGGATGTTGGATTTTATT ACTGCATGCAAGGTACACACTGGCCTCGGACTTTTGGCCAGGGGACCAAGCTGG AGATCAAACGAACTGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGA GCAGTTGAAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCC AGAGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCC CAGGAGAGTGTCACAGAGCAGGACAGCAAGGACAGCACCTACAGCCTCAGCAG CACCCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTACGCCTGCGA AGTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGA GTGTTAG (SEQIDNO: 366) LC Amino Acid Sequence DVVMTQSPLSLPVTLGQSASISCRSSQSLVYSNGNTYLNWFQQRPGQSPRRLFYKVS NRDSGVPDRFSGIGSGTDFTLKISRVEAEDVGFYYCMQGTHWPRTFGQGTKLEIKRT VAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQ DSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC* (SEQIDNO: 367) REGN14177 HCVR DNA Sequence CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTCAAGCCTGGAGGGTCCCTG AGACTCTCCTGTGCAGCCTCTGGATTCACCTTCAGCGACTATTACATGAGCTGGA TCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGGTTTCATACATCAGTAAAAGTG GTACTACCAAATACTACGCAGACTCTGTGAAGGGCCGATTCACCATCTCCAGGG ACAACGCCAAGAACTCAGTGTATCTGCAAATGAACAGTTTGAGAGCCGAGGACA CGGCCGTCTATTACTGTGAGAAAAGGGGCAGCTTGGGCCAGGGAACCCTGGTCA CCGTCTCCTCA (SEQIDNO: 368) HCVR Amino Acid Sequence QVQLVESGGGLVKPGGSLRLSCAASGFTFSDYYMSWIRQAPGKGLEWVSYISKSGTT KYYADSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCEKRGSLGQGTLVTVSS (SEQIDNO: 369) CDR1 DNA Sequence GGA TTC ACC TTC AGC GAC TAT TAC (SEQIDNO: 370) CDR1 Amino Acid Sequence GFTFSDYY (SEQIDNO: 371) CDR2 DNA Sequence ATC AGT AAA AGT GGT ACT ACC AAA (SEQIDNO: 372) CDR2 Amino Acid Sequence I S K S G T T K (SEQIDNO: 373) CDR3 DNA Sequence GAG AAA AGG GGC AGC (SEQIDNO: 374) CDR3 Amino Acid Sequence E K R G S (SEQIDNO: 375) LCVR DNA Sequence GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAG TCACCATCACTTGCCAGGCGAGTCAGGACATTAGCAAGTATTTAAATTGGTATCA GCAGAAGCCAGGGAAAGCCCCTAAGCTCCTGATCTACGGTGCATCCTATTTGGA AACAGGGGTCCCATCAAGGTTCAGTGGAAGTGGATCTGGGACAGATTTTACTTTT ACCATCAGCAGCCTGCAGCCTGAAGATATTGCAACATATTTCTGTCAACAATATG ATATTGTCCGGTTCACTTTTGGCCAGGGGACCAAGCTGGAGATCAAA (SEQIDNO: 376) LCVR Amino Acid Sequence DIQMTQSPSSLSASVGDRVTITCQASQDISKYLNWYQQKPGKAPKLLIYGASYLETG VPSRFSGSGSGTDFTFTISSLQPEDIATYFCQQYDIVRFTFGQGTKLEIK (SEQIDNO: 377) CDR1 DNA Sequence CAG GAC ATT AGC AAG TAT (SEQIDNO: 378) CDR1 Amino Acid Sequence Q D I S K Y (SEQIDNO: 379) CDR2 DNA Sequence GGT GCA TCC (SEQIDNO: 165) CDR2 Amino Acid Sequence GAS (SEQIDNO: 90) CDR3 DNA Sequence CAA CAA TAT GAT ATT GTC CGG TTC ACT (SEQIDNO: 380) CDR3 Amino Acid Sequence QQYDIVRFT (SEQIDNO: 381) HC DNA Sequence CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTCAAGCCTGGAGGGTCCCTG AGACTCTCCTGTGCAGCCTCTGGATTCACCTTCAGCGACTATTACATGAGCTGGA TCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGGTTTCATACATCAGTAAAAGTG GTACTACCAAATACTACGCAGACTCTGTGAAGGGCCGATTCACCATCTCCAGGG ACAACGCCAAGAACTCAGTGTATCTGCAAATGAACAGTTTGAGAGCCGAGGACA CGGCCGTCTATTACTGTGAGAAAAGGGGCAGCTTGGGCCAGGGAACCCTGGTCA CCGTCTCCTCAGCCTCCACCAAGGGCCCATCGGTCTTCCCCCTGGCGCCCTGCTC CAGGAGCACCTCCGAGAGCACAGCCGCCCTGGGCTGCCTGGTCAAGGACTACTT CCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCA CACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTG ACCGTGCCCTCCAGCAGCTTGGGCACGAAGACCTACACCTGCAACGTAGATCAC AAGCCCAGCAACACCAAGGTGGACAAGAGAGTTGAGTCCAAATATGGTCCCCCA TGCCCACCGTGCCCAGCACCACCTGTGGCAGGACCATCAGTCTTCCTGTTCCCCC CAAAACCCAAGGACACTCTCATGATCTCCCGGACCCCTGAGGTCACGTGCGTGGT GGTGGACGTGAGCCAGGAAGACCCCGAGGTCCAGTTCAACTGGTACGTGGATGG CGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTTCAACAGCA CGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAACGGCAA GGAGTACAAGTGCAAGGTCTCCAACAAAGGCCTCCCGTCCTCCATCGAGAAAAC CATCTCCAAAGCCAAAGGGCAGCCCCGAGAGCCACAGGTGTACACCCTGCCCCC ATCCCAGGAGGAGATGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGG CTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAA CAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTAC AGCAGGCTCACCGTGGACAAGAGCAGGTGGCAGGAGGGGAATGTCTTCTCATGC TCCGTGATGCATGAGGCTCTGCACAACCACTACACACAGAAGTCCCTCTCCCTGT CTCTGGGTAAATGA (SEQIDNO: 382) HC Amino Acid Sequence QVQLVESGGGLVKPGGSLRLSCAASGFTFSDYYMSWIRQAPGKGLEWVSYISKSGTT KYYADSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCEKRGSLGQGTLVTVSSA STKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQS SGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPPVAGP SVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREE QFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTL PPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYS RLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK* (SEQIDNO: 383) LC DNA Sequence GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAG TCACCATCACTTGCCAGGCGAGTCAGGACATTAGCAAGTATTTAAATTGGTATCA GCAGAAGCCAGGGAAAGCCCCTAAGCTCCTGATCTACGGTGCATCCTATTTGGA AACAGGGGTCCCATCAAGGTTCAGTGGAAGTGGATCTGGGACAGATTTTACTTTT ACCATCAGCAGCCTGCAGCCTGAAGATATTGCAACATATTTCTGTCAACAATATG ATATTGTCCGGTTCACTTTTGGCCAGGGGACCAAGCTGGAGATCAAACGAACTGT GGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGA ACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAGTAC AGTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAGGAGAGTGTCACAG AGCAGGACAGCAAGGACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGAGCA AAGCAGACTACGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGGGCC TGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGTTAG (SEQIDNO: 384) LC Amino Acid Sequence DIQMTQSPSSLSASVGDRVTITCQASQDISKYLNWYQQKPGKAPKLLIYGASYLETG VPSRFSGSGSGTDFTFTISSLQPEDIATYFCQQYDIVRFTFGQGTKLEIKRTVAAPSVFI FPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTY SLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC* (SEQIDNO: 385) REGN14178 HCVR DNA Sequence CAGGTTCAGCTGGTGCAGTCTGGACCTGAGGTGAAGAAGCCTGGGGCCTCAGTG AAGGTCTCCTGCAAGGCTTCTGGTTACACCTTTACCAGCTATGGTTTCAGTTGGG TGCGACAGGCCCCTGGACAAGGGCTTGAGTGGATGGGATGGATCAGCGCTTACA ATGGTAACACAAACTATGCACAGAAGTTCCAGGACAGAGTCACCATGACCACAG ACTCATCCACGAGCACAGCCTACATGGAGCTGAGGAGCCTGAGATCTGACGACA CGGCCGTTTATTCCTGTGCGAGAGATCGTGGATTTTGGAGAGCCTATTATGTCTTT GACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCA (SEQIDNO: 386) HCVR Amino Acid Sequence QVQLVQSGPEVKKPGASVKVSCKASGYTFTSYGFSWVRQAPGQGLEWMGWISAYN GNTNYAQKFQDRVTMTTDSSTSTAYMELRSLRSDDTAVYSCARDRGFWRAYYVFD YWGQGTLVTVSS (SEQIDNO: 387) CDR1 DNA Sequence GGT TAC ACC TTT ACC AGC TAT GGT (SEQIDNO: 137) CDR1 Amino Acid Sequence GYTFTSYG (SEQIDNO: 138) CDR2 DNA Sequence ATC AGC GCT TAC AAT GGT AAC ACA (SEQIDNO: 318) CDR2 Amino Acid Sequence I S A Y N G N T (SEQIDNO: 319) CDR3 DNA Sequence GCG AGA GAT CGT GGA TTT TGG AGA GCC TAT TAT GTC TTT GAC TAC (SEQIDNO: 388) CDR3 Amino Acid Sequence ARDRGFWRAYYVFDY (SEQIDNO: 389) LCVR DNA Sequence GATGTTGTGATGACTCAGTCTCCACTCTCCCTGCCCGTCACCCTTGGACAGCCGG CCTCCATCTCCTGCAGGTCTAGTCAAAGCCTCGTGTACAGTGATGGAAACAACTA CTTGAATTGGTTTCAGCGGAGGCCAGGCCAATCTCCAAGGCGCCTAATTTATAAG GTTTCTGATCGGGACTCTGGGGTCCCAGACAGATTCAGCGGCAGTGGGTCAGGC ACTGATTTCACACTGAAAATCAGCAGGGTGGAGGCTGAGGATGTTGGGGTTTATT ACTGCATGCAATATACACACTGGCCGTACACTTTTGGCCAGGGGACCAAGCTGG AGATCAAA (SEQIDNO: 390) LCVR Amino Acid Sequence DVVMTQSPLSLPVTLGQPASISCRSSQSLVYSDGNNYLNWFQRRPGQSPRRLIYKVS DRDSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQYTHWPYTFGQGTKLEIK (SEQIDNO: 391) CDR1 DNA Sequence CAA AGC CTC GTG TAC AGT GAT GGA AAC AAC TAC (SEQIDNO: 392) CDR1 Amino Acid Sequence QSLVYSDGNNY (SEQIDNO: 393) CDR2 DNA Sequence AAG GTT TCT (SEQIDNO: 360) CDR2 Amino Acid Sequence K V S (SEQIDNO: 361) CDR3 DNA Sequence ATG CAA TAT ACA CAC TGG CCG TAC ACT (SEQIDNO: 394) CDR3 Amino Acid Sequence MQYTHWPYT (SEQIDNO: 395) HC DNA Sequence CAGGTTCAGCTGGTGCAGTCTGGACCTGAGGTGAAGAAGCCTGGGGCCTCAGTG AAGGTCTCCTGCAAGGCTTCTGGTTACACCTTTACCAGCTATGGTTTCAGTTGGG TGCGACAGGCCCCTGGACAAGGGCTTGAGTGGATGGGATGGATCAGCGCTTACA ATGGTAACACAAACTATGCACAGAAGTTCCAGGACAGAGTCACCATGACCACAG ACTCATCCACGAGCACAGCCTACATGGAGCTGAGGAGCCTGAGATCTGACGACA CGGCCGTTTATTCCTGTGCGAGAGATCGTGGATTTTGGAGAGCCTATTATGTCTTT GACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAGCCTCCACCAAGGGC CCATCGGTCTTCCCCCTGGCGCCCTGCTCCAGGAGCACCTCCGAGAGCACAGCCG CCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAA CTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCA GGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCACGA AGACCTACACCTGCAACGTAGATCACAAGCCCAGCAACACCAAGGTGGACAAGA GAGTTGAGTCCAAATATGGTCCCCCATGCCCACCGTGCCCAGCACCACCTGTGGC AGGACCATCAGTCTTCCTGTTCCCCCCAAAACCCAAGGACACTCTCATGATCTCC CGGACCCCTGAGGTCACGTGCGTGGTGGTGGACGTGAGCCAGGAAGACCCCGAG GTCCAGTTCAACTGGTACGTGGATGGCGTGGAGGTGCATAATGCCAAGACAAAG CCGCGGGAGGAGCAGTTCAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTC CTGCACCAGGACTGGCTGAACGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAA GGCCTCCCGTCCTCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGA GAGCCACAGGTGTACACCCTGCCCCCATCCCAGGAGGAGATGACCAAGAACCAG GTCAGCCTGACCTGCCTGGTCAAAGGCTTCTACCCCAGCGACATCGCCGTGGAGT GGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGG ACTCCGACGGCTCCTTCTTCCTCTACAGCAGGCTCACCGTGGACAAGAGCAGGTG GCAGGAGGGGAATGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCAC TACACACAGAAGTCCCTCTCCCTGTCTCTGGGTAAATGA (SEQIDNO: 396) HC Amino Acid Sequence QVQLVQSGPEVKKPGASVKVSCKA.SGYTFTSYGFSWVRQAPGQGLEWMGWISAYN GNTNYAQKFQDRVTMTTDSSTSTAYMELRSLRSDDTAVYSCARDRGFWRAYYVFD YWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGA LTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKY GPPCPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVD GVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTIS KAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKT TPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK* (SEQIDNO: 397) LC DNA Sequence GATGTTGTGATGACTCAGTCTCCACTCTCCCTGCCCGTCACCCTTGGACAGCCGG CCTCCATCTCCTGCAGGTCTAGTCAAAGCCTCGTGTACAGTGATGGAAACAACTA CTTGAATTGGTTTCAGCGGAGGCCAGGCCAATCTCCAAGGCGCCTAATTTATAAG GTTTCTGATCGGGACTCTGGGGTCCCAGACAGATTCAGCGGCAGTGGGTCAGGC ACTGATTTCACACTGAAAATCAGCAGGGTGGAGGCTGAGGATGTTGGGGTTTATT ACTGCATGCAATATACACACTGGCCGTACACTTTTGGCCAGGGGACCAAGCTGG AGATCAAACGAACTGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGA GCAGTTGAAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCC AGAGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCC CAGGAGAGTGTCACAGAGCAGGACAGCAAGGACAGCACCTACAGCCTCAGCAG CACCCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTACGCCTGCGA AGTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGA GTGTTAG (SEQIDNO: 398) LC Amino Acid Sequence DVVMTQSPLSLPVTLGQPASISCRSSQSLVYSDGNNYLNWFQRRPGQSPRRLIYKVS DRDSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQYTHWPYTFGQGTKLEIKR TVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTE QDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC* (SEQIDNO: 399) REGN14179 HCVR DNA Sequence GAAGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGCAGGTCCCTG AGACTCTCCTGTGCAGCCTCTGGATTCACCTTTGATGCTTATGCCATGCACTGGGT CCGTCAAGTTCCAGGAAAGGGCCTGCAGTGGGTCTCAGGTATTAGTTGGAATAG TGATAATATAGACTATACGGACTCTGTGAAGGGCCGATTCACCATCTCCAGAGAC AACGCCAAGAACTCCCTGTATCTGCAAATGGACAGTCTGAGAGATGAGGACACG GCCTTGTATTTCTGTGCAAAAGATAGGGTTCGGGGAGTTCGTTACTACTACCACT ACGGCATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCA (SEQIDNO: 400) HCVR Amino Acid Sequence EVQLVESGGGLVQPGRSLRLSCAASGFTFDAYAMHWVRQVPGKGLQWVSGISWNS DNIDYTDSVKGRFTISRDNAKNSLYLQMDSLRDEDTALYFCAKDRVRGVRYYYHYG MDVWGQGTTVTVSS (SEQIDNO: 401) CDR1 DNA Sequence GGA TTC ACC TTT GAT GCT TAT GCC (SEQIDNO: 402) CDR1 Amino Acid Sequence GFTFDAYA (SEQIDNO: 403) CDR2 DNA Sequence ATT AGT TGG AAT AGT GAT AAT ATA (SEQIDNO: 404) CDR2 Amino Acid Sequence I S W N S D N I (SEQIDNO: 405) CDR3 DNA Sequence GCA AAA GAT AGG GTT CGG GGA GTT CGT TAC TAC TAC CAC TAC GGC ATG GAC GTC (SEQIDNO: 406) CDR3 Amino Acid Sequence AKDRVRGVRYYYHYGMDV (SEQIDNO: 407) LCVR DNA Sequence GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAG TCACCATCACTTGCCGGGCAAGTCAGAGCATTAGCAGCTATTTAAATTGGTATCA GCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGCTGCATCCAGTTTGCA AAGTGGGGTCCCGTCAAGGTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTC ACCATCAGCAGTCTGCAACCTGAAGATTTTGCAACTTACTACTGTCAACAGAGTT ACAGTACCCCTCCGATCACCTTCGGCCAAGGGACACGACTGGAGATTAAA (SEQIDNO: 408) LCVR Amino Acid Sequence DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGV PSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPPITFGQGTRLEIK (SEQIDNO: 409) CDR1 DNA Sequence CAG AGC ATT AGC AGC TAT (SEQIDNO: 236) CDR1 Amino Acid Sequence Q S I S S Y (SEQIDNO: 237) CDR2 DNA Sequence GCT GCA TCC (SEQIDNO: 13) CDR2 Amino Acid Sequence A A S (SEQIDNO: 14) CDR3 DNA Sequence CAA CAG AGT TAC AGT ACC CCT CCG ATC ACC (SEQIDNO: 410) CDR3 Amino Acid Sequence QQSYSTPPIT (SEQIDNO: 411) HC DNA Sequence GAAGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGCAGGTCCCTG AGACTCTCCTGTGCAGCCTCTGGATTCACCTTTGATGCTTATGCCATGCACTGGGT CCGTCAAGTTCCAGGAAAGGGCCTGCAGTGGGTCTCAGGTATTAGTTGGAATAG TGATAATATAGACTATACGGACTCTGTGAAGGGCCGATTCACCATCTCCAGAGAC AACGCCAAGAACTCCCTGTATCTGCAAATGGACAGTCTGAGAGATGAGGACACG GCCTTGTATTTCTGTGCAAAAGATAGGGTTCGGGGAGTTCGTTACTACTACCACT ACGGCATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCAGCCTCCA CCAAGGGCCCATCGGTCTTCCCCCTGGCGCCCTGCTCCAGGAGCACCTCCGAGAG CACAGCCGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGT GTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTA CAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCT TGGGCACGAAGACCTACACCTGCAACGTAGATCACAAGCCCAGCAACACCAAGG TGGACAAGAGAGTTGAGTCCAAATATGGTCCCCCATGCCCACCGTGCCCAGCAC CACCTGTGGCAGGACCATCAGTCTTCCTGTTCCCCCCAAAACCCAAGGACACTCT CATGATCTCCCGGACCCCTGAGGTCACGTGCGTGGTGGTGGACGTGAGCCAGGA AGACCCCGAGGTCCAGTTCAACTGGTACGTGGATGGCGTGGAGGTGCATAATGC CAAGACAAAGCCGCGGGAGGAGCAGTTCAACAGCACGTACCGTGTGGTCAGCGT CCTCACCGTCCTGCACCAGGACTGGCTGAACGGCAAGGAGTACAAGTGCAAGGT CTCCAACAAAGGCCTCCCGTCCTCCATCGAGAAAACCATCTCCAAAGCCAAAGG GCAGCCCCGAGAGCCACAGGTGTACACCCTGCCCCCATCCCAGGAGGAGATGAC CAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTACCCCAGCGACAT CGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGC CTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTACAGCAGGCTCACCGTGGA CAAGAGCAGGTGGCAGGAGGGGAATGTCTTCTCATGCTCCGTGATGCATGAGGC TCTGCACAACCACTACACACAGAAGTCCCTCTCCCTGTCTCTGGGTAAATGA (SEQIDNO: 412) HC Amino Acid Sequence EVQLVESGGGLVQPGRSLRLSCAASGFTFDAYAMHWVRQVPGKGLQWVSGISWNS DNIDYTDSVKGRFTISRDNAKNSLYLQMDSLRDEDTALYFCAKDRVRGVRYYYHYG MDVWGQGTTVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNS GALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVES KYGPPCPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWY VDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEK TISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNY KTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK* (SEQIDNO: 413) LC DNA Sequence GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAG TCACCATCACTTGCCGGGCAAGTCAGAGCATTAGCAGCTATTTAAATTGGTATCA GCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGCTGCATCCAGTTTGCA AAGTGGGGTCCCGTCAAGGTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTC ACCATCAGCAGTCTGCAACCTGAAGATTTTGCAACTTACTACTGTCAACAGAGTT ACAGTACCCCTCCGATCACCTTCGGCCAAGGGACACGACTGGAGATTAAACGAA CTGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCT GGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAG TACAGTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAGGAGAGTGTCA CAGAGCAGGACAGCAAGGACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGA GCAAAGCAGACTACGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGG GCCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGTTAG (SEQIDNO: 414) LC Amino Acid Sequence DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGV PSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPPITFGQGTRLEIKRTVAAPSVFIF PPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYS LSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC* (SEQIDNO: 415) REGN14180 HCVRDNA Sequence GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTG AGACTCTCCTGTACAGCCTCTGGATTCACCTTTAGCAGCTTTGTCATGAGCTGGG TCCGCCAGGCTCCAGGGAAGGGACTGGAGTGGGTCTCAGCTATTCGGGATACTG GTGATAACACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCAGAG ACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGAGAACCGAGGACA CGGCCGTAATTTACTGTGCGAGAGGGGGGAGAACTAGAATTCCGTTTGACTACT GGGGCCAGGGAACCCTGGTCACCGTCTCCTCA (SEQIDNO: 416) HCVR Amino Acid Sequence EVQLVESGGGLVQPGGSLRLSCTASGFTFSSFVMSWVRQAPGKGLEWVSAIRDTGD NTYYADSVKGRFTISRDNSKNTLYLQMNSLRTEDTAVIYCARGGRTRIPFDYWGQG TLVTVSS (SEQIDNO: 417) CDR1 DNA Sequence GGA TTC ACC TTT AGC AGC TTT GTC (SEQIDNO: 418) CDR1 Amino Acid Sequence GFTFSSFV (SEQIDNO: 419) CDR2 DNA Sequence ATT CGG GAT ACT GGT GAT AAC AC A (SEQIDNO: 420) CDR2 Amino Acid Sequence I R D T G D N T (SEQIDNO: 421) CDR3 DNA Sequence GCG AGA GGG GGG AGA ACT AGA ATT CCG TTT GAC TAC (SEQIDNO: 422) CDR3 Amino Acid Sequence ARGGRTRIPFDY (SEQIDNO: 423) LCVR DNA Sequence GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAG TCACCATCACTTGCCGGGCAAGTCAGAGCATTAGCAGCTATTTAAATTGGTATCA GCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGCTGCATCCAGTTTGCA AAGTGGGGTCCCGTCAAGGTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTC ACCATCAGCAGTCTGCAACCTGAAGATTTTGCAACTTACTACTGTCAACAGAGTT ACAGTACCCCTCCGATCACCTTCGGCCAAGGGACACGACTGGAGATTAAA (SEQIDNO: 408) LCVR Amino Acid Sequence DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGV PSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPPITFGQGTRLEIK (SEQIDNO: 409) CDR1 DNA Sequence CAG AGC ATT AGC AGC TAT (SEQIDNO: 236) CDR1 Amino Acid Sequence Q S I S S Y (SEQIDNO: 237) CDR2 DNA Sequence GCT GCA TCC (SEQIDNO: 13) CDR2 Amino Acid Sequence A A S (SEQIDNO: 14) CDR3 DNA Sequence CAA CAG AGT TAC AGT ACC CCT CCG ATC ACC (SEQIDNO: 410) CDR3 Amino Acid Sequence QQSYSTPPIT (SEQIDNO: 411) HC DNA Sequence GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTG AGACTCTCCTGTACAGCCTCTGGATTCACCTTTAGCAGCTTTGTCATGAGCTGGG TCCGCCAGGCTCCAGGGAAGGGACTGGAGTGGGTCTCAGCTATTCGGGATACTG GTGATAACACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCAGAG ACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGAGAACCGAGGACA CGGCCGTAATTTACTGTGCGAGAGGGGGGAGAACTAGAATTCCGTTTGACTACT GGGGCCAGGGAACCCTGGTCACCGTCTCCTCAGCCTCCACCAAGGGCCCATCGG TCTTCCCCCTGGCGCCCTGCTCCAGGAGCACCTCCGAGAGCACAGCCGCCCTGGG CTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGC GCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCT ACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCACGAAGACCT ACACCTGCAACGTAGATCACAAGCCCAGCAACACCAAGGTGGACAAGAGAGTTG AGTCCAAATATGGTCCCCCATGCCCACCGTGCCCAGCACCACCTGTGGCAGGACC ATCAGTCTTCCTGTTCCCCCCAAAACCCAAGGACACTCTCATGATCTCCCGGACC CCTGAGGTCACGTGCGTGGTGGTGGACGTGAGCCAGGAAGACCCCGAGGTCCAG TTCAACTGGTACGTGGATGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGG GAGGAGCAGTTCAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACC AGGACTGGCTGAACGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGGCCTCC CGTCCTCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAGCCAC AGGTGTACACCCTGCCCCCATCCCAGGAGGAGATGACCAAGAACCAGGTCAGCC TGACCTGCCTGGTCAAAGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGA GCAATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCG ACGGCTCCTTCTTCCTCTACAGCAGGCTCACCGTGGACAAGAGCAGGTGGCAGG AGGGGAATGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACAC ACAGAAGTCCCTCTCCCTGTCTCTGGGTAAATGA (SEQIDNO: 424) HC Amino Acid Sequence EVQLVESGGGLVQPGGSLRLSCTASGFTFSSFVMSWVRQAPGKGLEWVSAIRDTGD NTYYADSVKGRFTISRDNSKNTLYLQMNSLRTEDTAVIYCARGGRTRIPFDYWGQG TLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVH TFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPC PAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNA KTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPR EPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSD GSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK* (SEQIDNO: 425) LC DNA Sequence GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAG TCACCATCACTTGCCGGGCAAGTCAGAGCATTAGCAGCTATTTAAATTGGTATCA GCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGCTGCATCCAGTTTGCA AAGTGGGGTCCCGTCAAGGTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTC ACCATCAGCAGTCTGCAACCTGAAGATTTTGCAACTTACTACTGTCAACAGAGTT ACAGTACCCCTCCGATCACCTTCGGCCAAGGGACACGACTGGAGATTAAACGAA CTGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCT GGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAG TACAGTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAGGAGAGTGTCA CAGAGCAGGACAGCAAGGACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGA GCAAAGCAGACTACGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGG GCCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGTTAG (SEQIDNO: 414) LC Amino Acid Sequence DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGV PSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPPITFGQGTRLEIKRTVAAPSVFIF PPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYS LSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC* (SEQIDNO: 415) REGN14181 HCVR DNA Sequence CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTG AGACTCTCCTGTGCAGCCTCTGGATTCATCTTCAGTAACTATGGCATGCACTGGG TCCGCCAGGCTCCAGGCAAGGGGCTGGAGTGGGTGGCAATTATATCTTTTGATGG AAATAATAAATACTATGCAGACTCCGTGAAGCGCCGATTCACCATCTCCAGAGA CAATTTCAAGAGCACGCTGTATCTGCAATTGAACAGCCTGACAATTGAGGACAC GGCTGTATATTTCTGTGCGAAAGAGTTTAGCAGGCGGAATTTCTTTGACCACTGG GGCCAGGGAACCCTGGTCACCGTCTCCTCA (SEQIDNO: 426) HCVR Amino Acid Sequence QVQLVESGGGVVQPGRSLRLSCAASGFIFSNYGMHWVRQAPGKGLEWVAIISFDGN NKYYADSVKRRFTISRDNFKSTLYLQLNSLTIEDTAVYFCAKEFSRRNFFDHWGQGT LVTVSS (SEQIDNO: 427) CDR1 DNA Sequence GGA TTC ATC TTC AGT AAC TAT GGC (SEQIDNO: 428) CDR1 Amino Acid Sequence G F I F S N Y G (SEQIDNO: 429) CDR2 DNA Sequence ATA TCT TTT GAT GGA AAT AAT AAA (SEQIDNO: 430) CDR2 Amino Acid Sequence I S F D G N N K (SEQIDNO: 431) CDR3 DNA Sequence GCG AAA GAG TTT AGC AGG CGG AAT TTC TTT GAC CAC (SEQIDNO: 432) CDR3 Amino Acid Sequence AKEFSRRNFFDH (SEQIDNO: 433) LCVR DNA Sequence GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAG TCACCATCACTTGCCGGGCAAGTCAGAGCATTAGCAGCTATTTAAATTGGTATCA GCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGCTGCATCCAGTTTGCA AAGTGGGGTCCCGTCAAGGTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTC ACCATCAGCAGTCTGCAACCTGAAGATTTTGCAACTTACTACTGTCAACAGAGTT ACAGTACCCCTCCGATCACCTTCGGCCAAGGGACACGACTGGAGATTAAA (SEQIDNO: 408) LCVR Amino Acid Sequence DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGV PSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPPITFGQGTRLEIK (SEQIDNO: 409) CDR1 DNA Sequence CAG AGC ATT AGC AGC TAT (SEQIDNO: 236) CDR1 Amino Acid Sequence Q S I S S Y (SEQIDNO: 237) CDR2 DNA Sequence GCT GCA TCC (SEQIDNO: 13) CDR2 Amino Acid Sequence A A S (SEQIDNO: 14) CDR3 DNA Sequence CAA CAG AGT TAC AGT ACC CCT CCG ATC ACC (SEQIDNO: 410) CDR3 Amino Acid Sequence QQSYSTPPIT (SEQIDNO: 411) HC DNA Sequence CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTG AGACTCTCCTGTGCAGCCTCTGGATTCATCTTCAGTAACTATGGCATGCACTGGG TCCGCCAGGCTCCAGGCAAGGGGCTGGAGTGGGTGGCAATTATATCTTTTGATGG AAATAATAAATACTATGCAGACTCCGTGAAGCGCCGATTCACCATCTCCAGAGA CAATTTCAAGAGCACGCTGTATCTGCAATTGAACAGCCTGACAATTGAGGACAC GGCTGTATATTTCTGTGCGAAAGAGTTTAGCAGGCGGAATTTCTTTGACCACTGG GGCCAGGGAACCCTGGTCACCGTCTCCTCAGCCTCCACCAAGGGCCCATCGGTCT TCCCCCTGGCGCCCTGCTCCAGGAGCACCTCCGAGAGCACAGCCGCCCTGGGCTG CCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGC CCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTAC TCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCACGAAGACCTAC ACCTGCAACGTAGATCACAAGCCCAGCAACACCAAGGTGGACAAGAGAGTTGAG TCCAAATATGGTCCCCCATGCCCACCGTGCCCAGCACCACCTGTGGCAGGACCAT CAGTCTTCCTGTTCCCCCCAAAACCCAAGGACACTCTCATGATCTCCCGGACCCC TGAGGTCACGTGCGTGGTGGTGGACGTGAGCCAGGAAGACCCCGAGGTCCAGTT CAACTGGTACGTGGATGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGA GGAGCAGTTCAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAG GACTGGCTGAACGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGGCCTCCCG TCCTCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAGCCACAG GTGTACACCCTGCCCCCATCCCAGGAGGAGATGACCAAGAACCAGGTCAGCCTG ACCTGCCTGGTCAAAGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGC AATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGAC GGCTCCTTCTTCCTCTACAGCAGGCTCACCGTGGACAAGAGCAGGTGGCAGGAG GGGAATGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACAC AGAAGTCCCTCTCCCTGTCTCTGGGTAAATGA (SEQIDNO: 434) HC Amino Acid Sequence QVQLVESGGGVVQPGRSLRLSCAASGFIFSNYGMHWVRQAPGKGLEWVAIISFDGN NKYYADSVKRRFTISRDNFKSTLYLQLNSLTIEDTAVYFCAKEFSRRNFFDHWGQGT LVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHT FPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCP APPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNA KTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPR EPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSD GSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK* (SEQIDNO: 435) LC DNA Sequence GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAG TCACCATCACTTGCCGGGCAAGTCAGAGCATTAGCAGCTATTTAAATTGGTATCA GCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGCTGCATCCAGTTTGCA AAGTGGGGTCCCGTCAAGGTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTC ACCATCAGCAGTCTGCAACCTGAAGATTTTGCAACTTACTACTGTCAACAGAGTT ACAGTACCCCTCCGATCACCTTCGGCCAAGGGACACGACTGGAGATTAAACGAA CTGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCT GGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAG TACAGTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAGGAGAGTGTCA CAGAGCAGGACAGCAAGGACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGA GCAAAGCAGACTACGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGG GCCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGTTAG (SEQIDNO: 414) LC Amino Acid Sequence DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGV PSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPPITFGQGTRLEIKRTVAAPSVFIF PPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYS LSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC* (SEQIDNO: 415) REGN14182 HCVR DNA Sequence CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTG AGACTCTCCTGTGCAGCCTCTGGATTCACCTTCAGTCATTATGGCATGCACTGGG TCCGCCAGGCTCCAGGCAAGGGGCTGGAGTGGATGGCTATCATCTCATATGACG GAAGTGATAAATACTATGCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAG ACAATTCCGAGAACACACTATATCTGCAAATGAGCAGCCTGAGAACTGAAGACA CGGCTGTGTATTACTGTGCGAAAGCCAGTATAACTGGAACTTACTACTTCTTCTA CGGTATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCA (SEQIDNO: 436) HCVR Amino Acid Sequence QVQLVESGGGVVQPGRSLRLSCAASGFTFSHYGMHWVRQAPGKGLEWMAIISYDG SDKYYADSVKGRFTISRDNSENTLYLQMSSLRTEDTAVYYCAKASITGTYYFFYGM DVWGQGTTVTVSS (SEQIDNO: 437) CDR1 DNA Sequence GGA TTC ACC TTC AGT CAT TAT GGC (SEQIDNO: 438) CDR1 Amino Acid Sequence GFTFSHYG (SEQIDNO: 191) CDR2 DNA Sequence ATC TCA TAT GAC GGA AGT GAT AAA (SEQIDNO: 439) CDR2 Amino Acid Sequence I S Y D G S D K (SEQIDNO: 335) CDR3 DNA Sequence GCG AAA GCC AGT ATA ACT GGA ACT TAC TAC TTC TTC TAC GGT ATG GAC GTC (SEQIDNO: 440) CDR3 Amino Acid Sequence AKASITGTYYFFYGMDV (SEQIDNO: 441) LCVR DNA Sequence GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAG TCACCATCACTTGCCGGGCAAGTCAGAGCATTAGCAGCTATTTAAATTGGTATCA GCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGCTGCATCCAGTTTGCA AAGTGGGGTCCCGTCAAGGTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTC ACCATCAGCAGTCTGCAACCTGAAGATTTTGCAACTTACTACTGTCAACAGAGTT ACAGTACCCCTCCGATCACCTTCGGCCAAGGGACACGACTGGAGATTAAA (SEQIDNO: 408) LCVR Amino Acid Sequence DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGV PSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPPITFGQGTRLEIK (SEQIDNO: 409) CDR1 DNA Sequence CAG AGC ATT AGC AGC TAT (SEQIDNO: 236) CDR1 Amino Acid Sequence Q S I S S Y (SEQIDNO: 237) CDR2 DNA Sequence GCT GCA TCC (SEQIDNO: 13) CDR2 Amino Acid Sequence A A S (SEQIDNO: 14) CDR3 DNA Sequence CAA CAG AGT TAC AGT ACC CCT CCG ATC ACC (SEQIDNO: 410) CDR3 Amino Acid Sequence QQSYSTPPIT (SEQIDNO: 411) HC DNA Sequence CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTG AGACTCTCCTGTGCAGCCTCTGGATTCACCTTCAGTCATTATGGCATGCACTGGG TCCGCCAGGCTCCAGGCAAGGGGCTGGAGTGGATGGCTATCATCTCATATGACG GAAGTGATAAATACTATGCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAG ACAATTCCGAGAACACACTATATCTGCAAATGAGCAGCCTGAGAACTGAAGACA CGGCTGTGTATTACTGTGCGAAAGCCAGTATAACTGGAACTTACTACTTCTTCTA CGGTATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCAGCCTCCACC AAGGGCCCATCGGTCTTCCCCCTGGCGCCCTGCTCCAGGAGCACCTCCGAGAGCA CAGCCGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTC GTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAG TCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGG GCACGAAGACCTACACCTGCAACGTAGATCACAAGCCCAGCAACACCAAGGTGG ACAAGAGAGTTGAGTCCAAATATGGTCCCCCATGCCCACCGTGCCCAGCACCAC CTGTGGCAGGACCATCAGTCTTCCTGTTCCCCCCAAAACCCAAGGACACTCTCAT GATCTCCCGGACCCCTGAGGTCACGTGCGTGGTGGTGGACGTGAGCCAGGAAGA CCCCGAGGTCCAGTTCAACTGGTACGTGGATGGCGTGGAGGTGCATAATGCCAA GACAAAGCCGCGGGAGGAGCAGTTCAACAGCACGTACCGTGTGGTCAGCGTCCT CACCGTCCTGCACCAGGACTGGCTGAACGGCAAGGAGTACAAGTGCAAGGTCTC CAACAAAGGCCTCCCGTCCTCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCA GCCCCGAGAGCCACAGGTGTACACCCTGCCCCCATCCCAGGAGGAGATGACCAA GAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTACCCCAGCGACATCGCC GTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCC CGTGCTGGACTCCGACGGCTCCTTCTTCCTCTACAGCAGGCTCACCGTGGACAAG AGCAGGTGGCAGGAGGGGAATGTCTTCTCATGCTCCGTGATGCATGAGGCTCTG CACAACCACTACACACAGAAGTCCCTCTCCCTGTCTCTGGGTAAATGA (SEQIDNO: 442) HC Amino Acid Sequence QVQLVESGGGVVQPGRSLRLSCAASGFTFSHYGMHWVRQAPGKGLEWMAIISYDG SDKYYADSVKGRFTISRDNSENTLYLQMSSLRTEDTAVYYCAKASITGTYYFFYGM DVWGQGTTVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSG ALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESK YGPPCPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYV DGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKT ISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYK TTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK* (SEQIDNO: 443) LC DNA Sequence GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAG TCACCATCACTTGCCGGGCAAGTCAGAGCATTAGCAGCTATTTAAATTGGTATCA GCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGCTGCATCCAGTTTGCA AAGTGGGGTCCCGTCAAGGTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTC ACCATCAGCAGTCTGCAACCTGAAGATTTTGCAACTTACTACTGTCAACAGAGTT ACAGTACCCCTCCGATCACCTTCGGCCAAGGGACACGACTGGAGATTAAACGAA CTGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCT GGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAG TACAGTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAGGAGAGTGTCA CAGAGCAGGACAGCAAGGACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGA GCAAAGCAGACTACGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGG GCCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGTTAG (SEQIDNO: 414) LC Amino Acid Sequence DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGV PSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPPITFGQGTRLEIKRTVAAPSVFIF PPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYS LSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC* (SEQIDNO: 415) REGN14183 HCVR DNA Sequence GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTG AGACTCTCCTGTGCAGTCTCTGGATTCACCTTTAGCAGCTATGTCATGAGCTGGG TCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGGTCTCAGCTATTAGTGATAGTG GTGGTAACACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCAGAG ACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCAGAGAGCCGAGGACA CGGCCGTGTATTATTGTGCGAAGGGGGGGCGCAGCAGGTTCCCTTTTGACTACTG GGGCCAGGGAACCCTGGTCACCGTCTCCTCA (SEQIDNO: 444) HCVR Amino Acid Sequence EVQLVESGGGLVQPGGSLRLSCAVSGFTFSSYVMSWVRQAPGKGLEWVSAISDSGG NTYYADSVKGRFTISRDNSKNTLYLQMNSQRAEDTAVYYCAKGGRSRFPFDYWGQ GTLVTVSS (SEQIDNO: 445) CDR1 DNA Sequence GGA TTC ACC TTT AGC AGC TAT GTC (SEQIDNO: 446) CDR1 Amino Acid Sequence GFTFSSYV (SEQIDNO: 447) CDR2 DNA Sequence ATT AGT GAT AGT GGT GGT AAC ACA (SEQIDNO: 448) CDR2 Amino Acid Sequence I S D S G G N T (SEQIDNO: 449) CDR3 DNA Sequence GCG AAG GGG GGG CGC AGO AGG TTC CCT TTT GAC TAC (SEQIDNO: 450) CDR3 Amino Acid Sequence AKGGRSRFPFDY (SEQIDNO: 451) LCVR DNA Sequence GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAG TCACCATCACTTGCCGGGCAAGTCAGAGCATTAGCAGCTATTTAAATTGGTATCA GCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGCTGCATCCAGTTTGCA AAGTGGGGTCCCGTCAAGGTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTC ACCATCAGCAGTCTGCAACCTGAAGATTTTGCAACTTACTACTGTCAACAGAGTT ACAGTACCCCTCCGATCACCTTCGGCCAAGGGACACGACTGGAGATTAAA (SEQIDNO: 408) LCVR Amino Acid Sequence DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGV PSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPPITFGQGTRLEIK (SEQIDNO: 409) CDR1 DNA Sequence CAG AGC ATT AGC AGC TAT (SEQIDNO: 236) CDR1 Amino Acid Sequence Q S I S S Y (SEQIDNO: 237) CDR2 DNA Sequence GCT GCA TCC (SEQIDNO: 13) CDR2 Amino Acid Sequence A A S (SEQIDNO: 14) CDR3 DNA Sequence CAA CAG AGT TAC AGT ACC CCT CCG ATC ACC (SEQIDNO: 410) CDR3 Amino Acid Sequence QQSYSTPPIT (SEQIDNO: 411) HC DNA Sequence GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTG AGACTCTCCTGTGCAGTCTCTGGATTCACCTTTAGCAGCTATGTCATGAGCTGGG TCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGGTCTCAGCTATTAGTGATAGTG GTGGTAACACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCAGAG ACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCAGAGAGCCGAGGACA CGGCCGTGTATTATTGTGCGAAGGGGGGGCGCAGCAGGTTCCCTTTTGACTACTG GGGCCAGGGAACCCTGGTCACCGTCTCCTCAGCCTCCACCAAGGGCCCATCGGTC TTCCCCCTGGCGCCCTGCTCCAGGAGCACCTCCGAGAGCACAGCCGCCCTGGGCT GCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCG CCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTA CTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCACGAAGACCTAC ACCTGCAACGTAGATCACAAGCCCAGCAACACCAAGGTGGACAAGAGAGTTGAG TCCAAATATGGTCCCCCATGCCCACCGTGCCCAGCACCACCTGTGGCAGGACCAT CAGTCTTCCTGTTCCCCCCAAAACCCAAGGACACTCTCATGATCTCCCGGACCCC TGAGGTCACGTGCGTGGTGGTGGACGTGAGCCAGGAAGACCCCGAGGTCCAGTT CAACTGGTACGTGGATGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGA GGAGCAGTTCAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAG GACTGGCTGAACGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGGCCTCCCG TCCTCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAGCCACAG GTGTACACCCTGCCCCCATCCCAGGAGGAGATGACCAAGAACCAGGTCAGCCTG ACCTGCCTGGTCAAAGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGC AATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGAC GGCTCCTTCTTCCTCTACAGCAGGCTCACCGTGGACAAGAGCAGGTGGCAGGAG GGGAATGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACAC AGAAGTCCCTCTCCCTGTCTCTGGGTAAATGA (SEQIDNO: 452) HC Amino Acid Sequence EVQLVESGGGLVQPGGSLRLSCAVSGFTFSSYVMSWVRQAPGKGLEWVSAISDSGG NTYYADSVKGRFTISRDNSKNTLYLQMNSQRAEDTAVYYCAKGGRSRFPFDYWGQ GTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGV HTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPP CPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHN AKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQP REPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDS DGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK* (SEQIDNO: 453) LC DNA Sequence GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAG TCACCATCACTTGCCGGGCAAGTCAGAGCATTAGCAGCTATTTAAATTGGTATCA GCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGCTGCATCCAGTTTGCA AAGTGGGGTCCCGTCAAGGTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTC ACCATCAGCAGTCTGCAACCTGAAGATTTTGCAACTTACTACTGTCAACAGAGTT ACAGTACCCCTCCGATCACCTTCGGCCAAGGGACACGACTGGAGATTAAACGAA CTGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCT GGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAG TACAGTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAGGAGAGTGTCA CAGAGCAGGACAGCAAGGACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGA GCAAAGCAGACTACGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGG GCCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGTTAG (SEQIDNO: 414) LC Amino Acid Sequence DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGV PSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPPITFGQGTRLEIKRTVAAPSVFIF PPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYS LSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC* (SEQIDNO: 415) REGN14184 HCVR DNA Sequence GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTG AGACTCTCCTGTGCAGCCTCTAAATTCATCTTTAGCAACTATGCCATGACCTGGG TCCGCCAGGCTCCAGGGAAGGGGCTGGAATGGGTCTCAATTATTAGTGGTAGTG GTGGAAATTCATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCAGAG ACAATTCCAAGAACACGCTATATCTGCAAATGAACAGCCTGAGAGCCGAGGACA CGGCCGTTTATTACTGTGCGAAAGGGGGAACAGCTCGAAGCTGGTTCGACCCCT GGGGCCAGGGAACCCTGGTCACCGTCTCCTCA (SEQIDNO: 454) HCVR Amino Acid Sequence EVQLVESGGGLVQPGGSLRLSCAASKFIFSNYAMTWVRQAPGKGLEWVSIISGSGGN SYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKGGTARSWFDPWGQG TLVTVSS (SEQIDNO: 455) CDR1 DNA Sequence AAA TTC ATC TTT AGC AAC TAT GCC (SEQIDNO: 456) CDR1 Amino Acid Sequence K F I F S N Y A (SEQIDNO: 457) CDR2 DNA Sequence ATT AGT GGT AGT GGT GGA AAT TCA (SEQIDNO: 458) CDR2 Amino Acid Sequence I S G S G G N S (SEQIDNO: 459) CDR3 DNA Sequence GCG AAA GGG GGA ACA GCT CGA AGC TGG TTC GAC CCC (SEQIDNO: 460) CDR3 Amino Acid Sequence AKGGTARSWFDP (SEQIDNO: 461) LCVR DNA Sequence GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAG TCACCATCACTTGCCGGGCAAGTCAGAGCATTAGCAGCTATTTAAATTGGTATCA GCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGCTGCATCCAGTTTGCA AAGTGGGGTCCCGTCAAGGTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTC ACCATCAGCAGTCTGCAACCTGAAGATTTTGCAACTTACTACTGTCAACAGAGTT ACAGTACCCCTCCGATCACCTTCGGCCAAGGGACACGACTGGAGATTAAA (SEQIDNO: 408) LCVR Amino Acid Sequence DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGV PSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPPITFGQGTRLEIK (SEQIDNO: 409) CDR1 DNA Sequence CAG AGC ATT AGC AGC TAT (SEQIDNO: 236) CDR1 Amino Acid Sequence Q S I S S Y (SEQIDNO: 237) CDR2 DNA Sequence GCT GCA TCC (SEQIDNO: 13) CDR2 Amino Acid Sequence A A S (SEQIDNO: 14) CDR3 DNA Sequence CAA CAG AGT TAC AGT ACC CCT CCG ATC ACC (SEQIDNO: 410) CDR3 Amino Acid Sequence QQSYSTPPIT (SEQIDNO: 411) HC DNA Sequence GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTG AGACTCTCCTGTGCAGCCTCTAAATTCATCTTTAGCAACTATGCCATGACCTGGG TCCGCCAGGCTCCAGGGAAGGGGCTGGAATGGGTCTCAATTATTAGTGGTAGTG GTGGAAATTCATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCAGAG ACAATTCCAAGAACACGCTATATCTGCAAATGAACAGCCTGAGAGCCGAGGACA CGGCCGTTTATTACTGTGCGAAAGGGGGAACAGCTCGAAGCTGGTTCGACCCCT GGGGCCAGGGAACCCTGGTCACCGTCTCCTCAGCCTCCACCAAGGGCCCATCGG TCTTCCCCCTGGCGCCCTGCTCCAGGAGCACCTCCGAGAGCACAGCCGCCCTGGG CTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGC GCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCT ACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCACGAAGACCT ACACCTGCAACGTAGATCACAAGCCCAGCAACACCAAGGTGGACAAGAGAGTTG AGTCCAAATATGGTCCCCCATGCCCACCGTGCCCAGCACCACCTGTGGCAGGACC ATCAGTCTTCCTGTTCCCCCCAAAACCCAAGGACACTCTCATGATCTCCCGGACC CCTGAGGTCACGTGCGTGGTGGTGGACGTGAGCCAGGAAGACCCCGAGGTCCAG TTCAACTGGTACGTGGATGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGG GAGGAGCAGTTCAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACC AGGACTGGCTGAACGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGGCCTCC CGTCCTCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAGCCAC AGGTGTACACCCTGCCCCCATCCCAGGAGGAGATGACCAAGAACCAGGTCAGCC TGACCTGCCTGGTCAAAGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGA GCAATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCG ACGGCTCCTTCTTCCTCTACAGCAGGCTCACCGTGGACAAGAGCAGGTGGCAGG AGGGGAATGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACAC ACAGAAGTCCCTCTCCCTGTCTCTGGGTAAATGA (SEQIDNO: 462) HC Amino Acid Sequence EVQLVESGGGLVQPGGSLRLSCAASKFIFSNYAMTWVRQAPGKGLEWVSIISGSGGN SYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKGGTARSWFDPWGQG TLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVH TFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPC PAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNA KTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPR EPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSD GSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK* (SEQIDNO: 463) LC DNA Sequence GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAG TCACCATCACTTGCCGGGCAAGTCAGAGCATTAGCAGCTATTTAAATTGGTATCA GCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGCTGCATCCAGTTTGCA AAGTGGGGTCCCGTCAAGGTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTC ACCATCAGCAGTCTGCAACCTGAAGATTTTGCAACTTACTACTGTCAACAGAGTT ACAGTACCCCTCCGATCACCTTCGGCCAAGGGACACGACTGGAGATTAAACGAA CTGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCT GGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAG TACAGTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAGGAGAGTGTCA CAGAGCAGGACAGCAAGGACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGA GCAAAGCAGACTACGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGG GCCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGTTAG (SEQIDNO: 414) LC Amino Acid Sequence DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGV PSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPPITFGQGTRLEIKRTVAAPSVFIF PPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYS LSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC* (SEQIDNO: 415) REGN14185 HCVR DNA Sequence GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTG AGACTCTCCTGTGCAGCCTCTGGATTCACTCTTAGCAGCTATGCCATGAGCTGGG TCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGGTCTCAGCAATTAGTGATAGTG GTGATAACAAATACCACGCAGACTCCGTGAAGGGCCGGTTCTCCATCTCCAGAG ACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGAGAGCCGAGGACG CGGCCGTATATTACTGTGCGAAAGGGGGGAGAACTAGAACTCCTTTTGACTATTG GGGCCAGGGAACCCTGGTCACCGTCTCCTCA (SEQIDNO: 464) HCVR Amino Acid Sequence EVQLVESGGGLVQPGGSLRLSCAASGFTLSSYAMSWVRQAPGKGLEWVSAISDSGD NKYHADSVKGRFSISRDNSKNTLYLQMNSLRAEDAAVYYCAKGGRTRTPFDYWGQ GTLVTVSS (SEQIDNO: 465) CDR1 DNA Sequence GGA TTC ACT CTT AGC AGC TAT GCC (SEQIDNO: 466) CDR1 Amino Acid Sequence GFTLSSYA (SEQIDNO: 467) CDR2 DNA Sequence ATT AGT GAT AGT GGT GAT AAC AAA (SEQIDNO: 468) CDR2 Amino Acid Sequence I S D S G D N K (SEQIDNO: 469) CDR3 DNA Sequence GCG AAA GGG GGG AGA ACT AGA ACT CCT TTT GAC TAT (SEQIDNO: 470) CDR3 Amino Acid Sequence AKGGRTRTPFDY (SEQIDNO: 471) LCVR DNA Sequence GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAG TCACCATCACTTGCCGGGCAAGTCAGAGCATTAGCAGCTATTTAAATTGGTATCA GCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGCTGCATCCAGTTTGCA AAGTGGGGTCCCGTCAAGGTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTC ACCATCAGCAGTCTGCAACCTGAAGATTTTGCAACTTACTACTGTCAACAGAGTT ACAGTACCCCTCCGATCACCTTCGGCCAAGGGACACGACTGGAGATTAAA (SEQIDNO: 408) LCVR Amino Acid Sequence DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGV PSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPPITFGQGTRLEIK (SEQIDNO: 409) CDR1 DNA Sequence CAG AGC ATT AGC AGC TAT (SEQIDNO: 236) CDR1 Amino Acid Sequence Q S I S S Y (SEQIDNO: 237) CDR2 DNA Sequence GCT GCA TCC (SEQIDNO: 13) CDR2 Amino Acid Sequence A A S (SEQIDNO: 14) CDR3 DNA Sequence CAA CAG AGT TAC AGT ACC CCT CCG ATC ACC (SEQIDNO: 410) CDR3 Amino Acid Sequence QQSYSTPPIT (SEQIDNO: 411) HC DNA Sequence GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTG AGACTCTCCTGTGCAGCCTCTGGATTCACTCTTAGCAGCTATGCCATGAGCTGGG TCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGGTCTCAGCAATTAGTGATAGTG GTGATAACAAATACCACGCAGACTCCGTGAAGGGCCGGTTCTCCATCTCCAGAG ACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGAGAGCCGAGGACG CGGCCGTATATTACTGTGCGAAAGGGGGGAGAACTAGAACTCCTTTTGACTATTG GGGCCAGGGAACCCTGGTCACCGTCTCCTCAGCCTCCACCAAGGGCCCATCGGTC TTCCCCCTGGCGCCCTGCTCCAGGAGCACCTCCGAGAGCACAGCCGCCCTGGGCT GCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCG CCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTA CTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCACGAAGACCTAC ACCTGCAACGTAGATCACAAGCCCAGCAACACCAAGGTGGACAAGAGAGTTGAG TCCAAATATGGTCCCCCATGCCCACCGTGCCCAGCACCACCTGTGGCAGGACCAT CAGTCTTCCTGTTCCCCCCAAAACCCAAGGACACTCTCATGATCTCCCGGACCCC TGAGGTCACGTGCGTGGTGGTGGACGTGAGCCAGGAAGACCCCGAGGTCCAGTT CAACTGGTACGTGGATGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGA GGAGCAGTTCAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAG GACTGGCTGAACGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGGCCTCCCG TCCTCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAGCCACAG GTGTACACCCTGCCCCCATCCCAGGAGGAGATGACCAAGAACCAGGTCAGCCTG ACCTGCCTGGTCAAAGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGC AATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGAC GGCTCCTTCTTCCTCTACAGCAGGCTCACCGTGGACAAGAGCAGGTGGCAGGAG GGGAATGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACAC AGAAGTCCCTCTCCCTGTCTCTGGGTAAATGA (SEQIDNO: 472) HC Amino Acid Sequence EVQLVESGGGLVQPGGSLRLSCAASGFTLSSYAMSWVRQAPGKGLEWVSAISDSGD NKYHADSVKGRFSISRDNSKNTLYLQMNSLRAEDAAVYYCAKGGRTRTPFDYWGQ GTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGV HTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPP CPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHN AKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQP REPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDS DGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK* (SEQIDNO: 473) LC DNA Sequence GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAG TCACCATCACTTGCCGGGCAAGTCAGAGCATTAGCAGCTATTTAAATTGGTATCA GCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGCTGCATCCAGTTTGCA AAGTGGGGTCCCGTCAAGGTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTC ACCATCAGCAGTCTGCAACCTGAAGATTTTGCAACTTACTACTGTCAACAGAGTT ACAGTACCCCTCCGATCACCTTCGGCCAAGGGACACGACTGGAGATTAAACGAA CTGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCT GGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAG TACAGTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAGGAGAGTGTCA CAGAGCAGGACAGCAAGGACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGA GCAAAGCAGACTACGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGG GCCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGTTAG (SEQIDNO: 414) LC Amino Acid Sequence DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGV PSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPPITFGQGTRLEIKRTVAAPSVFIF PPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYS LSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC* (SEQIDNO: 415) REGN14186 HCVRDNA Sequence GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTG AGACTCTCCTGTGCAGCCTCTGGATTCACCTTTAGCGCCTATGCCATGACCTGGG TCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGGTCTCACTTATTAGTGGAAGTG GTGGTAACACATACTATGCAGACACCGTGAAGGGCCGGTCCACCATCTCCAGAG ACAACTCCAAGACCACGCTGTATCTGCAAATGAACAGCCTGAGAGCCGAGGACA CGGCCGTATATTACTGTGCGAAATGGGGCCTAATGGTGTATGCTATGAGGGCCTT TGACTATTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCA (SEQIDNO: 474) HCVR Amino Acid Sequence EVQLVESGGGLVQPGGSLRLSCAASGFTFSAYAMTWVRQAPGKGLEWVSLISGSGG NTYYADTVKGRSTISRDNSKTTLYLQMNSLRAEDTAVYYCAKWGLMVYAMRAFD YWGQGTLVTVSS (SEQIDNO: 475) CDR1 DNA Sequence GGA TTC ACC TTT AGC GCC TAT GCC (SEQIDNO: 476) CDR1 Amino Acid Sequence GFTFSAYA (SEQIDNO: 477) CDR2 DNA Sequence ATT AGT GGA AGT GGT GGT AAC ACA (SEQIDNO: 478) CDR2 Amino Acid Sequence I S G S G G N T (SEQIDNO: 158) CDR3 DNA Sequence GCG AAA TGG GGC CTA ATG GTG TAT GCT ATG AGG GCC TTT GAC TAT (SEQIDNO: 479) CDR3 Amino Acid Sequence AKWGLMVYAMRAFDY (SEQIDNO: 480) LCVR DNA Sequence GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAG TCACCATCACTTGCCGGGCAAGTCAGAGCATTAGCAGCTATTTAAATTGGTATCA GCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGCTGCATCCAGTTTGCA AAGTGGGGTCCCGTCAAGGTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTC ACCATCAGCAGTCTGCAACCTGAAGATTTTGCAACTTACTACTGTCAACAGAGTT ACAGTACCCCTCCGATCACCTTCGGCCAAGGGACACGACTGGAGATTAAA (SEQIDNO: 408) LCVR Amino Acid Sequence DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGV PSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPPITFGQGTRLEIK (SEQIDNO: 409) CDR1 DNA Sequence CAG AGC ATT AGC AGC TAT (SEQIDNO: 236) CDR1 Amino Acid Sequence Q S I S S Y (SEQIDNO: 237) CDR2 DNA Sequence GCT GCA TCC (SEQIDNO: 13) CDR2 Amino Acid Sequence A A S (SEQIDNO: 14) CDR3 DNA Sequence CAA CAG AGT TAC AGT ACC CCT CCG ATC ACC (SEQIDNO: 410) CDR3 Amino Acid Sequence QQSYSTPPIT (SEQIDNO: 411) HC DNA Sequence GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTG AGACTCTCCTGTGCAGCCTCTGGATTCACCTTTAGCGCCTATGCCATGACCTGGG TCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGGTCTCACTTATTAGTGGAAGTG GTGGTAACACATACTATGCAGACACCGTGAAGGGCCGGTCCACCATCTCCAGAG ACAACTCCAAGACCACGCTGTATCTGCAAATGAACAGCCTGAGAGCCGAGGACA CGGCCGTATATTACTGTGCGAAATGGGGCCTAATGGTGTATGCTATGAGGGCCTT TGACTATTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAGCCTCCACCAAGGGC CCATCGGTCTTCCCCCTGGCGCCCTGCTCCAGGAGCACCTCCGAGAGCACAGCCG CCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAA CTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCA GGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCACGA AGACCTACACCTGCAACGTAGATCACAAGCCCAGCAACACCAAGGTGGACAAGA GAGTTGAGTCCAAATATGGTCCCCCATGCCCACCGTGCCCAGCACCACCTGTGGC AGGACCATCAGTCTTCCTGTTCCCCCCAAAACCCAAGGACACTCTCATGATCTCC CGGACCCCTGAGGTCACGTGCGTGGTGGTGGACGTGAGCCAGGAAGACCCCGAG GTCCAGTTCAACTGGTACGTGGATGGCGTGGAGGTGCATAATGCCAAGACAAAG CCGCGGGAGGAGCAGTTCAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTC CTGCACCAGGACTGGCTGAACGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAA GGCCTCCCGTCCTCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGA GAGCCACAGGTGTACACCCTGCCCCCATCCCAGGAGGAGATGACCAAGAACCAG GTCAGCCTGACCTGCCTGGTCAAAGGCTTCTACCCCAGCGACATCGCCGTGGAGT GGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGG ACTCCGACGGCTCCTTCTTCCTCTACAGCAGGCTCACCGTGGACAAGAGCAGGTG GCAGGAGGGGAATGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCAC TACACACAGAAGTCCCTCTCCCTGTCTCTGGGTAAATGA (SEQIDNO: 481) HC Amino Acid Sequence EVQLVESGGGLVQPGGSLRLSCAASGFTFSAYAMTWVRQAPGKGLEWVSLISGSGG NTYYADTVKGRSTISRDNSKTTLYLQMNSLRAEDTAVYYCAKWGLMVYAMRAFD YWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGA LTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKY GPPCPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVD GVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTIS KAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKT TPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK* (SEQIDNO: 482) LC DNA Sequence GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAG TCACCATCACTTGCCGGGCAAGTCAGAGCATTAGCAGCTATTTAAATTGGTATCA GCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGCTGCATCCAGTTTGCA AAGTGGGGTCCCGTCAAGGTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTC ACCATCAGCAGTCTGCAACCTGAAGATTTTGCAACTTACTACTGTCAACAGAGTT ACAGTACCCCTCCGATCACCTTCGGCCAAGGGACACGACTGGAGATTAAACGAA CTGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCT GGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAG TACAGTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAGGAGAGTGTCA CAGAGCAGGACAGCAAGGACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGA GCAAAGCAGACTACGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGG GCCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGTTAG (SEQIDNO: 414) LC Amino Acid Sequence DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGV PSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPPITFGQGTRLEIKRTVAAPSVFIF PPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYS LSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC* (SEQIDNO: 415) REGN14187 HCVR DNA Sequence GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTCCAGCCGGGGGGGTCCCTG AGACTCTCCTGTGCAGCCTCTGGATTCACCTTTAGTTACTATTGGATGAACTGGG TCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGGTGGCCAACATAAAGCAAGATG GAAGTGAGAAATACTATGTGGACTCTGTGAAGGGCCGAGTCACCATCTCCAGAG ACAACGCCAAGAACTCACTGTATCTGCAAATGAACAGCCTGAGAGCCGAGGACA CGGGTGTGTATTACTGTGCGACAGATAAGGTTCGCGGGCGATACCACGACCACT ACGGTTTGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCA (SEQIDNO: 483) HCVR Amino Acid Sequence EVQLVESGGGLVQPGGSLRLSCAASGFTFSYYWMNWVRQAPGKGLEWVANIKQDG SEKYYVDSVKGRVTISRDNAKNSLYLQMNSLRAEDTGVYYCATDKVRGRYHDHYG LDVWGQGTTVTVSS (SEQIDNO: 484) CDR1 DNA Sequence GGA TTC ACC TTT AGT TAC TAT TGG (SEQIDNO: 485) CDR1 Amino Acid Sequence GFTFSYYW (SEQIDNO: 486) CDR2 DNA Sequence ATA AAG CAA GAT GGA AGT GAG AAA (SEQIDNO: 487) CDR2 Amino Acid Sequence I K Q D G S E K (SEQIDNO: 283) CDR3 DNA Sequence GCG ACA GAT AAG GTT CGC GGG CGA TAC CAC GAC CAC TAC GGT TTG GAC GTC (SEQIDNO: 488) CDR3 Amino Acid Sequence ATDKVRGRYHDHYGLDV (SEQIDNO: 489) LCVR DNA Sequence GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAG TCACCATCACTTGCCGGGCAAGTCAGAGCATTAGCAGCTATTTAAATTGGTATCA GCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGCTGCATCCAGTTTGCA AAGTGGGGTCCCGTCAAGGTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTC ACCATCAGCAGTCTGCAACCTGAAGATTTTGCAACTTACTACTGTCAACAGAGTT ACAGTACCCCTCCGATCACCTTCGGCCAAGGGACACGACTGGAGATTAAA (SEQIDNO: 408) LCVR Amino Acid Sequence DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGV PSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPPITFGQGTRLEIK (SEQIDNO: 409) CDR1 DNA Sequence CAG AGC ATT AGC AGC TAT (SEQIDNO: 236) CDR1 Amino Acid Sequence Q S I S S Y (SEQIDNO: 237) CDR2 DNA Sequence GCT GCA TCC (SEQIDNO: 13) CDR2 Amino Acid Sequence A A S (SEQIDNO: 14) CDR3 DNA Sequence CAA CAG AGT TAC AGT ACC CCT CCG ATC ACC (SEQIDNO: 410) CDR3 Amino Acid Sequence QQSYSTPPIT (SEQIDNO: 411) HC DNA Sequence GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTCCAGCCGGGGGGGTCCCTG AGACTCTCCTGTGCAGCCTCTGGATTCACCTTTAGTTACTATTGGATGAACTGGG TCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGGTGGCCAACATAAAGCAAGATG GAAGTGAGAAATACTATGTGGACTCTGTGAAGGGCCGAGTCACCATCTCCAGAG ACAACGCCAAGAACTCACTGTATCTGCAAATGAACAGCCTGAGAGCCGAGGACA CGGGTGTGTATTACTGTGCGACAGATAAGGTTCGCGGGCGATACCACGACCACT ACGGTTTGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCAGCCTCCAC CAAGGGCCCATCGGTCTTCCCCCTGGCGCCCTGCTCCAGGAGCACCTCCGAGAGC ACAGCCGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGT CGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACA GTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTG GGCACGAAGACCTACACCTGCAACGTAGATCACAAGCCCAGCAACACCAAGGTG GACAAGAGAGTTGAGTCCAAATATGGTCCCCCATGCCCACCGTGCCCAGCACCA CCTGTGGCAGGACCATCAGTCTTCCTGTTCCCCCCAAAACCCAAGGACACTCTCA TGATCTCCCGGACCCCTGAGGTCACGTGCGTGGTGGTGGACGTGAGCCAGGAAG ACCCCGAGGTCCAGTTCAACTGGTACGTGGATGGCGTGGAGGTGCATAATGCCA AGACAAAGCCGCGGGAGGAGCAGTTCAACAGCACGTACCGTGTGGTCAGCGTCC TCACCGTCCTGCACCAGGACTGGCTGAACGGCAAGGAGTACAAGTGCAAGGTCT CCAACAAAGGCCTCCCGTCCTCCATCGAGAAAACCATCTCCAAAGCCAAAGGGC AGCCCCGAGAGCCACAGGTGTACACCCTGCCCCCATCCCAGGAGGAGATGACCA AGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTACCCCAGCGACATCG CCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCCT CCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTACAGCAGGCTCACCGTGGACA AGAGCAGGTGGCAGGAGGGGAATGTCTTCTCATGCTCCGTGATGCATGAGGCTC TGCACAACCACTACACACAGAAGTCCCTCTCCCTGTCTCTGGGTAAATGA (SEQIDNO: 490) HC Amino Acid Sequence EVQLVESGGGLVQPGGSLRLSCAASGFTFSYYWMNWVRQAPGKGLEWVANIKQDG SEKYYVDSVKGRVTISRDNAKNSLYLQMNSLRAEDTGVYYCATDKVRGRYHDHYG LDVWGQGTTVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNS GALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVES KYGPPCPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWY VDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEK TISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNY KTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK* (SEQIDNO: 491) LC DNA Sequence GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAG TCACCATCACTTGCCGGGCAAGTCAGAGCATTAGCAGCTATTTAAATTGGTATCA GCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGCTGCATCCAGTTTGCA AAGTGGGGTCCCGTCAAGGTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTC ACCATCAGCAGTCTGCAACCTGAAGATTTTGCAACTTACTACTGTCAACAGAGTT ACAGTACCCCTCCGATCACCTTCGGCCAAGGGACACGACTGGAGATTAAACGAA CTGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCT GGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAG TACAGTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAGGAGAGTGTCA CAGAGCAGGACAGCAAGGACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGA GCAAAGCAGACTACGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGG GCCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGTTAG (SEQIDNO: 414) LC Amino Acid Sequence DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGV PSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPPITFGQGTRLEIKRTVAAPSVFIF PPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYS LSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC* (SEQIDNO: 415) REGN14188 HCVR DNA Sequence GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTG AGACTCTCCTGTGCAGCCTCTGGATTCACCTTTACCAACTATGCCATGAGCTGGG TCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCAACTATTAGTGATAGTG GTGGTGGCACATACTACGCAGACTCCGTGAGGGGCCGGTTCACCATCTCCAGAG ACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGAGAGCCGAGGACA CGGCCATATATTTCTGTGCGAAAGGGACAAGATCTCGTTTCCCCTTGGACTACTG GGGCCAGGGAACCCTGGTCACCGTCTCCTCA (SEQIDNO: 492) HCVR Amino Acid Sequence EVQLVESGGGLVQPGGSLRLSCAASGFTFTNYAMSWVRQAPGKGLEWVSTISDSGG GTYYADSVRGRFTISRDNSKNTLYLQMNSLRAEDTAIYFCAKGTRSRFPLDYWGQG TLVTVSS (SEQIDNO: 493) CDR1 DNA Sequence GGA TTC ACC TTT ACC AAC TAT GCC (SEQIDNO: 494) CDR1 Amino Acid Sequence GFTFTNYA (SEQIDNO: 495) CDR2 DNA Sequence ATT AGT GAT AGT GGT GGT GGC ACA (SEQIDNO: 496) CDR2 Amino Acid Sequence I S D S G G G T (SEQIDNO: 497) CDR3 DNA Sequence GCG AAA GGG ACA AGA TCT CGT TTC CCC TTG GAC TAC (SEQIDNO: 498) CDR3 Amino Acid Sequence AKGTRSRFPLDY (SEQIDNO: 499) LCVR DNA Sequence GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAG TCACCATCACTTGCCGGGCAAGTCAGAGCATTAGCAGCTATTTAAATTGGTATCA GCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGCTGCATCCAGTTTGCA AAGTGGGGTCCCGTCAAGGTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTC ACCATCAGCAGTCTGCAACCTGAAGATTTTGCAACTTACTACTGTCAACAGAGTT ACAGTACCCCTCCGATCACCTTCGGCCAAGGGACACGACTGGAGATTAAA (SEQIDNO: 408) LCVR Amino Acid Sequence DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGV PSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPPITFGQGTRLEIK (SEQIDNO: 409) CDR1 DNA Sequence CAG AGC ATT AGC AGC TAT (SEQIDNO: 236) CDR1 Amino Acid Sequence Q S I S S Y (SEQIDNO: 237) CDR2 DNA Sequence GCT GCA TCC (SEQIDNO: 13) CDR2 Amino Acid Sequence A A S (SEQIDNO: 14) CDR3 DNA Sequence CAA CAG AGT TAC AGT ACC CCT CCG ATC ACC (SEQIDNO: 410) CDR3 Amino Acid Sequence QQSYSTPPIT (SEQIDNO: 411) HC DNA Sequence GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTG AGACTCTCCTGTGCAGCCTCTGGATTCACCTTTACCAACTATGCCATGAGCTGGG TCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCAACTATTAGTGATAGTG GTGGTGGCACATACTACGCAGACTCCGTGAGGGGCCGGTTCACCATCTCCAGAG ACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGAGAGCCGAGGACA CGGCCATATATTTCTGTGCGAAAGGGACAAGATCTCGTTTCCCCTTGGACTACTG GGGCCAGGGAACCCTGGTCACCGTCTCCTCAGCCTCCACCAAGGGCCCATCGGTC TTCCCCCTGGCGCCCTGCTCCAGGAGCACCTCCGAGAGCACAGCCGCCCTGGGCT GCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCG CCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTA CTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCACGAAGACCTAC ACCTGCAACGTAGATCACAAGCCCAGCAACACCAAGGTGGACAAGAGAGTTGAG TCCAAATATGGTCCCCCATGCCCACCGTGCCCAGCACCACCTGTGGCAGGACCAT CAGTCTTCCTGTTCCCCCCAAAACCCAAGGACACTCTCATGATCTCCCGGACCCC TGAGGTCACGTGCGTGGTGGTGGACGTGAGCCAGGAAGACCCCGAGGTCCAGTT CAACTGGTACGTGGATGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGA GGAGCAGTTCAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAG GACTGGCTGAACGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGGCCTCCCG TCCTCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAGCCACAG GTGTACACCCTGCCCCCATCCCAGGAGGAGATGACCAAGAACCAGGTCAGCCTG ACCTGCCTGGTCAAAGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGC AATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGAC GGCTCCTTCTTCCTCTACAGCAGGCTCACCGTGGACAAGAGCAGGTGGCAGGAG GGGAATGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACAC AGAAGTCCCTCTCCCTGTCTCTGGGTAAATGA (SEQIDNO: 500) HC Amino Acid Sequence EVQLVESGGGLVQPGGSLRLSCAASGFTFTNYAMSWVRQAPGKGLEWVSTISDSGG GTYYADSVRGRFTISRDNSKNTLYLQMNSLRAEDTAIYFCAKGTRSRFPLDYWGQG TLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVH TFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPC PAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNA KTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPR EPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSD GSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK* (SEQIDNO: 501) LC DNA Sequence GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAG TCACCATCACTTGCCGGGCAAGTCAGAGCATTAGCAGCTATTTAAATTGGTATCA GCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGCTGCATCCAGTTTGCA AAGTGGGGTCCCGTCAAGGTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTC ACCATCAGCAGTCTGCAACCTGAAGATTTTGCAACTTACTACTGTCAACAGAGTT ACAGTACCCCTCCGATCACCTTCGGCCAAGGGACACGACTGGAGATTAAACGAA CTGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCT GGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAG TACAGTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAGGAGAGTGTCA CAGAGCAGGACAGCAAGGACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGA GCAAAGCAGACTACGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGG GCCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGTTAG (SEQIDNO: 414) LC Amino Acid Sequence DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGV PSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPPITFGQGTRLEIKRTVAAPSVFIF PPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYS LSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC* (SEQIDNO: 415) REGN14189 HCVR DNA Sequence GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTG AGCCTCTCCTGTGCAGCCTCTGGATTCACCTTTATCAACTATGCCATGACCTGGGT CCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGGTCTCAATTATAAGTGGTAGTGG TGGTAGAAAGTACTAC GC AGACTCC GTGAAGGGC CGGTTC AC C ATCTC C AGAGA CAATTCCAAGAACACGCTGTCTCTGCAAATGAACAGCCTGAGAGCCGAGGACAC GGCCGTATATTACTGTGCGAGATTTCCGGGTTTAGCAGCAGCCGTCTTAGACTAC TGGGGCCAGGGAACCCTGGTCACCGTCTCCTCA (SEQIDNO: 502) HCVR Amino Acid Sequence EVQLVESGGGLVQPGGSLSLSCAASGFTFINYAMTWVRQAPGKGLEWVSIISGSGGR KYYADSVKGRFTISRDNSKNTLSLQMNSLRAEDTAVYYCARFPGLAAAVLDYWGQ GTLVTVSS (SEQIDNO: 503) CDR1 DNA Sequence GGA TTC ACC TTT ATC AAC TAT GCC (SEQIDNO: 504) CDR1 Amino Acid Sequence G F T F I N Y A (SEQIDNO: 505) CDR2 DNA Sequence ATA AGT GGT AGT GGT GGT AGA AAG (SEQIDNO: 506) CDR2 Amino Acid Sequence I S G S G G R K (SEQIDNO: 507) CDR3 DNA Sequence GCG AGA TTT CCG GGT TTA GCA GCA GCC GTC TTA GAC TAC (SEQIDNO: 508) CDR3 Amino Acid Sequence ARFPGLAAAVLDY (SEQIDNO: 509) LCVR DNA Sequence GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAG TCACCATCACTTGCCGGGCAAGTCAGAGCATTAGCAGCTATTTAAATTGGTATCA GCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGCTGCATCCAGTTTGCA AAGTGGGGTCCCGTCAAGGTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTC ACCATCAGCAGTCTGCAACCTGAAGATTTTGCAACTTACTACTGTCAACAGAGTT ACAGTACCCCTCCGATCACCTTCGGCCAAGGGACACGACTGGAGATTAAA (SEQIDNO: 408) LCVR Amino Acid Sequence DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGV PSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPPITFGQGTRLEIK (SEQIDNO: 409) CDR1 DNA Sequence CAG AGC ATT AGC AGC TAT (SEQIDNO: 236) CDR1 Amino Acid Sequence Q S I S S Y (SEQIDNO: 237) CDR2 DNA Sequence GCT GCA TCC (SEQIDNO: 13) CDR2 Amino Acid Sequence A A S (SEQIDNO: 14) CDR3 DNA Sequence CAA CAG AGT TAC AGT ACC CCT CCG ATC ACC (SEQIDNO: 410) CDR3 Amino Acid Sequence QQSYSTPPIT (SEQIDNO: 411) HC DNA Sequence GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTG AGCCTCTCCTGTGCAGCCTCTGGATTCACCTTTATCAACTATGCCATGACCTGGGT CCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGGTCTCAATTATAAGTGGTAGTGG TGGTAGAAAGTACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCAGAGA CAATTCCAAGAACACGCTGTCTCTGCAAATGAACAGCCTGAGAGCCGAGGACAC GGCCGTATATTACTGTGCGAGATTTCCGGGTTTAGCAGCAGCCGTCTTAGACTAC TGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAGCCTCCACCAAGGGCCCATCG GTCTTCCCCCTGGCGCCCTGCTCCAGGAGCACCTCCGAGAGCACAGCCGCCCTGG GCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAG GCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACT CTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCACGAAGACC TACACCTGCAACGTAGATCACAAGCCCAGCAACACCAAGGTGGACAAGAGAGTT GAGTCCAAATATGGTCCCCCATGCCCACCGTGCCCAGCACCACCTGTGGCAGGA CCATCAGTCTTCCTGTTCCCCCCAAAACCCAAGGACACTCTCATGATCTCCCGGA CCCCTGAGGTCACGTGCGTGGTGGTGGACGTGAGCCAGGAAGACCCCGAGGTCC AGTTCAACTGGTACGTGGATGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGC GGGAGGAGCAGTTCAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGC ACCAGGACTGGCTGAACGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGGCC TCCCGTCCTCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAGC CACAGGTGTACACCCTGCCCCCATCCCAGGAGGAGATGACCAAGAACCAGGTCA GCCTGACCTGCCTGGTCAAAGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGG AGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACT CCGACGGCTCCTTCTTCCTCTACAGCAGGCTCACCGTGGACAAGAGCAGGTGGCA GGAGGGGAATGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTAC ACACAGAAGTCCCTCTCCCTGTCTCTGGGTAAATGA (SEQIDNO: 510) HC Amino Acid Sequence EVQLVESGGGLVQPGGSLSLSCAASGFTFINYAMTWVRQAPGKGLEWVSIISGSGGR KYYADSVKGRFTISRDNSKNTLSLQMNSLRAEDTAVYYCARFPGLAAAVLDYWGQ GTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGV HTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPP CPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHN AKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQP REPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDS DGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK* (SEQIDNO: 511) LC DNA Sequence GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAG TCACCATCACTTGCCGGGCAAGTCAGAGCATTAGCAGCTATTTAAATTGGTATCA GCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGCTGCATCCAGTTTGCA AAGTGGGGTCCCGTCAAGGTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTC ACCATCAGCAGTCTGCAACCTGAAGATTTTGCAACTTACTACTGTCAACAGAGTT ACAGTACCCCTCCGATCACCTTCGGCCAAGGGACACGACTGGAGATTAAACGAA CTGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCT GGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAG TACAGTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAGGAGAGTGTCA CAGAGCAGGACAGCAAGGACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGA GCAAAGCAGACTACGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGG GCCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGTTAG (SEQIDNO: 414) LC Amino Acid Sequence DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGV PSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPPITFGQGTRLEIKRTVAAPSVFIF PPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYS LSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC* (SEQIDNO: 415) REGN14190 HCVR DNA Sequence CAGGTTCAGCTGGTGCAGTCTGGAGCTGAGGTGAAGAAGCCTGGGGCCTCAGTG AAGGTCTCCTGCAAGGCTTCTGGTTACACCTTTACCAGCTATGGTATCAGCTGGG TGCGACAGGCCCCTGGACAAGGACTTGAGTGGATGGGATGGATCAGCGCTTACA ATGGTAACACAAAGTATGCACAGAAGTTCCAGGGCAGAGTCACCATGACCAGAG ACACATCCACGAGCACAGCCTACATGGAGCTGAGGAGCCTGAGATCTGACGACA CGGCCGTTTATTACTGTGCGAGATGGGTCTCTATGTTTCGGGGAGTCCCGGGGGA CTCCTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCA (SEQIDNO: 512) HCVR Amino Acid Sequence QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGWISAYN GNTKYAQKFQGRVTMTRDTSTSTAYMELRSLRSDDTAVYYCARWVSMFRGVPGDS WGQGTLVTVSS (SEQIDNO: 513) CDR1 DNA Sequence GGT TAC ACC TTT ACC AGC TAT GGT (SEQIDNO: 137) CDR1 Amino Acid Sequence GYTFTSYG (SEQIDNO: 138) CDR2 DNA Sequence ATC AGC GCT TAC AAT GGT AAC ACA (SEQIDNO: 318) CDR2 Amino Acid Sequence I S A Y N G N T (SEQIDNO: 319) CDR3 DNA Sequence GCG AGA TGG GTC TCT ATG TTT CGG GGA GTC CCG GGG GAC TCC (SEQIDNO: 514) CDR3 Amino Acid Sequence ARWVSMFRGVPGDS (SEQIDNO: 515) LCVR DNA Sequence GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAG TCACCATCACTTGCCGGGCAAGTCAGAGCATTAGCAGCTATTTAAATTGGTATCA GCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGCTGCATCCAGTTTGCA AAGTGGGGTCCCGTCAAGGTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTC ACCATCAGCAGTCTGCAACCTGAAGATTTTGCAACTTACTACTGTCAACAGAGTT ACAGTACCCCTCCGATCACCTTCGGCCAAGGGACACGACTGGAGATTAAA (SEQIDNO: 408) LCVR Amino Acid Sequence DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGV PSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPPITFGQGTRLEIK (SEQIDNO: 409) CDR1 DNA Sequence CAG AGC ATT AGC AGC TAT (SEQIDNO: 236) CDR1 Amino Acid Sequence Q S I S S Y (SEQIDNO: 237) CDR2 DNA Sequence GCT GCA TCC (SEQIDNO: 13) CDR2 Amino Acid Sequence A A S (SEQIDNO: 14) CDR3 DNA Sequence CAA CAG AGT TAC AGT ACC CCT CCG ATC ACC (SEQIDNO: 410) CDR3 Amino Acid Sequence QQSYSTPPIT (SEQIDNO: 411) HC DNA Sequence CAGGTTCAGCTGGTGCAGTCTGGAGCTGAGGTGAAGAAGCCTGGGGCCTCAGTG AAGGTCTCCTGCAAGGCTTCTGGTTACACCTTTACCAGCTATGGTATCAGCTGGG TGCGACAGGCCCCTGGACAAGGACTTGAGTGGATGGGATGGATCAGCGCTTACA ATGGTAACACAAAGTATGCACAGAAGTTCCAGGGCAGAGTCACCATGACCAGAG ACACATCCACGAGCACAGCCTACATGGAGCTGAGGAGCCTGAGATCTGACGACA CGGCCGTTTATTACTGTGCGAGATGGGTCTCTATGTTTCGGGGAGTCCCGGGGGA CTCCTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAGCCTCCACCAAGGGCCCA TCGGTCTTCCCCCTGGCGCCCTGCTCCAGGAGCACCTCCGAGAGCACAGCCGCCC TGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTC AGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGA CTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCACGAAGA CCTACACCTGCAACGTAGATCACAAGCCCAGCAACACCAAGGTGGACAAGAGAG TTGAGTCCAAATATGGTCCCCCATGCCCACCGTGCCCAGCACCACCTGTGGCAGG ACCATCAGTCTTCCTGTTCCCCCCAAAACCCAAGGACACTCTCATGATCTCCCGG ACCCCTGAGGTCACGTGCGTGGTGGTGGACGTGAGCCAGGAAGACCCCGAGGTC CAGTTCAACTGGTACGTGGATGGCGTGGAGGTGCATAATGCCAAGACAAAGCCG CGGGAGGAGCAGTTCAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTG CACCAGGACTGGCTGAACGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGGC CTCCCGTCCTCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAG CCACAGGTGTACACCCTGCCCCCATCCCAGGAGGAGATGACCAAGAACCAGGTC AGCCTGACCTGCCTGGTCAAAGGCTTCTACCCCAGCGACATCGCCGTGGAGTGG GAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGAC TCCGACGGCTCCTTCTTCCTCTACAGCAGGCTCACCGTGGACAAGAGCAGGTGGC AGGAGGGGAATGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTA CACACAGAAGTCCCTCTCCCTGTCTCTGGGTAAATGA (SEQIDNO: 516) HC Amino Acid Sequence QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGWISAYN GNTKYAQKFQGRVTMTRDTSTSTAYMELRSLRSDDTAVYYCARWVSMFRGVPGDS WGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGAL TSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYG PPCPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDG VEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISK AKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTP PVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK* (SEQIDNO: 517) LC DNA Sequence GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAG TCACCATCACTTGCCGGGCAAGTCAGAGCATTAGCAGCTATTTAAATTGGTATCA GCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGCTGCATCCAGTTTGCA AAGTGGGGTCCCGTCAAGGTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTC ACCATCAGCAGTCTGCAACCTGAAGATTTTGCAACTTACTACTGTCAACAGAGTT ACAGTACCCCTCCGATCACCTTCGGCCAAGGGACACGACTGGAGATTAAACGAA CTGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCT GGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAG TACAGTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAGGAGAGTGTCA CAGAGCAGGACAGCAAGGACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGA GCAAAGCAGACTACGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGG GCCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGTTAG (SEQIDNO: 414) LC Amino Acid Sequence DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGV PSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPPITFGQGTRLEIKRTVAAPSVFIF PPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYS LSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC* (SEQIDNO: 415) REGN14191 HCVR DNA Sequence CAGGTGCAGCTGGTGCAGTCTGGGGCTGAAGTGAAGAAGCCTGGGGCCTCAGTG AAGGTCTCCTGCAAGGCTTCTGGATACACCTTCACCGGCTACTATTTACACTGGC TGCGACAGGCCCCTGGACAAGGACTTGAGTGGATGGGATGGATCAACCCTAACA GTGGTCGCCCAAACTATGCACAGAAGTTTCAGGGCAGGGTCACCATGACCAGGG ACACGTCCATCAGCACGGCCTACATGGAACTGCACAGTCTGAGATCTGACGACA CGGCCGTGTATTATTGTGCGAAAGAAACGGGAACTACGAGGGGCTGGTTCGACC CCTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCA (SEQIDNO: 518) HCVR Amino Acid Sequence QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYLHWLRQAPGQGLEWMGWINPN SGRPNYAQKFQGRVTMTRDTSISTAYMELHSLRSDDTAVYYCAKETGTTRGWFDP WGQGTLVTVSS (SEQIDNO: 519) CDR1 DNA Sequence GGA TAC ACC TTC ACC GGC TAC TAT (SEQIDNO: 520) CDR1 Amino Acid Sequence GYTFTGYY (SEQIDNO: 521) CDR2 DNA Sequence ATC AAC CCT AAC AGT GGT CGC CCA (SEQIDNO: 522) CDR2 Amino Acid Sequence I N P N S G R P (SEQIDNO: 523) CDR3 DNA Sequence GCG AAA GAA ACG GGA ACT ACG AGG GGC TGG TTC GAC CCC (SEQIDNO: 524) CDR3 Amino Acid Sequence AKETGTTRGWFDP (SEQIDNO: 525) LCVR DNA Sequence GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAG TCACCATCACTTGCCGGGCAAGTCAGAGCATTAGCAGCTATTTAAATTGGTATCA GCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGCTGCATCCAGTTTGCA AAGTGGGGTCCCGTCAAGGTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTC ACCATCAGCAGTCTGCAACCTGAAGATTTTGCAACTTACTACTGTCAACAGAGTT ACAGTACCCCTCCGATCACCTTCGGCCAAGGGACACGACTGGAGATTAAA (SEQIDNO: 408) LCVR Amino Acid Sequence DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGV PSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPPITFGQGTRLEIK (SEQIDNO: 409) CDR1 DNA Sequence CAG AGC ATT AGC AGC TAT (SEQIDNO: 236) CDR1 Amino Acid Sequence Q S I S S Y (SEQIDNO: 237) CDR2 DNA Sequence GCT GCA TCC (SEQIDNO: 13) CDR2 Amino Acid Sequence A A S (SEQIDNO: 14) CDR3 DNA Sequence CAA CAG AGT TAC AGT ACC CCT CCG ATC ACC (SEQIDNO: 410) CDR3 Amino Acid Sequence QQSYSTPPIT (SEQIDNO: 411) HC DNA Sequence CAGGTGCAGCTGGTGCAGTCTGGGGCTGAAGTGAAGAAGCCTGGGGCCTCAGTG AAGGTCTCCTGCAAGGCTTCTGGATACACCTTCACCGGCTACTATTTACACTGGC TGCGACAGGCCCCTGGACAAGGACTTGAGTGGATGGGATGGATCAACCCTAACA GTGGTCGCCCAAACTATGCACAGAAGTTTCAGGGCAGGGTCACCATGACCAGGG ACACGTCCATCAGCACGGCCTACATGGAACTGCACAGTCTGAGATCTGACGACA CGGCCGTGTATTATTGTGCGAAAGAAACGGGAACTACGAGGGGCTGGTTCGACC CCTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAGCCTCCACCAAGGGCCCATC GGTCTTCCCCCTGGCGCCCTGCTCCAGGAGCACCTCCGAGAGCACAGCCGCCCTG GGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCA GGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGAC TCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCACGAAGAC CTACACCTGCAACGTAGATCACAAGCCCAGCAACACCAAGGTGGACAAGAGAGT TGAGTCCAAATATGGTCCCCCATGCCCACCGTGCCCAGCACCACCTGTGGCAGGA CCATCAGTCTTCCTGTTCCCCCCAAAACCCAAGGACACTCTCATGATCTCCCGGA CCCCTGAGGTCACGTGCGTGGTGGTGGACGTGAGCCAGGAAGACCCCGAGGTCC AGTTCAACTGGTACGTGGATGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGC GGGAGGAGCAGTTCAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGC ACCAGGACTGGCTGAACGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGGCC TCCCGTCCTCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAGC CACAGGTGTACACCCTGCCCCCATCCCAGGAGGAGATGACCAAGAACCAGGTCA GCCTGACCTGCCTGGTCAAAGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGG AGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACT CCGACGGCTCCTTCTTCCTCTACAGCAGGCTCACCGTGGACAAGAGCAGGTGGCA GGAGGGGAATGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTAC ACACAGAAGTCCCTCTCCCTGTCTCTGGGTAAATGA (SEQIDNO: 526) HC Amino Acid Sequence QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYLHWLRQAPGQGLEWMGWINPN SGRPNYAQKFQGRVTMTRDTSISTAYMELHSLRSDDTAVYYCAKETGTTRGWFDP WGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGAL TSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYG PPCPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDG VEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISK AKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTP PVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK* (SEQIDNO: 527) LC DNA Sequence GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAG TCACCATCACTTGCCGGGCAAGTCAGAGCATTAGCAGCTATTTAAATTGGTATCA GCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGCTGCATCCAGTTTGCA AAGTGGGGTCCCGTCAAGGTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTC ACCATCAGCAGTCTGCAACCTGAAGATTTTGCAACTTACTACTGTCAACAGAGTT ACAGTACCCCTCCGATCACCTTCGGCCAAGGGACACGACTGGAGATTAAACGAA CTGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCT GGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAG TACAGTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAGGAGAGTGTCA CAGAGCAGGACAGCAAGGACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGA GCAAAGCAGACTACGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGG GCCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGTTAG (SEQIDNO: 414) LC Amino Acid Sequence DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGV PSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPPITFGQGTRLEIKRTVAAPSVFIF PPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYS LSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC* (SEQIDNO: 415) REGN19513 HCVRDNA Sequence GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTGCAGCCTGGGGGGTCCCTG AGGCTCTCCTGTGCAGCCTCTGGATTCACCTTTAACAACTATGCCATGACCTGGG TCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGGTCTCAGCTGTTACTGGTAGTG GTCGTGACACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCGTCTCCAGAG ACAATTCCAAGAACACGCTGTATCTGCAAATGAGCAGCCTGAGAGCCGAGGACA CGGCCGTATATTTCTGTGCGAAGAAAGCTGCGGACTACTATTACGGTATGGACGT CTGGGGCCAAGGGACCACGGTCACCGTCTCCTCA (SEQIDNO: 528) HCVR Amino Acid Sequence EVQLVESGGGLVQPGGSLRLSCAASGFTFNNYAMTWVRQAPGKGLEWVSAVTGSG RDTYYADSVKGRFTVSRDNSKNTLYLQMSSLRAEDTAVYFCAKKAADYYYGMDV WGQGTTVTVSS (SEQIDNO: 529) CDR1 DNA Sequence GGA TTC ACC TTT AAC AAC TAT GCC (SEQIDNO: 530) CDR1 Amino Acid Sequence GFTFNNYA (SEQIDNO: 531) CDR2 DNA Sequence GTT ACT GGT AGT GGT CGT GAC ACA (SEQIDNO: 532) CDR2 Amino Acid Sequence VTGSGRDT (SEQIDNO: 533) CDR3 DNA Sequence GCG AAG AAA GCT GCG GAC TAC TAT TAC GGT ATG GAC GTC (SEQIDNO: 534) CDR3 Amino Acid Sequence AKKAADYYYGMDV (SEQIDNO: 535) LCVR DNA Sequence GACATCCAGATGACCCAGTCTCCATCTTCCGTGTCTGCATCTGTGGGAGACAGAG TCACCATCACTTGTCGGGCGAGTCAGGGTATTAGCAGCTGGTCAGCCTGGTATCA GCAGAAACCAGGAAAAGCCCCTAAACTCCTGATCTATACTACATCCAGTTTCCAA AGTGGGGTCCCATCAAGGTTCAGCGGCAGTGGATCTGGGACAGATTTCACTCTCA CCATCAGCAGCCTGCAGCCTGAAGATTTTGCAAGTTACTATTGTCAACAGGCTCA CGACTTCTCGCTCACTTTCGGCGGAGGGACCAAGGTGGAGATCAAA (SEQIDNO: 536) LCVR Amino Acid Sequence DIQMTQSPSSVSASVGDRVTITCRASQGISSWSAWYQQKPGKAPKLLIYTTSSFQSGV PSRFSGSGSGTDFTLTISSLQPEDFASYYCQQAHDFSLTFGGGTKVEIK (SEQIDNO: 537) CDR1 DNA Sequence CAG GGT ATT AGC AGC TGG (SEQIDNO: 538) CDR1 Amino Acid Sequence Q G I S S W (SEQIDNO: 539) CDR2 DNA Sequence ACT ACA TCC (SEQIDNO: 540) CDR2 Amino Acid Sequence T T S (SEQIDNO: 541) CDR3 DNA Sequence CAA CAG GCT CAC GAC TTC TCG CTC ACT (SEQIDNO: 542) CDR3 Amino Acid Sequence QQAHDFSLT (SEQIDNO: 543) HC DNA Sequence GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTGCAGCCTGGGGGGTCCCTG AGGCTCTCCTGTGCAGCCTCTGGATTCACCTTTAACAACTATGCCATGACCTGGG TCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGGTCTCAGCTGTTACTGGTAGTG GTCGTGACACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCGTCTCCAGAG ACAATTCCAAGAACACGCTGTATCTGCAAATGAGCAGCCTGAGAGCCGAGGACA CGGCCGTATATTTCTGTGCGAAGAAAGCTGCGGACTACTATTACGGTATGGACGT CTGGGGCCAAGGGACCACGGTCACCGTCTCCTCAGCCTCCACCAAGGGCCCATC GGTCTTCCCCCTGGCGCCCTGCTCCAGGAGCACCTCCGAGAGCACAGCCGCCCTG GGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCA GGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGAC TCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCACGAAGAC CTACACCTGCAACGTAGATCACAAGCCCAGCAACACCAAGGTGGACAAGAGAGT TGAGTCCAAATATGGTCCCCCATGCCCACCCTGCCCAGCACCTGAGTTCCTGGGG GGACCATCAGTCTTCCTGTTCCCCCCAAAACCCAAGGACACTCTCATGATCTCCC GGACCCCTGAGGTCACGTGCGTGGTGGTGGACGTGAGCCAGGAAGACCCCGAGG TCCAGTTCAACTGGTACGTGGATGGCGTGGAGGTGCATAATGCCAAGACAAAGC CGCGGGAGGAGCAGTTCAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCC TGCACCAGGACTGGCTGAACGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAG GCCTCCCGTCCTCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAG AGCCACAGGTGTACACCCTGCCCCCATCCCAGGAGGAGATGACCAAGAACCAGG TCAGCCTGACCTGCCTGGTCAAAGGCTTCTACCCCAGCGACATCGCCGTGGAGTG GGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGA CTCCGACGGCTCCTTCTTCCTCTACAGCAGGCTCACCGTGGACAAGAGCAGGTGG CAGGAGGGGAATGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACT ACACACAGAAGTCCCTCTCCCTGTCTCTGGGTAAATGA (SEQIDNO: 544) HC Amino Acid Sequence EVQLVESGGGLVQPGGSLRLSCAASGFTFNNYAMTWVRQAPGKGLEWVSAVTGSG RDTYYADSVKGRFTVSRDNSKNTLYLQMSSLRAEDTAVYFCAKKAADYYYGMDV WGQGTTVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGAL TSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYG PPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDG VEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISK AKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTP PVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK* (SEQIDNO: 545) LC DNA Sequence GACATCCAGATGACCCAGTCTCCATCTTCCGTGTCTGCATCTGTGGGAGACAGAG TCACCATCACTTGTCGGGCGAGTCAGGGTATTAGCAGCTGGTCAGCCTGGTATCA GCAGAAACCAGGAAAAGCCCCTAAACTCCTGATCTATACTACATCCAGTTTCCAA AGTGGGGTCCCATCAAGGTTCAGCGGCAGTGGATCTGGGACAGATTTCACTCTCA CCATCAGCAGCCTGCAGCCTGAAGATTTTGCAAGTTACTATTGTCAACAGGCTCA CGACTTCTCGCTCACTTTCGGCGGAGGGACCAAGGTGGAGATCAAACGAACTGT GGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGA ACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAGTAC AGTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAGGAGAGTGTCACAG AGCAGGACAGCAAGGACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGAGCA AAGCAGACTACGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGGGCC TGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGTTAG (SEQIDNO: 546) LC Amino Acid Sequence DIQMTQSPSSVSASVGDRVTITCRASQGISSWSAWYQQKPGKAPKLLIYTTSSFQSGV PSRFSGSGSGTDFTLTISSLQPEDFASYYCQQAHDFSLTFGGGTKVEIKRTVAAPSVFI FPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTY SLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC* (SEQIDNO: 547) REGN19514 HCVR DNA Sequence GAGGTGCAGCTGGTGGAGTCTGGGGGAGACTTGGTCCAGCCGGGGGGGTCCCTG AGACTCTCCTGTGTAGCCTCTGGATTCACCTTTAGTAGCTTTTGGATGAGCTGGGT CCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGGTGGCCAACATAAAACAAGATG GAAGTGAGAACTACTATGTGGACTCTGTGAAGGGCCGATTCACCATCTCCAGAG ACAACGCCAAGAACTCACTGTATCTGCAAATGAACAGCCTGAGAGCAGAGGACA CGGCTATGTATTACTGTGCGGTAAACTGGGGAAACTACTGGGGCCAGGGAACCC TGGTCACCGTCTCCTCA (SEQIDNO: 548) HCVR Amino Acid Sequence EVQLVESGGDLVQPGGSLRLSCVASGFTFSSFWMSWVRQAPGKGLEWVANIKQDGS ENYYVDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAMYYCAVNWGNYWGQGTLV TVSS (SEQIDNO: 549) CDR1 DNA Sequence GGA TTC ACC TTT AGT AGC TTT TGG (SEQIDNO: 550) CDR1 Amino Acid Sequence GFTFSSFW (SEQIDNO: 551) CDR2 DNA Sequence ATA AAA CAA GAT GGA AGT GAG AAC (SEQIDNO: 552) CDR2 Amino Acid Sequence I K Q D G S E N (SEQIDNO: 553) CDR3 DNA Sequence GCG GTA AAC TGG GGA AAC TAC (SEQIDNO: 554) CDR3 Amino Acid Sequence A V N W G N Y (SEQIDNO: 555) LCVR DNA Sequence GACATCGTGATGACCCAGTCTCCAGACTCCCTGGCTGTGTCTCTGGGCGTGCGGG CCACCATCAACTGCAGGTCCAGCCAGAGTGTTTTATACAGCTCCAACAATAAAA ACTACTTAGCTTGGTTCATGCAGAAGCCAGGACAGCCTCCCAAGTTGCTCATTTA CTGGGCATCTACCCGGGACTCCGGGGTCCCTGACCGATTCAGTGGCAGCGGGTCT GGGACAGATTTCACTCTCACCATCACCAGTCTACAGGCTGAAGATGTGGCAGTTT ATTACTGTCAGCAAAATTATGGTATTCCTTGGACGTTCGGCCAAGGGACCAAGGT GGAAATCAAA (SEQIDNO: 556) LCVR Amino Acid Sequence DIVMTQSPDSLAVSLGVRATINCRSSQSVLYSSNNKNYLAWFMQKPGQPPKLLIYWA STRDSGVPDRFSGSGSGTDFTLTITSLQAEDVAVYYCQQNYGIPWTFGQGTKVEIK (SEQIDNO: 557) CDR1 DNA Sequence CAG AGT GTT TTA TAC AGC TCC AAC AAT AAA AAC TAC (SEQIDNO: 558) CDR1 Amino Acid Sequence QSVLYSSNNKNY (SEQIDNO: 559) CDR2 DNA Sequence TGG GCA TCT (SEQIDNO: 560) CDR2 Amino Acid Sequence WAS (SEQIDNO: 561) CDR3 DNA Sequence CAG CAA AAT TAT GGT ATT CCT TGG ACG (SEQIDNO: 562) CDR3 Amino Acid Sequence QQNYGIPWT (SEQIDNO: 563) HC DNA Sequence GAGGTGCAGCTGGTGGAGTCTGGGGGAGACTTGGTCCAGCCGGGGGGGTCCCTG AGACTCTCCTGTGTAGCCTCTGGATTCACCTTTAGTAGCTTTTGGATGAGCTGGGT CCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGGTGGCCAACATAAAACAAGATG GAAGTGAGAACTACTATGTGGACTCTGTGAAGGGCCGATTCACCATCTCCAGAG ACAACGCCAAGAACTCACTGTATCTGCAAATGAACAGCCTGAGAGCAGAGGACA CGGCTATGTATTACTGTGCGGTAAACTGGGGAAACTACTGGGGCCAGGGAACCC TGGTCACCGTCTCCTCAGCCTCCACCAAGGGCCCATCGGTCTTCCCCCTGGCGCC CTGCTCCAGGAGCACCTCCGAGAGCACAGCCGCCCTGGGCTGCCTGGTCAAGGA CTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGG CGTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGC GTGGTGACCGTGCCCTCCAGCAGCTTGGGCACGAAGACCTACACCTGCAACGTA GATCACAAGCCCAGCAACACCAAGGTGGACAAGAGAGTTGAGTCCAAATATGGT CCCCCATGCCCACCCTGCCCAGCACCTGAGTTCCTGGGGGGACCATCAGTCTTCC TGTTCCCCCCAAAACCCAAGGACACTCTCATGATCTCCCGGACCCCTGAGGTCAC GTGCGTGGTGGTGGACGTGAGCCAGGAAGACCCCGAGGTCCAGTTCAACTGGTA CGTGGATGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTT CAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTG AACGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGGCCTCCCGTCCTCCATC GAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAGCCACAGGTGTACACC CTGCCCCCATCCCAGGAGGAGATGACCAAGAACCAGGTCAGCCTGACCTGCCTG GTCAAAGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAG CCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCT TCCTCTACAGCAGGCTCACCGTGGACAAGAGCAGGTGGCAGGAGGGGAATGTCT TCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACACAGAAGTCCCT CTCCCTGTCTCTGGGTAAATGA (SEQIDNO: 564) HC Amino Acid Sequence EVQLVESGGDLVQPGGSLRLSCVASGFTFSSFWMSWVRQAPGKGLEWVANIKQDGS ENYYVDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAMYYCAVNWGNYWGQGTLV TVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFP AVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAP EFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKT KPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREP QVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGS FFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK* (SEQIDNO: 565) LC DNA Sequence GACATCGTGATGACCCAGTCTCCAGACTCCCTGGCTGTGTCTCTGGGCGTGCGGG CCACCATCAACTGCAGGTCCAGCCAGAGTGTTTTATACAGCTCCAACAATAAAA ACTACTTAGCTTGGTTCATGCAGAAGCCAGGACAGCCTCCCAAGTTGCTCATTTA CTGGGCATCTACCCGGGACTCCGGGGTCCCTGACCGATTCAGTGGCAGCGGGTCT GGGACAGATTTCACTCTCACCATCACCAGTCTACAGGCTGAAGATGTGGCAGTTT ATTACTGTCAGCAAAATTATGGTATTCCTTGGACGTTCGGCCAAGGGACCAAGGT GGAAATCAAACGAACTGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGAT GAGCAGTTGAAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATC CCAGAGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCCAATCGGGTAACT CCCAGGAGAGTGTCACAGAGCAGGACAGCAAGGACAGCACCTACAGCCTCAGC AGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTACGCCTGC GAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGA GAGTGTTAG (SEQIDNO: 566) LC Amino Acid Sequence DIVMTQSPDSLAVSLGVRATINCRSSQSVLYSSNNKNYLAWFMQKPGQPPKLLIYWA STRDSGVPDRFSGSGSGTDFTLTITSLQAEDVAVYYCQQNYGIPWTFGQGTKVEIKRT VAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQ DSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC* (SEQIDNO: 567) REGN19515 HCVR DNA Sequence CAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGTCCTCGGTG AAGGTCTCCTGCAAGTCTTCTGGAGGCACCTTCAGTAGTTATGGTATCAGCTGGG TGCGACAGGCCCCTGGACAAGGGCTTGAGTGGATGGGAGGGATCATCCCTCTCT TTGGTACAACAAATTACGCACAGAAGTTCCAGGCCAGAGTCACGATTACCTCGG TCGAATCAACGACCACAGCCTACATGGAACTGAACAGCCTGAGATCTGAGGACA CGGCCGTATATTACTGTGCGAAAGATCGACGTGGATACAGCTCTGTTTCCCTACC TCAGTTCCACTCCTTCGGTTTGGACGTCTGGGGCCAAGGGACCACGGTCACCGTC TCCTCA (SEQIDNO: 568) HCVR Amino Acid Sequence QVQLVQSGAEVKKPGSSVKVSCKSSGGTFSSYGISWVRQAPGQGLEWMGGIIPLFGT TNYAQKFQARVTITSVESTTTAYMELNSLRSEDTAVYYCAKDRRGYSSVSLPQFHSF GLDVWGQGTTVTVSS (SEQIDNO: 569) CDR1 DNA Sequence GGA GGC ACC TTC AGT AGT TAT GGT (SEQIDNO: 570) CDR1 Amino Acid Sequence GGTFSSYG (SEQIDNO: 571) CDR2 DNA Sequence ATC ATC CCT CTC TTT GGT AC A AC A (SEQIDNO: 572) CDR2 Amino Acid Sequence I I P L F G T T (SEQIDNO: 573) CDR3 DNA Sequence GCGAAAGATCGACGTGGATACAGCTCTGTTTCCCTACCTCAGTTCCACTCCTTCG GTTTGGACGTC (SEQIDNO: 574) CDR3 Amino Acid Sequence AKDRRGYSSVSLPQFHSFGLDV (SEQIDNO: 575) LCVR DNA Sequence GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAG TCACCATCACTTGCCGGGCAAGTCAGAGCATTAGCAGCTATTTAAATTGGTATCA GCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGCTGCATCCAGTTTGCA AAGTGGGGTCCCGTCAAGGTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTC ACCATCAGCAGTCTGCAACCTGAAGATTTTGCAACTTACTACTGTCAACAGAGTT ACAGTACCCCTCCGATCACCTTCGGCCAAGGGACACGACTGGAGATTAAA (SEQIDNO: 576) LCVR Amino Acid Sequence DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGV PSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPPITFGQGTRLEIK (SEQIDNO: 577) CDR1 DNA Sequence CAG AGC ATT AGC AGC TAT (SEQIDNO: 578) CDR1 Amino Acid Sequence Q S I S S Y (SEQIDNO: 579) CDR2 DNA Sequence GCT GCA TCC (SEQIDNO: 580) CDR2 Amino Acid Sequence A A S (SEQIDNO: 581) CDR3 DNA Sequence CAA CAG AGT TAC AGT ACC CCT CCG ATC ACC (SEQIDNO: 582) CDR3 Amino Acid Sequence QQSYSTPPIT (SEQIDNO: 583) HC DNA Sequence CAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGTCCTCGGTG AAGGTCTCCTGCAAGTCTTCTGGAGGCACCTTCAGTAGTTATGGTATCAGCTGGG TGCGACAGGCCCCTGGACAAGGGCTTGAGTGGATGGGAGGGATCATCCCTCTCT TTGGTACAACAAATTACGCACAGAAGTTCCAGGCCAGAGTCACGATTACCTCGG TCGAATCAACGACCACAGCCTACATGGAACTGAACAGCCTGAGATCTGAGGACA CGGCCGTATATTACTGTGCGAAAGATCGACGTGGATACAGCTCTGTTTCCCTACC TCAGTTCCACTCCTTCGGTTTGGACGTCTGGGGCCAAGGGACCACGGTCACCGTC TCCTCAGCCTCCACCAAGGGCCCATCGGTCTTCCCCCTGGCGCCCTGCTCCAGGA GCACCTCCGAGAGCACAGCCGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCG AACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCT TCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGT GCCCTCCAGCAGCTTGGGCACGAAGACCTACACCTGCAACGTAGATCACAAGCC CAGCAACACCAAGGTGGACAAGAGAGTTGAGTCCAAATATGGTCCCCCATGCCC ACCCTGCCCAGCACCTGAGTTCCTGGGGGGACCATCAGTCTTCCTGTTCCCCCCA AAACCCAAGGACACTCTCATGATCTCCCGGACCCCTGAGGTCACGTGCGTGGTG GTGGACGTGAGCCAGGAAGACCCCGAGGTCCAGTTCAACTGGTACGTGGATGGC GTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTTCAACAGCAC GTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAACGGCAA GGAGTACAAGTGCAAGGTCTCCAACAAAGGCCTCCCGTCCTCCATCGAGAAAAC CATCTCCAAAGCCAAAGGGCAGCCCCGAGAGCCACAGGTGTACACCCTGCCCCC ATCCCAGGAGGAGATGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGG CTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAA CAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTAC AGCAGGCTCACCGTGGACAAGAGCAGGTGGCAGGAGGGGAATGTCTTCTCATGC TCCGTGATGCATGAGGCTCTGCACAACCACTACACACAGAAGTCCCTCTCCCTGT CTCTGGGTAAATGA (SEQIDNO: 584) HC Amino Acid Sequence QVQLVQSGAEVKKPGSSVKVSCKSSGGTFSSYGISWVRQAPGQGLEWMGGIIPLFGT TNYAQKFQARVTITSVESTTTAYMELNSLRSEDTAVYYCAKDRRGYSSVSLPQFHSF GLDVWGQGTTVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWN SGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVE SKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNW YVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIE KTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENN YKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLG K* (SEQIDNO: 585) LC DNA Sequence GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAG TCACCATCACTTGCCGGGCAAGTCAGAGCATTAGCAGCTATTTAAATTGGTATCA GCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGCTGCATCCAGTTTGCA AAGTGGGGTCCCGTCAAGGTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTC ACCATCAGCAGTCTGCAACCTGAAGATTTTGCAACTTACTACTGTCAACAGAGTT ACAGTACCCCTCCGATCACCTTCGGCCAAGGGACACGACTGGAGATTAAACGAA CTGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCT GGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAG TACAGTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAGGAGAGTGTCA CAGAGCAGGACAGCAAGGACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGA GCAAAGCAGACTACGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGG GCCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGTTAG (SEQIDNO: 586) LC Amino Acid Sequence DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGV PSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPPITFGQGTRLEIKRTVAAPSVFIF PPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYS LSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC* (SEQIDNO: 587) REGN19516 HCVR DNA Sequence CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTG AGACTCTCCTGTGCAGCGTCTGGATTCACCTTCAGCGCCTATGTCATGCACTGGG TCCGCCAGGCTCCAGGCAAGGGGCTGGAGTGGATTACAGTTATTGATTATGATGC AAAGAATAAATACTATGCAGACTCCGTGAGGGGCCGATTCACCGTCTCCAGAGA CAATTCCAAGAACACGCTGTTTCTGCAAATGAACAGCCTGAGAGCCGAGGACAC GGCTGTGTATTACTGTGCGAGAAATAGAGGTGGCTACAATTACTTTGACTACTGG GGCCAGGGAACCCTGGTCACCGTCTCCTCA (SEQIDNO: 588) HCVR Amino Acid Sequence QVQLVESGGGVVQPGRSLRLSCAASGFTFSAYVMHWVRQAPGKGLEWITVIDYDA KNKYYADSVRGRFTVSRDNSKNTLFLQMNSLRAEDTAVYYCARNRGGYNYFDYW GQGTLVTVSS (SEQIDNO: 589) CDR1 DNA Sequence GGA TTC ACC TTC AGC GCC TAT GTC (SEQIDNO: 590) CDR1 Amino Acid Sequence GFTFSAYV (SEQIDNO: 591) CDR2 DNA Sequence ATT GAT TAT GAT GCA AAG AAT AAA (SEQIDNO: 592) CDR2 Amino Acid Sequence I D Y D A K N K (SEQIDNO: 593) CDR3 DNA Sequence GCG AGA AAT AGA GGT GGC TAC AAT TAC TTT GAC TAC (SEQIDNO: 594) CDR3 Amino Acid Sequence ARNRGGYNYFDY (SEQIDNO: 595) LCVR DNA Sequence GAAATAGTTTTGACACAGAGTCCCGGCACACTGTCACTCTCTCCCGGGGAAAGA GCCACCTTGTCATGTAGAGCAAGTCAGTCAGTCTCTAGCTCTTATCTCGCCTGGT ACCAGCAGAAGCCGGGACAGGCCCCTAGACTGCTGATCTACGGGGCAAGTTCCA GGGCCACCGGAATCCCCGACCGGTTCAGTGGAAGCGGAAGCGGAACCGATTTTA CTTTGACGATTTCTAGACTGGAGCCAGAGGATTTCGCCGTTTACTATTGTCAACA GTACGGAAGCAGCCCGTGGACGTTTGGCCAGGGCACGAAGGTAGAAATCAAG (SEQIDNO: 596) LCVR Amino Acid Sequence EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGI PDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPWTFGQGTKVEIK (SEQIDNO: 597) CDR1 DNA Sequence CAG TCA GTC TCT AGC TCT TAT (SEQIDNO: 598) CDR1 Amino Acid Sequence Q S V S S S Y (SEQIDNO: 599) CDR2 DNA Sequence GGG GCA AGT (SEQIDNO: 600) CDR2 Amino Acid Sequence GAS (SEQIDNO: 601) CDR3 DNA Sequence CAA CAG TAC GGA AGC AGC CCG TGG ACG (SEQIDNO: 602) CDR3 Amino Acid Sequence QQYGSSPWT (SEQIDNO: 603) HC DNA Sequence CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTG AGACTCTCCTGTGCAGCGTCTGGATTCACCTTCAGCGCCTATGTCATGCACTGGG TCCGCCAGGCTCCAGGCAAGGGGCTGGAGTGGATTACAGTTATTGATTATGATGC AAAGAATAAATACTATGCAGACTCCGTGAGGGGCCGATTCACCGTCTCCAGAGA CAATTCCAAGAACACGCTGTTTCTGCAAATGAACAGCCTGAGAGCCGAGGACAC GGCTGTGTATTACTGTGCGAGAAATAGAGGTGGCTACAATTACTTTGACTACTGG GGCCAGGGAACCCTGGTCACCGTCTCCTCAGCCTCCACCAAGGGCCCATCGGTCT TCCCCCTGGCGCCCTGCTCCAGGAGCACCTCCGAGAGCACAGCCGCCCTGGGCTG CCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGC CCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTAC TCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCACGAAGACCTAC ACCTGCAACGTAGATCACAAGCCCAGCAACACCAAGGTGGACAAGAGAGTTGAG TCCAAATATGGTCCCCCATGCCCACCCTGCCCAGCACCTGAGTTCCTGGGGGGAC CATCAGTCTTCCTGTTCCCCCCAAAACCCAAGGACACTCTCATGATCTCCCGGAC CCCTGAGGTCACGTGCGTGGTGGTGGACGTGAGCCAGGAAGACCCCGAGGTCCA GTTCAACTGGTACGTGGATGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCG GGAGGAGCAGTTCAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCA CCAGGACTGGCTGAACGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGGCCT CCCGTCCTCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAGCC ACAGGTGTACACCCTGCCCCCATCCCAGGAGGAGATGACCAAGAACCAGGTCAG CCTGACCTGCCTGGTCAAAGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGA GAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTC CGACGGCTCCTTCTTCCTCTACAGCAGGCTCACCGTGGACAAGAGCAGGTGGCA GGAGGGGAATGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTAC ACACAGAAGTCCCTCTCCCTGTCTCTGGGTAAATGA (SEQIDNO: 604) HC Amino Acid Sequence QVQLVESGGGVVQPGRSLRLSCAASGFTFSAYVMHWVRQAPGKGLEWITVIDYDA KNKYYADSVRGRFTVSRDNSKNTLFLQMNSLRAEDTAVYYCARNRGGYNYFDYW GQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTS GVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPP CPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGV EVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKA KGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPP VLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK* (SEQIDNO: 605) LC DNA Sequence GAAATAGTTTTGACACAGAGTCCCGGCACACTGTCACTCTCTCCCGGGGAAAGA GCCACCTTGTCATGTAGAGCAAGTCAGTCAGTCTCTAGCTCTTATCTCGCCTGGT ACCAGCAGAAGCCGGGACAGGCCCCTAGACTGCTGATCTACGGGGCAAGTTCCA GGGCCACCGGAATCCCCGACCGGTTCAGTGGAAGCGGAAGCGGAACCGATTTTA CTTTGACGATTTCTAGACTGGAGCCAGAGGATTTCGCCGTTTACTATTGTCAACA GTACGGAAGCAGCCCGTGGACGTTTGGCCAGGGCACGAAGGTAGAAATCAAGCG AACTGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAA TCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCA AAGTACAGTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAGGAGAGTG TCACAGAGCAGGACAGCAAGGACAGCACCTACAGCCTCAGCAGCACCCTGACGC TGAGCAAAGCAGACTACGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATC AGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGTTAG (SEQIDNO: 606) LC Amino Acid Sequence EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGI PDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPWTFGQGTKVEIKRTVAAPSVFI FPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTY SLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC* (SEQIDNO: 607) REGN19517 HCVR DNA Sequence GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTG AGACTCTCCTGTGCAGCCTCTGGATTCACCTTTAGCAGTTATGTCATGAGCTGGG TCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGGTCTCAGATATTAGTGGTCGTG GTGGTAGCACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATTTCCAGAG ACAATTCCAAGAGCACGCTGCATCTGCAAATGAACAGCCTGAGAGCCGAGGACA CGGCCGTATATTACTGTGCGAAAGTGGGGCACCTCGTCCGGGATCACTACTACTA CTACGGTATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCA (SEQIDNO: 608) HCVR Amino Acid Sequence EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYVMSWVRQAPGKGLEWVSDISGRGG STYYADSVKGRFTISRDNSKSTLHLQMNSLRAEDTAVYYCAKVGHLVRDHYYYYG MDVWGQGTTVTVSS (SEQIDNO: 609) CDR1 DNA Sequence GGA TTC ACC TTT AGC AGT TAT GTC (SEQIDNO: 610) CDR1 Amino Acid Sequence GFTFSSYV (SEQIDNO: 611) CDR2 DNA Sequence ATT AGT GGT CGT GGT GGT AGC ACA (SEQIDNO: 612) CDR2 Amino Acid Sequence I S G R G G S T (SEQIDNO: 613) CDR3 DNA Sequence GCG AAA GTG GGG CAC CTC GTC CGG GAT CAC TAC TAC TAC TAC GGT ATG GAC GTC (SEQIDNO: 614) CDR3 Amino Acid Sequence AKVGHLVRDHYYYYGMDV (SEQIDNO: 615) LCVR DNA Sequence GAAATAGTTTTGACACAGAGTCCCGGCACACTGTCACTCTCTCCCGGGGAAAGA GCCACCTTGTCATGTAGAGCAAGTCAGTCAGTCTCTAGCTCTTATCTCGCCTGGT ACCAGCAGAAGCCGGGACAGGCCCCTAGACTGCTGATCTACGGGGCAAGTTCCA GGGCCACCGGAATCCCCGACCGGTTCAGTGGAAGCGGAAGCGGAACCGATTTTA CTTTGACGATTTCTAGACTGGAGCCAGAGGATTTCGCCGTTTACTATTGTCAACA GTACGGAAGCAGCCCGTGGACGTTTGGCCAGGGCACGAAGGTAGAAATCAAG (SEQIDNO: 596) LCVR Amino Acid Sequence EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGI PDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPWTFGQGTKVEIK (SEQIDNO: 597) CDR1 DNA Sequence CAG TCA GTC TCT AGC TCT TAT (SEQIDNO: 598) CDR1 Amino Acid Sequence Q S V S S S Y (SEQIDNO: 599) CDR2 DNA Sequence GGG GCA AGT (SEQIDNO: 600) CDR2 Amino Acid Sequence GAS (SEQIDNO: 601) CDR3 DNA Sequence CAA CAG TAC GGA AGC AGC CCG TGG ACG (SEQIDNO: 602) CDR3 Amino Acid Sequence QQYGSSPWT (SEQIDNO: 603) HC DNA Sequence GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTG AGACTCTCCTGTGCAGCCTCTGGATTCACCTTTAGCAGTTATGTCATGAGCTGGG TCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGGTCTCAGATATTAGTGGTCGTG GTGGTAGCACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATTTCCAGAG ACAATTCCAAGAGCACGCTGCATCTGCAAATGAACAGCCTGAGAGCCGAGGACA CGGCCGTATATTACTGTGCGAAAGTGGGGCACCTCGTCCGGGATCACTACTACTA CTACGGTATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCAGCCTCC ACCAAGGGCCCATCGGTCTTCCCCCTGGCGCCCTGCTCCAGGAGCACCTCCGAGA GCACAGCCGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGG TGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCT ACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGC TTGGGCACGAAGACCTACACCTGCAACGTAGATCACAAGCCCAGCAACACCAAG GTGGACAAGAGAGTTGAGTCCAAATATGGTCCCCCATGCCCACCCTGCCCAGCA CCTGAGTTCCTGGGGGGACCATCAGTCTTCCTGTTCCCCCCAAAACCCAAGGACA CTCTCATGATCTCCCGGACCCCTGAGGTCACGTGCGTGGTGGTGGACGTGAGCCA GGAAGACCCCGAGGTCCAGTTCAACTGGTACGTGGATGGCGTGGAGGTGCATAA TGCCAAGACAAAGCCGCGGGAGGAGCAGTTCAACAGCACGTACCGTGTGGTCAG CGTCCTCACCGTCCTGCACCAGGACTGGCTGAACGGCAAGGAGTACAAGTGCAA GGTCTCCAACAAAGGCCTCCCGTCCTCCATCGAGAAAACCATCTCCAAAGCCAA AGGGCAGCCCCGAGAGCCACAGGTGTACACCCTGCCCCCATCCCAGGAGGAGAT GACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTACCCCAGCGA CATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCA CGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTACAGCAGGCTCACCGT GGACAAGAGCAGGTGGCAGGAGGGGAATGTCTTCTCATGCTCCGTGATGCATGA GGCTCTGCACAACCACTACACACAGAAGTCCCTCTCCCTGTCTCTGGGTAAATGA (SEQIDNO: 616) HC Amino Acid Sequence EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYVMSWVRQAPGKGLEWVSDISGRGG STYYADSVKGRFTISRDNSKSTLHLQMNSLRAEDTAVYYCAKVGHLVRDHYYYYG MDVWGQGTTVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNS GALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVES KYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWY VDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEK TISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNY KTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK* (SEQIDNO: 617) LC DNA Sequence GAAATAGTTTTGACACAGAGTCCCGGCACACTGTCACTCTCTCCCGGGGAAAGA GCCACCTTGTCATGTAGAGCAAGTCAGTCAGTCTCTAGCTCTTATCTCGCCTGGT ACCAGCAGAAGCCGGGACAGGCCCCTAGACTGCTGATCTACGGGGCAAGTTCCA GGGCCACCGGAATCCCCGACCGGTTCAGTGGAAGCGGAAGCGGAACCGATTTTA CTTTGACGATTTCTAGACTGGAGCCAGAGGATTTCGCCGTTTACTATTGTCAACA GTACGGAAGCAGCCCGTGGACGTTTGGCCAGGGCACGAAGGTAGAAATCAAGCG AACTGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAA TCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCA AAGTACAGTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAGGAGAGTG TCACAGAGCAGGACAGCAAGGACAGCACCTACAGCCTCAGCAGCACCCTGACGC TGAGCAAAGCAGACTACGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATC AGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGTTAG (SEQIDNO: 606) LC Amino Acid Sequence EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGI PDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPWTFGQGTKVEIKRTVAAPSVFI FPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTY SLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC* (SEQIDNO: 607)

[0089] Non-limiting examples of targeting ligands that bind p75NTR include: (i) Fab fragments; (ii) F(ab')2 fragments; (iii) Fd fragments; (iv) Fv fragments; (v) single-chain Fv (scFv) molecules; (vi) dAb fragments; and (vii) minimal recognition units consisting of the amino acid residues that mimic the hypervariable region of an antibody (e.g., an isolated complementarity determining region (CDR) such as a CDR3 peptide), or a constrained FR3-CDR3-FR4 peptide. Other engineered molecules, such as domain-specific antibodies, single domain antibodies, domain-deleted antibodies, chimeric antibodies, CDR-grafted antibodies, diabodies, triabodies, tetrabodies, minibodies, nanobodies (e.g. monovalent nanobodies, bivalent nanobodies, etc.), small modular immunopharmaceuticals (SMIPs), and shark variable IgNAR domains, are also encompassed within the expression "targeting ligand," as used herein. In non-limiting embodiments, an anti-p75NTR targeting ligand that binds p75NTR useful for retargeting viral capsids as described herein comprise comprises an scFv. As anon-limiting example, an scFv sequences in VL-(Gly4Ser)3-Vn format useful for retargeting viral capsids as described herein may comprise a heavy chain variable domain, light chain variable domain, heavy chain variable domain / light chain variable domain pair. HCDR1, HCDR2, HCDR3, LCDR1, LCDR2. LCDR3, and / or set of HCDR1-HCDR2-HCDR3-LCDR1-LCDR2-LCDR3 that is 90%, 95%, 97%, 98%, 99% or 100% identical, respectively, to any one of the amino acid sequences of a heavy chain variable domain, light chain variable domain, heavy chain variable domain / light chain variable domain pair, HCDR1, HCDR2, HCDR3, LCDR1, LCDR2. LCDR3, and / or set of HCDR1-HCDR2-HCDR3-LCDR1-LCDR2-LCDR3 as set forth in or encoded by a sequence or sequences set forth in Table 1 and / or any one of SEQ ID NOs: 1-617.

[0090] In some embodiments, the targeting ligand comprises an amino acid sequence or is encoded by a polynucleotide sequence selected from any of the HCDR1 amino acid or nucleic acid sequences listed in Table 1. or a substantially similar sequence thereof having at least about 70-99.9% (e.g., at least 70, 72, 74, 75, 76, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 99.5 or 99.9%) sequence identity thereto.

[0091] In some embodiments, the targeting ligand comprises an amino acid sequence or is encoded by a polynucleotide sequence selected from any of the HCDR2 amino acid or nucleic acid sequences listed in Table 1, or a substantially similar sequence thereof having at least about 70-99.9% (e.g., at least 70, 72, 74, 75, 76, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 99.5 or 99.9%) sequence identity thereto.

[0092] In some embodiments, the targeting ligand comprises an amino acid sequence or is encoded by a polynucleotide sequence selected from any of the HCDR3 amino acid or nucleic acid sequences listed in Table 1, or a substantially similar sequence thereof having at least about 70-99.9% (e.g., at least 70, 72, 74, 75, 76, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 99.5 or 99.9%) sequence identity thereto.

[0093] In some embodiments, the targeting ligand comprises a set of HCDR1-HCDR2-HCDR3 amino acid sequences comprising or encoded by a set of HCDR1-HCDR2-HCDR3 amino acid or nucleic acid sequences listed in Table 1, or substantially similar sequences thereof having at least about 70-99.9% (e.g.. at least 70, 72, 74, 75, 76, 79, 80, 81, 82. 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94. 95. 96. 97. 98. 99, 99.5 or 99.9%) sequence identity thereto.

[0094] In some embodiments, the targeting ligand comprises an amino acid sequence or is encoded by a polynucleotide sequence selected from any of the LCDR1 amino acid or nucleic acid sequences listed in Table 1. or a substantially similar sequence thereof having at least about 70-99.9% (e.g., at least 70, 72, 74, 75, 76, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 99.5 or 99.9%) sequence identity thereto.

[0095] In some embodiments, the targeting ligand comprises an amino acid sequence or is encoded by a polynucleotide sequence selected from any of the LCDR2 amino acid or nucleic acid sequences listed in Table 1. or a substantially similar sequence thereof having at least about 70-99.9% (e.g., at least 70, 72, 74, 75, 76, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 99.5 or 99.9%) sequence identity thereto.

[0096] In some embodiments, the targeting ligand comprises an amino acid sequence or is encoded by a polynucleotide sequence selected from any of the LCDR3 amino acid or nucleic acid sequences listed in Table 1, or a substantially similar sequence thereof having at least about 70-99.9% (e.g., at least 70, 72, 74, 75, 76, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 99.5 or 99.9%) sequence identity thereto.

[0097] In some embodiments, the targeting ligand comprises a set of LCDR1-LCDR2-LCDR3 amino acid sequences comprising or encoded by a set of LCDR1-LCDR2-LCDR3 amino acid or nucleic acid sequences listed in Table 1, or substantially similar sequences thereof having at least about 70-99.9% (e.g., at least 70, 72, 74, 75, 76, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94. 95. 96, 97, 98, 99, 99.5 or 99.9%) sequence identity thereto.

[0098] In some embodiments, the targeting ligand comprises a set of HCDR1-HCDR2-HCDR3-LCDR1-LCDR2-LCDR3 amino acid sequences comprising or encoded by a set of HCDR1-HCDR2-HCDR3-LCDR1-LCDR2-LCDR3 amino acid or nucleic acid sequences listed in Table 1, or substantially similar sequences thereof having at least about 70-99.9% (e.g., at least 70, 72, 74, 75, 76, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 99.5 or 99.9%) sequence identity thereto.

[0099] In some embodiments, the targeting ligand comprises an amino acid sequence or is encoded by a polynucleotide sequence selected from any of the HCVR amino acid or nucleic acid sequences listed in Table 1. or a substantially similar sequence thereof having at least about 70-99.9% (e.g, at least 70, 72, 74, 75, 76, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 99.5 or 99.9%) sequence identity thereto.

[00100] In some embodiments, the targeting ligand comprises an amino acid sequence or is encoded by a polynucleotide sequence selected from any of the LCVR amino acid or nucleic acid sequences listed in Table 1, or a substantially similar sequence thereof having at least about 70-99.9% (e.g., at least 70, 72, 74, 75, 76, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 99.5 or 99.9%) sequence identity thereto.

[00101] In some embodiments, the targeting ligand comprises an amino acid sequence or is encoded by a polynucleotide sequence selected from any of the heavy chain (HC) amino acid or nucleic acid sequences listed in Table 1, or a substantially similar sequence thereof having at least about 70-99.9% (e.g., at least 70, 72, 74, 75, 76, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99. 99.5 or 99.9%) sequence identity thereto.

[00102] In some embodiments, the targeting ligand comprises an amino acid sequence or is encoded by a polynucleotide sequence selected from any of the light chain (LC) amino acid or nucleic acid sequences listed in Table 1, or a substantially similar sequence thereof having at least about 70-99.9% (e.g., at least 70, 72, 74, 75, 76, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99. 99.5 or 99.9%) sequence identity thereto.

[00103] A targeting ligand that binds p75NTR may be associated with (e.g., displayed by, operably linked to, bound to) a modified AAV capsid protein and resulting AAV capsids according to well-known methods, e.g., a direct approach in which the targeting ligand is directly inserted into (e.g., using recombinatorial methods) according to well-known methods. See, e.g.. Stachler et al. (2006), supra'. White et al. (2004), supra'. Girod et al. (1999), supra:, Grifman et al. (2001), supra:, Shi et al. (2001), supra', Shi and Bartlett (2003), supra. A targeting ligand that binds p75NTR may be coupled to a modified AAV capsid protein and resulting AAV capsids using well-known chemical linkers, e.g., wherein the AAV capsid protein may be chemically modified to comprise a dibenzocycootyne group or an azide group, and optionally wherein a targeting ligand as described herein is attached to the dibenzocycootyne group or the azide group, see, e.g., U.S. 2022 / 028234, incorporated herein by reference in its entirety; wherein targeting ligand is covalently linked to a primary amino acid group of an AAV capsid protein, e.g,. via a -CSNH- bond, etc. In some embodiments, a modified capsid as described herein comprises a targeting ligand, e.g.. an anti-p75NTR antibody or binding portion thereof, directly inserted into or coupled to it according to well-known direct recombinatorial methods.

[00104] In various embodiments, an anti-p75NTR antigen-binding protein described herein demonstrates less than 10% to 70% inhibition of nerve growth factor (NGF)-dependent activation of tropomyosin receptor kinase A (TrkA) signaling by the extracellular domain of p75NTR as measured in a cell-based assay.

[00105] In various embodiments, an anti-p75NTR antigen-binding protein described antigen-binding protein demonstrates less than 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%. 55%. 60%. 65%. or 68% inhibition of NGF-dependent activation of TrkA signaling by the extracellular domain of p75NTR as measured in a cell-based assay.

[00106] In various embodiments, an anti-p75NTR antigen-binding protein described antigen-binding protein demonstrates less than 50% inhibition of NGF-dependent activation of TrkA signaling by the extracellular domain of p75NTR as measured in a cell-based assay.

[00107] In various embodiments, the cell-based assay is performed as described in Example 8 presented herein. Multispecific Targeting Ligands

[00108] In some embodiments, the targeting ligand comprises a multispecific binding molecule, e.g., a bispecific antigen-binding molecule, e.g., a bispecific antibody. In some embodiments, the multispecific antigen-binding molecule comprises a first antigen-binding domain and a second antigen-binding domain.

[00109] In some embodiments, the first antigen-binding domain binds to a mammalian p75 neurotrophin receptor (p75NTR). Accordingly, in some embodiments, the first antigenbinding domain comprises an anti-p75NTR antigen-binding protein as disclosed herein, or an antigen-binding portion thereof as described herein.

[00110] In some embodiments, the second antigen-binding domain binds to a first member of a protein:protein binding pair, e.g., a detectable label, comprised within, displayed by, etc., an AAV capsid protein, e.g., at a variable loop of an AAV capsid.

[00111] In some embodiments, the second antigen-binding domain of a multispecific targeting ligand described herein binds to a first member of a protein:protein binding pair, wherein the first member of the protein: protein binding pair is heterologous to the AAV capsid protein. “Heterologous” in this context means heterologous as compared to the AAV serotype from which the capsid protein is derived. In some embodiments, the second antigen-binding domain specifically binds to a c-myc epitope, e.g., comprising an amino acid sequence set forth as SEQ ID NO: 639. In some embodiments, the second antigen-binding domain comprises an antibody paratope that specifically binds to a c-myc epitope, e.g., comprising an amino acid sequence set forth as SEQ ID NO: 639. Thus, the present disclosure includes bispecific antigen-binding molecules, e.g., antibodies, wherein one domain of antigen-binding domain binds to a heterologous detectable label displayed by an AAV capsid (e.g., c-myc, Bl, etc ), and the other antigen-binding domain binds to a mammalian p75NTR. Accordingly, in some embodiments, the multispecific antigen-binding domain comprising the first and second antigen-binding domains retargets an AAV particle comprising an AAV capsid protein comprising the heterologous epitope to mammalian cell expressing p75NTR.

[00112] In some embodiments, the second antigen-binding domain of a multispecific targeting ligand described herein binds to a first member of a protein:protein binding pair, wherein the first member of a protein:protein binding pair comprises one or more epitopes of a capsid of an AAV particle. Thus, the present disclosure includes bispecific antigen-binding molecules, e.g., antibodies, wherein one domain of antigen-binding domain binds to a capsid of an AAV particle (e.g., a capsid comprising a wild-type and / or non-wild-type AAV capsid protein(s)). and the other antigen-binding domain binds to a mammalian p75NTR. Accordingly, in some embodiments, the multispecific antigen-binding domain comprising the first and second antigen-binding domains as described herein retargets an AAV particle (i.e., comprising an AAV capsid protein comprising one or more epitopes, e.g., epitopes comprised within a wildtype AAV capsid protein, recognized by at least one of the antigen-binding domains) to a cell expressing a mammalian p75NTR.

[00113] In some embodiments, the epitope of the capsid of the AAV particle may comprise any of various serotype-specific or serotype-non-specific (i.e., ‘'universal”) epitopes understood by one of ordinary7 skill in the art.

[00114] In some embodiments, the one or more epitope(s) of the capsid of the AAV particle are comprises of any amino acid residues of a capsid protein VP1, VP2 or VP3, or a combination thereof. The AAV particle can be derived from any AAV serotype described herein. In some embodiments, the one or more epitope(s) comprise any variable region of a capsid, or any combination thereof, e.g., a variable region comprised of a capsid protein VP1, VP2 or VP3, or a combination thereof (e.g., variable region I. II, III, IV, V. VI. VII, VIII, IX, or a combination thereof, as described in Emmanuel, et al., Journal of Virology, 2022, 96, 3).

[00115] As anon-limiting example, one or more epitope(s) of an AAV1 capsid may comprise any amino acid residue or combination thereof of a variable region I, II, III, IV, V, VI, VII, VIII, IX, or combination thereof. In some embodiments, the one or more AAV 1 epitope(s) comprise any of residues 456-459. 492-499. 582, 583. 588-591, 593-595, 597. or any combination thereof, as described in Tseng, et al., Front Immunol. 2014, 5: 9.

[00116] As a non-limiting example, one or more epitope(s) of an AAV2 capsid may comprise any amino acid residue or combination thereof of a variable region I, II, III, IV, V, VI. VII, VIII, IX, or combination thereof. In some embodiments, the one or more AAV2 epitope(s) comprise any of residues 253, 254, 258, 261-264, 272-281, 369-378, 381, 384, 385, 474-483, 492-502, 534, 548, 556, 560-573, 585-589, 601-610, 658-660, 708, 717, or any combination thereof, as described in Tseng, et al.. Front Immunol. 2014, 5: 9.

[00117] As a non-limiting example, one or more epitope(s) of an AAV5 capsid may comprise any amino acid residue or combination thereof of a variable region I, II, III, IV, V, VI, VII, VIII, IX, or combination thereof. In some embodiments, the one or more AAV5 epitope(s) comprise any of residues 246, 254-261, 374, 375, 483, 485-492, 494, 496, 499501, 530. 532-538, 653, 654, 656, 657, 704-708, or any combination thereof as described in Tseng, et al.. Front Immunol. 2014, 5: 9.

[00118] As a non-limiting example, one or more epitope(s) of an AAV8 capsid may comprise any amino acid residue or combination thereof of a variable region I, II, III, IV, V, VI, VII, VIII, IX, or combination thereof. In some embodiments, the one or more AAV8 epitope(s) comprise any of residues 586-591 or any combination thereof as described in Tseng, et al., Front Immunol. 2014, 5: 9.

[00119] As a non-limiting example, one or more epitope(s) of an AAV9 capsid may comprise any amino acid residue or combination thereof of a variable region I, II, III, IV, V, VI. VII, VIII, IX, or combination thereof. In some embodiments, the one or more AAV8 epitope(s) comprise any of residues 221, 228, 246-248, 250-256, 258-260, any of residues 262-273 of variable region I, any of residues 274, 275, 278, 291, 293, 324, 325, any of residues 327-333 of variable region II. any of residues 334, 335, 338, 341, 363-365, 369-373, 375, 376. any of residues 382-387, 389, 391 of variable region III, any of residues 438-441, 443, any of residues 446, 448, 449, 451-460, 462, 464-473 of variable region IV, any of residues 488, 491-501, 503-506, 510-515 of variable region V, any of residues 528-534, 545 of variable region VI, any of residues 547-560 of variable region VII, residue 572, any of residues 579. 584, 587-590 of variable region VIII, any of residues 651-653, 655-676, 678, any of residues 701-720, 722. 724-728 of variable region IX. or any of residues 730. 731, or any combination thereof, as described in Emmanuel, et al., Journal of Virology, 2022, 96, 3. Binding pairs

[00120] In some embodiments, a targeting ligand that binds p75NTR may be associated with (e.g., displayed by, operably linked to, bound to) a modified AAV capsid protein and resulting AAV capsids according to indirect recombinatorial approaches, wherein the AAV capsid protein is modified to comprise a first member of a binding pair (e.g., a heterologous scaffold), and optionally wherein the first member of the binding pair is linked to (e.g.. covalently or non-covalently bound to) a second cognate member of the binding pair (e.g., an adaptor), further optionally wherein the second cognate member of the binding pair is fused to the targeting ligand. Non-limiting and exemplary' binding pairs are listed in Buning and Srivastava (2019) Mol. Ther. Methods Clin Dev 12:248-265.

[00121] Accordingly, in some embodiments, modifications of a capsid protein as described herein include those that generally result from modifications at the genetic level, e.g., via modification of a cap gene, such as modifications that insert first member of a binding pair (e.g., a protein:protein binding pair, a proteimnucleic acid binding pair), a detectable label, etc., for display by the Cap protein.

[00122] In some embodiments, the first member forms a binding pair with an immunoglobulin constant domain. In some embodiments, the first member forms a binding pair with a metal ion, e.g., Ni2+, Co2+, Cu2+, Zn2+, Fe3+, etc. In some embodiments, the first member is selected from the group consisting of Streptavidin. Strep II, HA, L14, 4C-RGD, LH, and Protein A.

[00123] In some embodiments, the binding pair comprises an enzyme:nucleic acid binding pair. In some embodiments, the first member comprises a HUH-endonuclease or HUH-tag and the second member comprises a nucleic acid binding domain. In some embodiments, the first member comprises aHUH tag. See, e.g., U.S. 2021 / 0180082, incorporated herein in its entirety by reference.

[00124] In some embodiments, a capsid protein of the invention comprises at least a first member of a peptide:peptide binding pair.

[00125] In some embodiments, each of a first member and a second member of a peptide:peptide binding pair comprises an intein. See. e.g. Wagner et al., (2021) Adv. Sci. 8: 2004018 (1 of 22); Muik et al. (2017) Biomaterials 144: 84, each of which is incorporated herein in its entirety by reference.

[00126] In some embodiments, a first member is a B cell epitope, e.g., is between about 1 amino acid and about 35 amino acids in length, and forms a binding pair with an antibody paratope, e.g., an immunoglobulin variable domain. In some embodiments, a capsid protein of the invention may be modified to comprise a detectable label as a first member of a binding pair. Many detectable labels are known in the art. (See, e.g.: Nilsson et al. (1997) “Affinity fusion strategies for detection, purification, and immobilization of modified proteins”; Protein Expression and Purification 11: 1-16, Terpe et al. (2003); “Overview of tag protein fusions: From molecular and biochemical fundamentals to commercial systems” Applied Microbiology7 and Biotechnology7 60:523-533; and references therein). Detectable labels include, but are not limited to, a polyhistidine detectable labels (e.g., aHis-6, His-8, or His-10) that binds immobilized divalent cations (e.g.. Ni2+). a biotin moiety7 (e.g., on an in vivo biotinylated polypeptide sequence) that binds immobilized avidin, a GST (glutathione S-transferase) sequence that binds immobilized glutathione, an S tag that binds immobilized S protein, an antigen that binds an immobilized antibody or domain or fragment thereof (including, e.g., T7, myc, FLAG, and B tags that bind corresponding antibodies), a FLASH Tag (a high detectable label that couples to specific arsenic based moieties), a receptor or receptor domain that binds an immobilized ligand (or vice versa), protein A or a derivative thereof (e.g., Z) that binds immobilized IgG, maltose-binding protein (MBP) that binds immobilized amylose, an albumin-binding protein that binds immobilized albumin, a chitin binding domain that binds immobilized chitin, a calmodulin binding peptide that binds immobilized calmodulin, and a cellulose binding domain that binds immobilized cellulose. Another exemplary' detectable label is a SNAP-tag. In some embodiments, a detectable label disclosed herein comprises a detectable label recognized by an antibody paratope, wherein the detectable label and the antibody paratope form a protein:protein binding pair.

[00127] In some embodiments, a capsid protein of the invention comprises a first member of a protein:protein binding pair comprising a detectable label, which may also be used for the detection and / or isolation of the Cap protein and / or as a first member of a protein:protein binding pair. In some embodiments, a detectable label acts as a first member of a protein: protein binding pair for the binding of a targeting ligand comprising a multispecific binding protein that may bind both the detectable label and a target expressed by a cell of interest. In some embodiments, a Cap protein of the invention comprises a first member of a protein: protein binding pair comprising c-myc (EQKLISEEDL; SEQ ID NO: 639). Use of a detectable label as a first member of a protein:protein binding pair is described in, e.g., WO2019006043, incorporated herein in its entirety7 by reference.

[00128] In some embodiments, the first member comprises a Bl epitope (SEQ ID NO: 640). In some embodiments, a capsid protein is modified to comprise a Bl epitope in the VP3 region. In some embodiments, the first member is selected from the group consisting of FLAG, HA and c-myc (EQKLISEEDL; SEQ ID NO: 639).

[00129] In some embodiments, a capsid protein comprises a first member of a protein:protein binding pair, wherein the protein:protein binding pair forms a covalent isopeptide bond. In some embodiments, the first member of a peptide:peptide binding pair is covalently bound via an isopeptide bond to a cognate second member of the peptide:peptide binding pair, and optionally wherein the cognate second member of the peptide:peptide binding pair is fused with a targeting ligand, which targeting ligand binds a target expressed by a cell of interest. In some embodiments, the protein: protein binding pair may be selected from the group consisting of SpyTag: SpyCatcher. SpyTag002:SpyCatcher002, SpyTagOO3:SpyCatcherOO3, SpyTag:KTag, Isopeptag:pilin-C, and SnoopTag: SnoopCatcher. In some embodiments, wherein the first member is SpyTag (or a biologically active portion or variant thereof) and the protein (second cognate member) is SpyCatcher (or a biologically active portion or variant thereof). In some embodiments, wherein the first member is SpyTag (or a biologically active portion or variant thereof) and the protein (second cognate member) is KTag (or a biologically active portion or variant thereof). In some embodiments, wherein the first member is KTag (or a biologically active portion or variant thereof) and the protein (second cognate member) is SpyTag (or a biologically active portion or variant thereof). In some embodiments, wherein the first member is SnoopTag (or a biologically active portion or variant thereof) and the protein (second cognate member) is SnoopCatcher (or a biologically active portion or variant thereof). In some embodiments, wherein the first member is Isopeptag (or a biologically active portion or variant thereof) and the protein (second cognate member) is Pilin-C (or a biologically active portion or variant thereof). In some embodiments, wherein the first member is SpyTag002 (or a biologically active portion or variant thereof) and the protein (second cognate member) is SpyCatcher002 (or a biologically active portion or variant thereof). In some embodiments, wherein the first member is SpyTagOO3 (or a biologically active portion or variant thereof) and the protein (second cognate member) is SpyCatcher003 (or a biologically active portion or variant thereof). In some embodiments, a Cap protein of the invention comprises a SpyTag, or a biologically active portion or variant thereof. Use of a first member of a protein:protein binding pair is described in WO2019006046, incorporated herein in its entirety.

[00130] In some embodiments, a first member of a protein: protein binding pair and / or detectable label is operably linked to (translated in frame with, chemically attached to, and / or displayed by) a Cap protein of the invention via a first or second linker, e.g., an amino acid spacer that is at least one amino acid in length. In some embodiments, the first member of a protein:protein binding pair is flanked by a first and / or second linker, e g., a first and / or second amino acid spacer, each of which spacer is at least one amino acid in length.

[00131] In some embodiments, the first and / or second linkers are not identical. In some embodiments, the first and / or second linker is each independently one or two amino acids in length. In some embodiments, the first and / or second linker is each independently one, two or three amino acids in length. In some embodiments, the first and / or second linker is each independently one, two, three, or four amino acids in length. In some embodiments, the first and / or second linker is each independently one, two, three, four, or five amino acids in length. In some embodiments, the first and / or second linker are each independently one, two, three, four, or five amino acids in length. In some embodiments, the first and / or second linker is each independently one, two. three, four, five, or six amino acids in length. In some embodiments, the first and / or second linker is each independently one, two, three, four, five, six, or seven amino acids in length. In some embodiments, the first and / or second linker is each independently one, two, three...

Claims

1. A recombinant adeno-associated virus (AAV) particle comprising:(i) a modified AAV capsid protein, and(ii) a targeting ligand that binds a mammalian p75 neurotrophin receptor (p75NTR), wherein the modified AAV capsid protein is operably linked with the targeting ligand.

2. The recombinant AAV particle of claim 1. wherein:(a) the modified AAV capsid protein comprises a first member and a second member of a protein: protein binding pair, and(b) the second member of the protein:protein binding pair comprises the targeting ligand that binds the mammalian p75NTR,wherein the first member of the protein:protein binding pair and the second member of the protein: protein binding pair are associated to direct the tropism of the AAV particle to a mammalian p75NTR-expressing cell.

3. The recombinant AAV particle of claim 1 or claim 2, wherein the mammalian p75NTR is a human p75NTR.

4. The recombinant AAV particle of claim 2 or claim 3, wherein the mammalian p75NTR-expressing cell is selected from the group consisting of: a neuron, a Mueller glial cell, a Leydig cell, an ionocyte, a dorsal root ganglion (DRG) cell, a trigeminal ganglion cell, a sympathetic ganglion cell, a dermal fiber cell, a retina cell, a myenteric plexus cell, a celiac ganglion cell, a dendritic cell, a Schwann cell, a sali vary gland cell, a retinal bipolar neuron, a basal respiratory cell, a basal squamous epithelial cell, and an oligodendrocyte.

5. The recombinant AAV particle of any one of claims 2-4, comprising the modified AAV capsid protein bound to the mammalian p75NTR expressed on the surface of the mammalian p75NTR-expressing cell.

6. The recombinant AAV particle of any one of claims 2-5, comprising the modified AAV capsid protein bound to the mammalian p75NTR expressed on the surface of the mammalian p75NTR-expressing cell,wherein the mammalian p75NTR is a human p75NTR, andwherein the mammalian p75NTR-expressing cell is a non-human animal cell genetically modified to express the human p75NTR.

7. The recombinant AAV particle of any one of claims 2-6, comprising the modifiedAAV capsid protein bound to the mammalian p75NTR expressed on the surface of the mammalian p75NTR-expressing cell,wherein the mammalian p75NTR is a human p75NTR, andwherein the mammalian p75NTR-expressing cell is a rodent cell genetically modified to express the human p75NTR.

8. The recombinant AAV particle of claim 7, wherein the rodent p75NTR-expressing cell is a rat p75NTR-expressing cell or a mouse p75NTR-expressing cell.

9. The recombinant AAV particle of any one of claims 2-5, comprising the modified AAV capsid protein bound to the mammalian p75NTR expressed on the surface of the mammalian p75NTR-expressing cell,wherein the mammalian p75NTR is a human p75NTR . andwherein the mammalian p75NTR-expressing cell is a human p75NTR-expressing cell.

10. The recombinant AAV particle of any one of claims 1-9, wherein the recombinant AAV particle is in vitro.

11. The recombinant AAV particle of any one of claims 1-9, wherein the recombinant AAV particle is in vivo.

12. The recombinant AAV particle of any one of claims 1-11. wherein the targeting ligand is an antibody or a portion thereof.

13. The recombinant AAV particle of any one of claims 1-12, wherein the targeting ligand comprises a heavy chain variable domain, light chain variable domain, heavy chain variable domain / light chain variable domain pair, HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, LCDR3, and / or set of HCDR1-HCDR2-HCDR3-LCDR1-LCDR2-LCDR3 amino acid sequence(s) at least 90% identical to. respectively, an amino acid sequence of a heavy chain variable domain, light chain variable domain, heavy chain variable domain / light chain variable domain pair, HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, LCDR3, and / or set of HCDR1-HCDR2-HCDR3-LCDR1-LCDR2-LCDR3 as set forth in or encoded by any one of SEQ ID NOs: 1-617.

14. The recombinant AAV particle of any one of claims 1-13, wherein the targeting ligand comprises the HCDR1-HCDR2-HCDR3-LCDR1-LCDR2-LCDR3 amino acid sequence set contained within an HCVR / LCVR amino acid sequence pair selected from the group consisting of SEQ ID NOs: 2 / 10, 22 / 30, 42 / 50. 58 / 66, 78 / 86. 98 / 106, 116 / 124.136 / 144, 155 / 162, 173 / 179, 189 / 197, 207 / 215, 227 / 235, 245 / 251, 261 / 269, 279 / 287, 297 / 304, 315 / 323, 331 / 339, 349 / 357, 369 / 377, 387 / 391, 401 / 409, 417 / 409, 427 / 409, 437 / 409, 445 / 409, 455 / 409, 465 / 409, 475 / 409, 484 / 409, 493 / 409, 503 / 409, 513 / 409. 519 / 409, 529 / 537, 549 / 557, 569 / 577, 589 / 597, and 609 / 597, optionally wherein the targeting ligand comprises the HCDR1-HCDR2-HCDR3-LCDR1-LCDR2-LCDR3 amino acid sequence set contained within an HCVR / LCVR amino acid sequence pair selected from the group consisting of 529 / 537, 549 / 557, 569 / 577, 589 / 597, and 609 / 597.

15. The recombinant AAV particle of any one of claims 1-14, wherein the targeting ligand comprises an HCVR / LCVR amino acid sequence pair selected from the group consisting of SEQ ID NOs: 2 / 10, 22 / 30, 42 / 50, 58 / 66, 78 / 86, 98 / 106, 116 / 124, 136 / 144, 155 / 162, 173 / 179, 189 / 197, 207 / 215, 227 / 235, 245 / 251, 261 / 269. 279 / 287, 297 / 304, 315 / 323, 331 / 339. 349 / 357, 369 / 377, 387 / 391, 401 / 409, 417 / 409, 427 / 409. 437 / 409. 445 / 409. 455 / 409, 465 / 409, 475 / 409, 484 / 409, 493 / 409, 503 / 409, 513 / 409, 519 / 409, 529 / 537, 549 / 557, 569 / 577, 589 / 597, and 609 / 597, optionally wherein the targeting ligand comprises an HCVR / LCVR amino acid sequence pair selected from the group consisting of 529 / 537, 549 / 557, 569 / 577, 589 / 597, and 609 / 597.

16. The recombinant AAV particle of any one of claims 2-15, wherein:(a) the first member of the protein: protein binding pair comprises SpyTag, Isopeptag, SnoopTag, SpyTag002, SpyTag003. or any biologically active portions or variants thereof,(b) the second member of the protein:protein binding pair comprises(i) SpyCatcher, KTag, pilin-C, SnoopCatcher, SpyCatcher002, SpyCatcherOO3, or any biologically active portions or variants thereof, and(ii) the targeting ligand that binds the mammalian p75NTR, and(c) the first member of the protein: protein binding pair and the second member of the protein:protein binding pair are linked by an isopeptide bond.

17. The recombinant AAV particle of claim 16, wherein:(a) the first member of the protein:protein binding pair comprises SpyTag, or any biologically active portion or variant thereof, and(b) the second member of the protein:protein binding pair comprises SpyCatcher, or any biologically active portion or variant thereof, fused to the targeting ligand that binds the mammalian p75NTR.

18. The recombinant AAV particle of any one of claims 2-17, comprising a first and / or second linker operably linking the first member of the protein: protein binding pair to the modified AAV capsid protein.

19. The recombinant AAV particle of claim 18, wherein the first and second linker are not identical, or the first and second linker are identical.

20. The recombinant AAV particle of claim 18 or claim 19, wherein the first linker is 10 amino acids in length and / or the second linker is 10 amino acids in length.

21. The recombinant AAV particle of any one of claims 1-20, wherein the modified AAV capsid protein comprises a modified VP1 capsid protein, a modified VP2 capsid protein, and / or a modified VP3 capsid protein, andwherein the modified VP 1 capsid protein, the modified VP2 capsid protein, and / or the modified VP3 capsid protein comprises an insertion of a first member of a protein:protein binding pair and / or the targeting ligand, andand wherein a portion of the modified VP 1 capsid protein, the modified VP2 capsid protein, and / or the modified VP3 capsid protein, that comprises the insertion of the first member of the protein: protein binding pair and / or the targeting ligand, further comprises an amino acid sequence at least 90% identical to a corresponding capsid protein of a wild-type AAV.

22. The recombinant AAV particle of claim 21, wherein the modified VP1 capsid protein, the modified VP2 capsid protein, and / or the modified VP3 capsid protein further comprises, in addition to the insertion of the first member of the protein: protein binding pair and / or the targeting ligand:(i) a substitution, insertion, or deletion of an amino acid.(ii) a chimeric amino acid sequence, or (iii) any combination of (i) and (ii).

23. The recombinant AAV particle of claim 22, wherein the substitution, insertion, or deletion of an amino acid reduces the natural tropism of the AAV particle and / or creates a detectable label.

24. The recombinant AAV particle of any one of claims 1-23 , wherein the AAV is selected from the group consisting of AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, anon-primate animal AAV listed in Table 2, and any chimera thereof.

25. The recombinant AAV particle of any one of claims 1-24. wherein the AAV is AAV2.

26. The recombinant AAV particle of any one of claims 1-25, wherein the recombinant AAV particle comprises a modified AAV2 VP1 capsid protein that comprises a first memberof a protein:protein binding pair inserted at an amino acid position 1-453 and / or 1-587, and optionally linked to the AAV sequence via a linker on one or both sides.

27. The recombinant AAV particle of claim 26, wherein the recombinant AAV particle comprises the modified AAV2 VP1 capsid protein that comprises the first member of the protein:protein binding pair inserted, optionally via a linker, at position G453, optionally wherein the modified AAV2 VP1 capsid protein further comprises a mutation selected from R585A, R588A, R484A, R487A, K532A. and any combination thereof.

28. The recombinant AAV particle or composition of claim 26 or claim 27, wherein the recombinant AAV particle comprises a mosaic AAV capsid comprising a second set of AAV2 VP1 capsid proteins lacking the first member of the protein: protein binding pair, optionally wherein the second set of AAV2 VP1 capsid proteins comprises a mutation selected from R585A, R588A, R484A, R487A, K532A and any combination thereof.

29. The recombinant AAV particle of any one of claims 1-24. wherein the AAV is AAV9.

30. The recombinant AAV particle of claim 29, wherein the modified AAV capsid protein comprises a modified AAV9 VP1 capsid protein that comprises a first member of a protein:protein binding pair inserted, optionally via a linker, at position 1-453 or 1-589.

31. The recombinant AAV particle of claim 30, wherein the recombinant AAV particle comprises the modified AAV9 VP1 capsid protein that comprises the first member of the protein:protein binding pair inserted, optionally via a linker, at position G453, optionally wherein the modified AAV9 VP1 capsid protein further comprises a mutation selected from N272A, W503A, and a combination thereof32. The recombinant AAV particle of claim 30 or claim 31, wherein the recombinant AAV particle comprises a mosaic AAV capsid comprising a second set of AAV9 VP1 capsid proteins lacking the first member of the protein: protein binding pair,optionally wherein the second set of AAV9 VP1 capsid proteins comprises a mutation selected from N272A, W503A, and a combination thereof.

33. The recombinant AAV particle any one of claims 1-24, wherein the AAV is a nonprimate animal AAV.

34. The recombinant AAV particle of claim 33, wherein the non-primate animal AAV is an avian AAV (AAAV).

35. The recombinant AAV particle of claim 34, wherein the modified AAV capsid protein comprises a modified AAAV VP1 capsid protein that comprises a first member of a protein:protein binding pair inserted, optionally via a linker, at position 1-444 or 1-580.

36. The recombinant AAV particle of claim 33, wherein the non-primate animal AAV is a squamate AAV.

37. The recombinant AAV particle of claim 36, wherein the squamate AAV is a bearded dragon AAV.

38. The recombinant AAV particle of claim 37, wherein the modified AAV capsid protein comprises a modified bearded dragon AAV VP1 capsid protein that comprises a first member of a protein:protein binding pair inserted, optionally via a linker, at position 1-573 or 1-436.

39. The recombinant AAV particle of claim 33, wherein the non-primate animal AAV is a non-primate mammalian AAV.

40. The recombinant AAV particle of claim 39, wherein the non-primate mammalian AAV is a sea lion AAV.

41. The recombinant AAV particle of claim 40, wherein the modified AAV capsid protein comprises a modified sea lion AAV VP1 capsid protein that comprises a first member of a protein:protein binding pair inserted, optionally via a linker, at a position selected from the group consisting of 1-429,1-430,1-431,1-432,1-433,1-434,1-436,1-437, and 1-565.

42. The recombinant AAV particle of any one of claims 1-41. wherein the recombinant AAV particle comprises a mosaic AAV capsid, optionally wherein the mosaic AAV capsid comprises (i) a first plurality of reference AAV capsid proteins, each of which is not associated with the targeting ligand, and (ii) a second plurality of AAV capsid proteins, each of which is associated with the targeting ligand, optionally wherein the mosaic AAV capsid comprises the first plurality of reference AAV capsid proteins and the second plurality of AAV capsid proteins at a ratio of 1:7.

43. The recombinant AAV particle of any one of claims 1-42. further comprising a nucleotide of interest encapsidated within the recombinant AAV particle.

44. The recombinant AAV particle of claim 43, wherein the nucleotide of interest is a reporter gene.

45. The recombinant AAV particle of claim 43 or claim 44, wherein the nucleotide of interest encodes P-galactosidase, green fluorescent protein (GFP), enhanced Green Fluorescent Protein (eGFP), MmGFP, blue fluorescent protein (BFP), enhanced blue fluorescent protein (eBFP), mPlum, mCherry, tdTomato, mStrawberry, J-Red, DsRed, mOrange, mKO. mCitrine. Venus. YPet, yellow fluorescent protein (YFP). enhanced yellow fluorescent protein (eYFP), Emerald, CyPet, cyan fluorescent protein (CFP), Cerulean, T-Sapphire, luciferase, alkaline phosphatase, or a combination thereof.

46. The recombinant AAV particle of claim 43, wherein the nucleotide of interest encodes a therapeutic protein, a suicide gene, an antibody or a fragment thereof, a CRISPR / Cas system or a portion(s) thereof, an antisense oligonucleotide, a ribozyme, an RNAi molecule, or a shRNA molecule.

47. The recombinant AAV particle of claim 46, wherein the nucleotide of interest targets a gene or gene product associated with pain, itch, or a neurological disease or disorder.

48. The recombinant AAV particle of claim 47, wherein the gene or gene product associated with pain, itch, or a neurological disease or disorder is voltage-gated sodium channel Navi.7, voltage-gated sodium channel Navi.8, voltage-gated sodium channel Navi.9, voltage-gated sodium channel Navi.6, tropomyosin receptor kinase A (TrkA), tropomyosin receptor kinase C (TRKC). acid-sensing ion channel subunit 1 (ASIC 1), acidsensing ion channel subunit 3 (ASIC3), transient receptor potential vanilloid 1 (TRPV1). transient receptor potential vanilloid 4 (TRPV4), transient receptor potential cation channel, subfamily A, member 1 (TRPA1), transient receptor potential cation channel subfamily M, member 8 (TRPM8). fatty acid amide hydrolase (FAAH). piezo type mechanosensitive ion channel component 1 (PIEZO 1). piezo type mechanosensitive ion channel component 2 (PIEZO2), enkephalin, RET proto-oncogene (RET), interleukin 4 receptor (IL4R), interleukin 13 receptor (IL13R), interleukin 31 receptor (IL31R), interleukin 6 receptor alpha (IL6Ra), glycoprotein 130(gpl30), FXYD domain containing ion transport regulator 2 (FXYD2), P2X purinoceptor 3 (P2X3).

49. The recombinant AAV particle of any one of claims 46-48, wherein the nucleotide of interest encodes a molecule that reduces or ablates the expression of voltage-gated sodium channel Navi.7.

50. The recombinant AAV particle of any one of claims 46-49, wherein the nucleotide of interest encodes gRNA that targets a gene encoding voltage-gated sodium channel Navi.7 for silencing via CRISPR-Cas9.

51. The recombinant AAV particle of any one of claims 46-49, wherein the nucleotide of interest encodes shRNA that targets mRNA encoding voltage-gated sodium channel Navi.7 for silencing via RNAi.

52. A pharmaceutical composition comprising (a) the recombinant AAV particle according to any one of claims 43-50, and (b) a pharmaceutically acceptable carrier or excipient.

53. A method of delivering a nucleotide of interest to a mammalian p75NTR-expressing cell comprising contacting the mammalian p75KTR-expressing cell with (a) the recombinant AAV particle according to any one of claims 43-51, or (b) the pharmaceutical composition of claim 52.

54. The method of claim 53. wherein the contacting is performed ex vivo.

55. The method of claim 54, wherein the contacting is performed in a subject.

56. The method of claim 55, wherein the subject is a primate animal, preferably a human.

57. The method of any one of claims 53-56, wherein the p75NTR-expressing cell isselected from the group consisting of: a neuron, a Mueller glial cell, a Leydig cell, an ionocyte. a dorsal root ganglion (DRG) cell, a trigeminal ganglion cell, a sympathetic ganglion cell, a dermal fiber cell, a retina cell, a myenteric plexus cell, a celiac ganglion cell, a dendritic cell, a Schwann cell, a salivary gland cell, a retinal bipolar neuron, a basal respiratory cell, a basal squamous epithelial cell, and an oligodendrocyte.

58. The method of any one of claims 53-57. wherein the mammalian p75NTR is human p75NTR.

59. The method of any one of claims 53-58, wherein the nucleotide of interest encodes a therapeutic protein, a suicide gene, an antibody or a fragment thereof, a CRISPR / Cas systemor a portion(s) thereof, an antisense oligonucleotide, a ribozyme, an RNAi molecule, or a shRNA molecule.

60. The method of claim 59, wherein the nucleotide of interest targets a gene or gene product associated with pain, itch, or a neurological disease or disorder.

61. The method of claim 60, wherein the gene or gene product associated with pain, itch, or a neurological disease or disorder is voltage-gated sodium channel Navi.7, voltage-gated sodium channel Navi.8, voltage-gated sodium channel Navi.

9. voltage-gated sodium channel Navi.6, tropomyosin receptor kinase A (TrkA), tropomyosin receptor kinase C (TRKC), acid-sensing ion channel subunit 1 (ASIC 1), acid-sensing ion channel subunit 3 (ASIC3), transient receptor potential vanilloid 1 (TRPV1), transient receptor potential vanilloid 4 (TRPV4), transient receptor potential cation channel, subfamily A, member 1 (TRPA1), transient receptor potential cation channel subfamily M, member 8 (TRPM8). fatty acid amide hydrolase (FAAH), piezo type mechanosensitive ion channel component 1 (PIEZO 1), piezo type mechanosensitive ion channel component 2 (PIEZO2), enkephalin, RET proto-oncogene (RET), interleukin 4 receptor (IL4R), interleukin 13 receptor (IL13R), interleukin 31 receptor (IL31R). interleukin 6 receptor alpha (IL6Ra), glycoprotein 130(gpl30), FXYD domain containing ion transport regulator 2 (FXYD2), P2X purinoceptor 3 (P2X3).

62. The method of claim any one of claims 59-61. wherein the nucleotide of interest encodes a molecule that reduces or ablates the expression of voltage-gated sodium channel Navi. 7.

63. The method of any one of claims 59-62, wherein the nucleotide of interest encodes gRNA that targets a gene encoding voltage-gated sodium channel Navi.7 for silencing via CRISPR-Cas9.

64. The method of any one of claims 59-62, wherein the nucleotide of interest encodes shRNA that targets mRNA encoding voltage-gated sodium channel Navi.7 for silencing via RNAi.

65. A method of treating or preventing pain, itch, or a neurological disease or disorder in a subject in need thereof comprising:administering to the patient (a) a recombinant AAV particle according to any one of claims 1-51, or (b) the pharmaceutical composition of claim 52,wherein the recombinant AAV particle comprises a nucleotide of interest encapsidated within the recombinant AAV particle, andwherein the nucleotide of interest encodes a therapeutic protein, a suicide gene, an antibody or a fragment thereof, a CRISPR / Cas system or a portion(s) thereof, an antisense oligonucleotide, a ribozyme, an RNAi molecule, or a shRNA molecule.

66. The method of claim 65, wherein the administering comprises intramuscular, subcutaneous, or intravenous administration.

67. The method of claim 65, wherein the administering comprises intrathecal, intracistemal, intracerebroventricular, or intraparenchymal administration.

68. The method of claim 65, wherein the administering comprises intravitreal administration into the eye.

69. The method of any one of claims 65-68, wherein the pain is peripheral chronic pain, a chronic neuropathic pain, somatic pain, chronic post-operative pain, small fiber peripheral neuropathy, chemotherapy-induced neuropathy, painful diabetic-induced neuropathy, postherpetic neuralgia, osteoarthritis, back pain, joint pain, trigeminal neuralgia, trigeminal pain, temporo-mandibular pain, migraine, dysautonomia, myofascial pain syndrome or myalgic encephalomyelitis / chronic fatigue syndrome (ME / CFS).

70. The method of claim 69, wherein the chronic neuropathic pain is trigeminal pain or trigeminal neuralgia.

71. The method of any one of claims 65-68, wherein the itch is chronic itch.

72. The method of any one of claims 65-68, wherein the neurological disease or disorderis a neurodegenerative disease, a neurodevel opmental disease, a chronic neuropathic pain, a physical injury, a neuropsychiatric disease, or a neurological cancer.

73. The method of claim 72, wherein the neurodegenerative disease or disorder is Alzheimer’s disease (AD), Parkinson’s disease (PD), amyotrophic lateral sclerosis (ALS), or multiple sclerosis (MS).

74. The method of claim 72. wherein the physical injury is traumatic brain injury, spinal cord injury, stroke, or brain edema.

75. The method of claim 72, wherein the neurological cancer is a brain cancer or a peripheral nerve cancer.

76. The method of any one of claims 65-75, wherein the pain, itch, or a neurological disease or disorder is associated with a sensory neuron, a dorsal root ganglion cell, a trigeminal ganglion cell, or a population thereof.

77. The method of claim 65, wherein the nucleotide of interest encodes a molecule that reduces or ablates the expression of voltage-gated sodium channel Navi.7.

78. The method of claim 77. wherein the nucleotide of interest encodes gRNA that targets a gene encoding voltage-gated sodium channel Navi.7 for silencing via CRISPR-Cas9.

79. The method of claim 77, wherein the nucleotide of interest encodes shRNA that targets mRNA encoding voltage-gated sodium channel Navi.7 for silencing via RNAi.

80. Use of the recombinant AAV particle according to any one of claims 1-51 or the pharmaceutical composition of claim 52 for the manufacture of a medicament for treating or preventing pain, itch, or a neurological disease or disorder,wherein the recombinant AAV particle comprises a nucleotide of interest encapsidated within the AAV particle, andwherein the nucleotide of interest encodes a therapeutic protein, a suicide gene, an antibody or a fragment thereof, a CRISPR / Cas system or a portion(s) thereof, an antisense oligonucleotide, a ribozyme, an RNAi molecule, or a shRNA molecule.

81. The recombinant AAV particle or pharmaceutical composition thereof for use according to claim 80, wherein the pain is peripheral chronic pain, a chronic neuropathic pain, somatic pain, chronic post-operative pain, small fiber peripheral neuropathy, chemotherapy-induced neuropathy, painful diabetic-induced neuropathy, post-herpetic neuralgia, osteoarthritis, back pain, joint pain, trigeminal neuralgia, trigeminal pain, temporo-mandibular pain, migraine, dysautonomia, myofascial pain syndrome or myalgic encephalomyelitis / chronic fatigue syndrome (ME / CFS).

82. The recombinant AAV particle or pharmaceutical composition thereof for use according to claim 81, wherein the chronic neuropathic pain is trigeminal pain or trigeminal neuralgia.

83. The recombinant AAV particle or pharmaceutical composition thereof for use according to claim 80, wherein the itch is chronic itch.

84. The recombinant AAV particle or pharmaceutical composition thereof for use according to claim 80, wherein the neurological disease or disorder is a neurodegenerative disease, a neurodevelopmental disease, a chronic neuropathic pain, a physical injury, a neuropsychiatric disease, or a neurological cancer.

85. The recombinant AAV particle or pharmaceutical composition thereof for use according to claim 84, wherein the neurodegenerative disease or disorder is Alzheimer’s disease (AD), Parkinson’s disease (PD), amyotrophic lateral sclerosis (ALS), or multiple sclerosis (MS).

86. The recombinant AAV particle or pharmaceutical composition thereof for use according to claim 84, wherein the physical injury is traumatic brain injury, spinal cord injury, stroke, or brain edema.

87. The recombinant AAV particle or pharmaceutical composition thereof for use according to claim 84, wherein the neurological cancer is a brain cancer or a peripheral nerve cancer.

88. The recombinant AAV particle or pharmaceutical composition thereof for use according to any one of claims 80-87, wherein the pain, itch, or a neurological disease or disorder is associated with a sensory neuron, a dorsal root ganglion cell, a trigeminal ganglion cell, or a population thereof.

89. The recombinant AAV particle or pharmaceutical composition thereof for use according to claim 80, wherein the nucleotide of interest encodes a molecule that reduces or ablates the expression of voltage-gated sodium channel Navi .7.

90. The recombinant AAV particle or pharmaceutical composition thereof for use according to claim 89, wherein the nucleotide of interest encodes gRNA that targets a gene encoding voltage-gated sodium channel Navi.7 for silencing via CRISPR-Cas9.

91. The recombinant AAV particle or pharmaceutical composition thereof for use according to claim 89, wherein the nucleotide of interest encodes shRNA that targets mRNA encoding voltage-gated sodium channel Navi.7 for silencing via RNAi.

92. A composition comprising:(a) an AAV particle encapsulating a nucleotide of interest; and(b) a multispecific binding protein comprising:(i) a first antigen-binding domain that binds a mammalian p75 neurotrophin receptor (p75NTR), and(ii) a second antigen-binding domain that binds to one or more epitopes of an AAV capsid protein of the AAV particle;optionally wherein the composition further comprises:(c) a pharmaceutically acceptable carrier or excipient.

93. A method of delivering a nucleotide of interest to a mammalian p75NTR-expressing cell, comprising contacting the mammalian p75NTR-expressing cell with the composition of claim 92.

94. A method of treating or preventing pain, itch, or a neurological disease or disorder in a subject in need thereof comprising:administering to the patient the composition of claim 92,wherein the nucleotide of interest encodes a therapeutic protein, a suicide gene, an antibody or a fragment thereof, a CRISPR / Cas system or a portion(s) thereof, an antisense oligonucleotide, a ribozyme, an RNAi molecule, or a shRNA molecule.

95. Use of the composition of claim 92 for the manufacture of a medicament for treating or preventing pain, itch, or a neurological disease or disorder.wherein the nucleotide of interest encodes a therapeutic protein, a suicide gene, an antibody or a fragment thereof, a CRISPR / Cas system or a portion(s) thereof, an antisense oligonucleotide, a ribozy me, an RNAi molecule, or a shRNA molecule.

Images